Characterisation of the Hepatitis C Virus Genotype 3 Glycoproteins by Shaw, Megan Louise
Characterisation o f the Hepatitis C Virus Genotype 3
Glycoproteins
by
Megan Louise Shaw
A thesis presented for the degree of Doctor of Philosophy
in
The Faculty of Medicine 
at the
University of Glasgow
Institute of Virology 
University of Glasgow 
Church St 
Glasgow
G il 5JR December2001
ProQuest Number: 13818458
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13818458
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
/Glasgow"
Acknowledgements
Firstly, I would like to thank Prof. Richard Elliott and Prof Duncan McGeoch for 
providing research facilities in the Institute of Virology and the University of Glasgow and 
ORS awards scheme for funding me.
I would like to thank my supervisor, Dr Liz McCruden for her advice and encouragement 
throughout this project and especially for her assistance in proof-reading this thesis so 
promptly. I also wish to thank Prof. Richard Elliott for several helpful discussions during 
the course of this project.
I am indebted to Dr Arvind Patel and Dr John McLauchlan for providing numerous 
reagents, for their helpful advice and for their critical reading of parts of this thesis.
Thanks also go to Dr Janisha Patel for providing the genotype 1 SFV constructs and for 
her technical assistance at the beginning of the project and to Dr Reg Clayton for his 
assistance with the confocal microscopy.
I would like to thank Dr Alex Cochrane and Mr Alex Orr for heading the PePHD study 
and Suzanne Barnard for analysing the activity of the interferon-alpha. Thank you to Dr 
Hovanessian for providing the PKR monoclonal antibody.
I wish to thank all past and present members of lab 311/301 and lab 300 for both technical 
assistance and the endless banter which relieved the monotony of an average day. Special 
thanks go to Alex Orr for showing me the ropes at the beginning and to Carol-Anne Smith 
for looking after the sera so expertly and for doing all the PCR for the CD81-binding 
experiment.
Many thanks to all my friends in the Institute and elsewhere in the university who have 
made my stay in Glasgow so enjoyable, especially Maria and Iain who have made the bad 
days seem not so bad and the good days seem even better. A big thank you to all past and 
present flatmates of 69E who have been my surrogate family, particularly Houda who has 
been on the receiving end of most of my moans and groans -  you’re a star.
Finally, I wish to thank Mum, Dad, Christopher and Jonathan for providing endless 
support and encouragement and for keeping me up to date with events on the other side of 
the world, especially the cricket score!
Contents
Acknowledgements 
List of Figures and Tables 
Abbreviations 
Summary
Chapter 1 -  Introduction
1.1. Historical Background.
1.1.1. Viral Hepatitis.
1.1.2. Non-A, non-B hepatitis.
1.1.3. Cloning of the NANB hepatitis infectious agent.
1.1.4. Virus morphology.
1.1.5. Classification of HCV.
1.2. The HCV genome and its replication.
1.2.1. 5’ Untranslated region (5’ UTR).
1.2.2. 3’ UTR.
1.2.3. Processing of the HCV polyprotein.
1.2.4. NS2.
1.2.5. NS3.
1.2.5.1. NS3 protease.
1.2.5.2. NS3 NTPase/helicase.
1.2.6. NS4A and NS4B.
1.2.7. NS5A.
1.2.8. NS5B.
1.2.9. Replication of HCV.
1.2.9.1. Infectious clones.
1.2.9.2. Subgenomic replicon system.
1.3. Genetic variability of the HCV genome.
1.3.1. Genotypes.
1.3.2. Variability in the HCV genome.
1.3.3. Viral quasispecies.
1.4. The HCV structural proteins.
1.4.1. Core.
1.4.2. p7.
1.4.3. El and E2.
1.4.4. HCV glycoprotein complexes.
1.4.4.1. Native ElE2 complexes.
1.4.4.2. Aggregated E1E2 complexes.
1.4.4.3. Requirements for E1E2 complex formation.
1.4.5. Subcellular localisation of HCV glycoproteins.
1
1
3
4
5
5
6
6
7
8
9
10
10
12
13
14
15
16
17
18
19
19
21
21
22
22
24
25
26
27
28
29
30
1.4.6. Association of HCV glycoproteins with folding proteins. 31
1.5. Folding of glycoproteins in the ER. 32
1.5.1. Targeting proteins to the ER. 3 3
1.5.2. Glycosylation. 33
1.5.3. Protein folding in the ER. 34
1.5.4. ER stress response. 35
1.5.4.1. Transcriptional activation. 35
1.5.4.2. Translational attenuation. 36
1.5.4.3. Protein degradation. 37
1.6. Putative HCV receptors. 38
1.6.1. Cellular tropism of HCV. 3 8
1.6.2. E2 mediates binding of HCV. 38
1.6.3. CD81. 39
1.6.4. LDL receptor. 41
1.7. Natural history of HCV infection. 42
1.7.1. Epidemiology and transmission. 42
1.7.2. Clinical features of HCV infection. 43
1.7.2.1. Acute hepatitis C. 43
1.7.2.2. Chronic hepatitis C. 44
1.7.2.3. Extrahepatic HCV-associated diseases. 44
1.7.3. Genotypes and natural history of HCV. 45
1.8. Treatment and prevention of HCV. 45
1.8.1. Interferon as a therapeutic agent for chronic hepatitis C. 45
1.8.2. Predicting response to interferon treatment. 46
1.8.3. Antiviral action of interferon. 47
1.8.3.1. dsRNA-dependent protein kinase R (PKR). 48
1.8.3.2. 2 ’-5’ oligoadenylate synthetase / RNAse L pathway. 48
1.8.3.3. Alternative antiviral pathways. 49
1.8.4. Mechanisms for HCV evasion of the interferon response 49
1.8.4.1. NS5A and ISDR. 49
1.8.4.2. E2 and PePHD. 50
1.8.5. Prevention of HCV infection. 51
1.9. Aims and objectives. 53
Chapter 2 -  Materials and Methods.
2.1. Materials. 54
2.1.1. Bacterial strains. 54
2.1.2. Vectors. 54
2.1.3. Synthetic oligonucleotides. 55
2.1.4. Kits and enzymes for DNA/protein modification. 55
2.1.5. Mammalian cell lines and culture media. 55
2.1.6. Human sera. 56
2.1.7. Radiochemicals. 56
2.1.8. Antibodies. 56
2.1.9. Chemicals. 57
2.1.10. cDNA clones and proteins. 57
2.1.11. Solutions. 58
2.1.12. Other materials and apparatus. 59
2.2. Manipulation of DNA and RNA. 60
2.2.1. Purification of synthetic oligonucleotides. 60
2.2.2. Small scale preparation of plasmid DNA (minipreps). 60
2.2.3. Large scale preparation of plasmid DNA (midipreps). 61
2.2.4. Quantification of plasmid DNA and oligonucleotides. 61
2.2.5. Restriction enzyme digestion of DNA. 62
2.2.6. Dephosphorylation of linearised plasmid DNA. 62
2.2.7. Extraction of RNA from human sera. 62
2.2.8. Reverse transcription of RNA. 63
2.2.8.1. Superscript reverse transcriptase. 63
2.2.8.2. Omniscript reverse transcriptase. 63
2.2.9. Polymerase chain reaction (PCR) amplification of cDNA. 63
2.2.9.1. Amplification of core, El and E2. 64
2.2.9.2. Amplification of the PePHD region o f E2. 64
2.2.9.3. Amplification of HCV cDNA for quantification purposes. 65
2.2.10. Electrophoretic separation and isolation of DNA. 65
2.2.10.1. Agarose gel electrophoresis. 65
2.2.10.2. Purification of DNA from agarose gels. 66
2.2.10.3. Purification o f linearised DNA and digested PCR fragments. 66
2.2.10.4. Phenol/chloroform extraction. ‘ 66
2.2.10.5. Ethanol precipitation. 67
2.2.11. Ligation reactions. 67
2.2.12. In vitro transcription of linearised DNA. 67
2.2.13. Automated DNA sequencing 6 8
2.2.14. Site-directed mutagenesis. 68
2.3. Preparation of electrocompetent E.coli (DH5a) cells. 69
2.4. Transformation of competent E.coli cells. 69
2.4.1. Electroporation of DH5a cells. 69
2.4.2. Transformation of TOPI OF cells. 70
2.5. Maintenance of mammalian cells. 70
2.5.1. BHK cells. 70
2.5.2. Huh7 cells. 70
2.6. Transfection of mammalian cells. 70
2.6.1. Electroporation of recombinant SFV RNA. 70
2.6.2. Transfection of pcDNA constructs. 71
2.7. Radiolabelling of cells with 35S-methionine. 72
2.8. Treatment of Huh7 cells with interferon-a. 72
2.9. Preparation of cell extracts. 72
2.9.1. Western blot analysis. 72
2.9.2. ELISA analysis. 72
2.9.3. Immunoprecipitation analysis. 73
2.10. Immunoprecipitation. 73
2.11. Deglycosylation of protein using Endo H and PNGase F. 73
2.12. Protein analysis by SDS-PAGE. 74
2.13. Western blot analysis. 75
2.13.1. Electroblotting to nitrocellulose membrane. 75
2.13.2. Immunodetection. 75
2.14. Enzyme linked immunosorbant assay (ELISA). 76
2.14.1. GNA capture ELISA. 76
2.14.2. CD81 capture ELISA. 76
2.15. Immunofluorescence. 77
2.16. CD81 binding of virus particles. 78
2.17. Computer software. 78
Chapter 3 -  Cloning of HCV genotype 3 core, E l and E2 from the serum 
of an infected patient.
3.1. Introduction. 79
3.2. Selection of patient serum. 82
3.3. Amplification of the HCV structural genes by RT-PCR. 83
3.3.1. Sequence comparison. 83
3.4. Cloning of the HCV structural genes into the SFV vector. 85
3.5. Site-directed mutagenesis of pSFVF2cEiE2. 86
3.6. Construction of genotype 3 E2 SFV clone. 88
3.7. Discussion. 89
Chapter 4 -  Expression and characterisation of the HCV genotype 3 
glycoproteins.
4.1. Introduction. 93
4.2. Reactivity of genotype 1 antibodies against genotype 3 glycoproteins. 95
4.2.1. Expression of genotype 3 structural proteins using the SFV system. 95
4.2.2. Recognition of genotype 3 E2 by genotype 1 E2 antibodies. 96
4.3. Localisation of genotype 3 E2. 100
4.4. Interaction of genotype 3 E l and E2. 101
4.4.1. Analysis of glycoprotein complex formation. 101
4.4.2. Comparison of El and E2 glycosylation states between genotypes 1 and 3.103
4.5. Discussion. 104
Chapter 5 -  Interaction of HCV E2 with PKR and PERK.
5.1. Investigation of HCV E2 interaction with Protein Kinase R (PKR). 112
5.1.1. Introduction. 112
5.1.2. Sequence analysis of the PePHD region of genotype 3 E2 in patients 115 
with differing responses to interferon therapy.
5.1.3. Localisation of E2 and PKR within the cell. 116
5.1.3.1. Cloning of H77 E2 into pcDNA 3.1. 116
5.1.3.2. Treatment o f cells with interferon-a. 117
5.1.3.3. Effect of interferon treatment on PKR expression. 117
5.1.3.4. Localisation of E2 and PKR. 118
5.1.4. Interaction of PKR and E2. 118
5.1.4.1. Lack of evidence for interaction of endogenous PKR and E2. 118
5.1.4.2. Effect of interferon on E2 expression in Huh7 cells. 119
5.1.5. Discussion. 120
5.2. Investigation of E2 interaction with PKR-like endoplasmic reticulum 123
resident kinase (PERK).
5.2.1. Introduction. 123
5.2.2. Localisation of E2 and PERK. 124
5.2.3. Colocalisation of PERK and calnexin. 124
5.2.4. Discussion. 125
Chapter 6 -  Binding of genotypes 1 and 3 E2 to human CD81.
6.1. Introduction. 127
6.2. Lack of binding of genotype 3 E2 to human CD81. 129
6.2.1. E2 capture by human CD81. 129
6.2.2. Genotype 3 E2 does not compete with genotype 1 E2 for CD81 binding. 131
6.2.3. Lack of CD81 binding of E2 when ELISA is performed in reverse. 132
6.3. Binding of virus particles from serum to human CD81. 134
6.4. Discussion. 135
Chapter 7 -  General Discussion.
7.1. H77 and R3 as representatives of genotypes 1 and 3. 141
7.2. Generalised differences between genotypes 1 and 3. 142
7.3. Differences between the H77 and R3 glycoproteins. 144
7.3.1. Antibody recognition. 144
7.3.2. Protein size and glycosylation states. 145
7.3.3. CD81 interaction. 146
References
List of Figures and Tables
Figure Previous page number
1.1 Schematic representation of the HCV genome and the protein 6
products of the polyprotein.
1.2 Secondary RNA structure of the HCV 5’UTR. 6
1.3 Predicted secondary RNA structure of the HCV 3’UTR. 7
1.4 Schematic representation of the method used to establish 18
HCV replicon-containing cell lines.
1.5 Phylogenetic tree showing the HCV genotypes and subtypes. 19
1.6 Domain structure of the core protein. 23
1.7 Transmembrane domain position on the HCV structural proteins. 26
1.8 A model for HCV glycoprotein assembly. 27
1.9 Targeting proteins to the ER. 33
1.10 A model for the quality control of glycoprotein folding in the ER. 34
1.11 The role of molecular chaperones in protein folding in the ER. 35
1.12 Illustration of the unfolded protein response. 36
1.13 a) Domain structure of PERK, Ire 1 and PKR. 36
b) The role of PERK in ER stress-induced translational attenuation. 36
1.14 The predicted secondary structure of CD81. 39
1.15 Illustration of the improving efficacy of interferon therapy. 46
3.1 Illustration of the amplification of the HCV structural genes by RT-PCR. 83
3.2 Agarose gel electrophoresis of genotype 3 structural genes second 83
round PCR products.
3.3 Alignment of the nucleotide sequence of the HCV structural genes 84
of genotype 3 isolates.
3.4 Alignment of the amino acid sequence derived from the HCV 84
structural genes of genotypes 3 and 1.
3.5 Schematic representation of the pSFVl plasmid and the polylinker region. 85
3.6 Alignment of the amino acid sequence derived from the core, El and E2 86 
genes of Gla-3a and pSFVF2cEiE2.
3.7 Schematic representation of the pGEM-1 plasmid. 86
3.8 Illustration of the cloning strategy for construction of the repaired 86
construct, pSFVR3cEiE2.
3.9 Illustration of the strategy for site-directed mutagenesis. 86
3.10 Agarose gel electrophoresis of the site-directed mutagenesis PCR product. 87
3.11 Alignment of the amino acid sequence derived from the core, El and E2 87 
genes of Gla-3a, R3 and H77.
3.12 Illustration of the cloning strategy for the construction of pSFVR3E2. 88
4.1 Agarose gel electrophoresis of in vitro transcribed RNA from SFV 95
constructs.
4.2 A) Western blot analysis of genotype 1 E2 antibodies that recognise 96
genotype 3 E2.
B) Western blot analysis of genotype 1 E2 antibodies that do not 97
recognise genotype 3 E2.
4.3 A) Immunofluorescence of anti-E2, ALP98. 97
B) Immunofluorescence of anti-E2, R646. 97
4.4 A) ELISA analysis of genotype 1 anti-E2 antibodies that do not 98
recognise genotype 3 E2.
B) ELISA analysis of genotype 1 anti-E2 antibodies that recognise 98
genotype 3 E2.
4.5 ELISA analysis of genotype 1 anti-E2 conformation-dependent antibodies. 99
4.6 Alignment of the derived amino acid sequences of El and E2 from R3 99
and H77, indicating the epitopes recognised by the El and E2 antibodies.
4.7 Colocalisation of E2 and calnexin. 100
4.8 Immuoprecipitation of El and E2. 102
4.9 Immunoprecipitation of El and El in both Huh7 and BHK cells. 102
4.10 Immunoprecipitation of glycosylated and unglycosylated forms of 103
El and E2.
5.1 Alignment of the PePHD in E2 with the autophosphorylation sites 114
of PKR and the phosphorylation sites of eIF2a.
5.2 Definitions of patient response to interferon treatment. 115
5.3 Alignment of the derived amino acid sequence of the PePHD region 116
amplified from the sera of patients infected with HCV genotype 3.
5.4 Schematic representation of the pcDNA 3.1 plasmid. 116
5.5 Cloning strategy for construction of pcH77E2. 116
5.6 Assessment of interferon-a activity. 117
5.7 PKR expression in untreated and interferon-a-treated cells. 117
5.8 Cellular localisation of E2 and PKR. 118
5.9 Immunoprecipitation of E2 and PKR. 119
5.10 Western blot analysis of E2 expression in untreated and interferon- 119
a-treated cells.
5.11 Apparent colocalisation of E2 and PERK. 124
5.12 Controls for immunofluorescence. 124
5.13 Localisation of E2 and PERK. 124
5.14 Localisation of PERK and calnexin. 124
6.1 Illustration of the GNA or human CD81 capture ELISA. 129
6.2 GNA and human CD81 capture of E2 detected with anti-E2, ALP98. 130
6.3 GNA and human CD81 capture of E2 detected with anti-E2, AP266. 130
6.4 Western blot analysis of genotype 1 and genotype 3 E2 expression levels. 130
6.5 Binding of genotype 1 E2 to GNA and human CD81 as detected with 131
anti-E2 conformation-dependent antibodies.
6.6 Analysis of the ability of genotype 3 E2 to compete with genotype 1 132
E2 for CD81 binding.
6.7 Illustration of the reverse human CD81 binding ELISA. 132
6.8 ELISA analysis of CD81 binding to E2. 133
6.9 Controls for reverse CD81 ELISA. 133
6.10 Depiction of the amount of PCR product generated in each PCR cycle 134 
as detected by the Gene Amp 5700 sequence detection system.
6.11 Quantification of virus particles in human sera binding to CD81. 134
Table Previous page number
3.1 Oligonucleotide primers for nested RT-PCR of genotype 3 
structural genes.
83
4.1 Summary of SFV constructs. 95
4.2 Details of the genotype 1 El and E2 antibodies. 96
4.3 Summary of the reactivity of genotype 1 E2 antibodies against both 
genotypes 1 and 3 E2 as determined by indirect immunofluorescence.
97
4.4 Summary of the reactivity of genotype 1 El antibodies against both 
genotypes 1 and 3 El as determined by indirect immunofluorescence.
97
Abbreviations
% percentage
°c degree Centigrade
P-ME p-mercaptoethanol
pF microfaraday
Pg microgram(s)
E1 microlitre(s)
sulphur isotope (35)
2YT broth 2 yeast tryptone broth
aa amino acid(s)
APS Ammonium persulphate
as antisense
(d)ATP (2'-deoxy)adenosine 5'-triphosphate
BHK Baby hamster kidney cells
bp base pair
BSA Bovine serum albumin
C-terminal Carboxy-terminal
CaCl2 Calcium chloride
cDNA Complementary DNA
Ci Curie(s)
CIP Calf intestinal phosphatase
cm centimetre
C 02 Carbon dioxide
(d)CTP (2'-deoxy)cytidine 5 '-triphosphate
dH20 Distilled water
DMEM Dulbecco’s modified Eagles Medium
DNA Deoxyribonucleic acid
DNase Deoxyribonuclease
DTT dithiothreitol
El envelope glycoprotein 1
E2 envelope glycoprotein 2
E.coli Escherichia coli
ECL Enhanced chemiluminescence
EDTA ethlenediaminetetra-acetic acid
(disodium salt)
EndoH endoglycosidase H
ELISA Enzyme-linked immunosorbant assay
ER Endoplasmic reticulum
FCS Foetal calf serum
g gram
GMEM Glasgow minimal Eagles Medium
GNA Galanthus nivalis agglutinin
GST glutathione S-transferase
(d)GTP (2'-deoxy)guanosine 5'-triphosphate
h 2o Water
h 2s o 4 Sulphuric acid
HC1 Hydrochloric acid
HRP Horseradish peroxidase
Huh7 Human hepatocellular carcinoma
IFN Interferon
IgG Immunoglobulin G
IP Immunoprecipitation
IU International units
K or kDa kilodalton
kb kilobase pair
KC1 Potassium chloride
k h 2p o 4 Potassium dihydrogen orthophosphate
KOAc Potassium acetate
KOH Potassium hydroxide
kV kilovolts
L-broth Luria Bertani medium
M molarity
MAb monoclonal antibody
MgCl2 Magnesium chloride
Mg(OAc)2 Magnesium acetate
MgS04 Magnesium sulphate
min minute(s)
ml millilitre(s)
mM millimolar
mm millimetre(s)
A-linked Asparagine-linked
N-terminal Amino-terminal
NaCl Sodium chloride
Na2HP04 di-sodium hydrogen orthophosphate 
anhydrous
NaOH Sodium hydroxide
NBCS New bom calf semm
NEM N-ethylmaleimide
(NH4)2S 04 Ammonium sulphate
ng nanogram(s)
nm nanometre(s)
NP-40 nonidet P40
NS non-stmctural
(d)NTP (deoxy)nucleotide triphosphate
OD Optical density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate-buffered saline
PCR Polymerase Chain Reaction
PCR 1 First round PCR
PCR 2 Second round PCR
PePHD PKR and eIF2a phosphorylation 
homology domain
PKR RNA-dependent protein kinase
pmoles picomoles
PMSF phenylmethyl sulphonyl fluoride
PNGase F peptide V-glycosidase F
PolyAb polyclonal antibody
RFLP Restriction fragment length 
polymorphism
RNA Ribonucleic acid
RNase Ribonuclease
RNasin Ribonuclease inhibitor
rpm revolutions per minute
RT Reverse transcription
RT-PCR Reverse transcription PCR
s sense
SDS sodium dodecyl sulphate
sec second(s)
SFV Semliki forest virus
SGB Stacking gel buffer
TBE Tris-boric acid-EDTA buffer
TEMED N,N,N'N-tetramethylethylenediamine
TMB Tetramethyl benzidine
TP broth Tryptose phosphate broth
(d)TTP (2'-deoxy)thymidine 5'-triphosphate
U unit
UTP uridine 5'-triphosphate
UTR untranslated region
UV ultra violet
V volts
v/v volume per volume
w/v weight per volume
Reference HCV isolates:
Genotype la 
Genotype 3 a
H77
HCV-la Gla (Gla)
NZL1
HPCHK6
HCVCENS1
AF046866
Accession no: AF011751 
R.M. Elliott, unpublished 
Accession no: D 17763 
Accession no: D28917 
Accession no: X76918 
Accession no: AF046866
One and three letter abbreviations for amino acids
Amino acid Three letter code One letter
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamic acid Glu E
Glutamine Gin Q
Glycine Gly G
Histidine His H
Isoleucine lie I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
Summary
Hepatitis C vims (HCV) can be classified into six genotypes (1-6) which show 30% 
nucleotide sequence variability throughout the genome. HCV genotypes 1, 2 and 3 have 
a world-wide distribution but their prevalence differs from one geographical area to 
another. In Scotland there is an approximate 50/50 split between individuals infected 
with HCV genotype 1 and genotype 3. There is little evidence that disease progression or 
severity differs between the genotypes. On the other hand, one difference which has been 
consistently demonstrated is the better response of patients infected with genotypes 2 and 
3 to interferon treatment than those infected with genotype 1. HCV encodes three 
stmctural proteins, core, El and E2. The two glycoproteins, El and E2, are believed to 
be the envelope proteins. The lack of a cell culture system for the production of HCV 
virions has meant that the proteins within the envelope of the HCV virion remain 
uncharacterised. However, recombinant forms of the El and E2 proteins have been 
shown to localise to the endoplasmic reticulum (ER) when expressed in cultured cells and 
to interact with one another to form a complex (Ralston et al., 1993). E2 has also recently 
been shown to bind to the cell-surface molecule, CD81, which, as a result, has been 
proposed to be an HCV receptor (Pileri et al., 1998). These characteristics of the HCV 
glycoproteins have been described using constructs derived from genotype 1 only. 
Comparison of the properties of El and E2 with those of other genotypes would identify 
both conserved features, which are possibly essential to the vims life cycle, and genotype- 
specific features. In this study, the El and E2 proteins of genotype 3 were compared with 
those of genotype 1 with respect to antibody recognition, subcellular localisation, complex 
formation, glycosylation status and CD81-binding. The role of E2 in mediating resistance 
to interferon (IFN) through a proposed interaction with PKR (Taylor et al., 1999) was also 
investigated.
The genotype 3 structural genes were amplified by reverse-transcription polymerase chain 
reaction (RT-PCR) from the serum of an HCV genotype 3a-infected patient. This isolate 
was named HCV 3a-Gla (Gla-3a) and was used as the genotype 3 representative, whereas 
genotype 1 was represented by the H77 isolate. Sequence comparison of Gla-3a with 
four published genotype 3a isolates and the genotype 1 isolate revealed that the genotype 
3 E2 protein was 6 amino acids longer and had one fewer cysteine residue than that of 
genotype 1. In terms of length and the number of cysteine residues, the El proteins of 
genotypes 1 and 3 were identical. E2 of Gla-3a (and three other genotype 3 isolates) had 
one fewer predicted glycosylation site compared to genotype 1, whereas the predicted 
glycosylation sites in El were identical between genotypes 3 and 1.
Expression of the core, El and E2 proteins was achieved using either the Semliki Forest 
Virus (SFV) expression system for production of large amounts of recombinant protein or 
the pcDNA system, in which recombinant gene expression is under control of a 
cytomegalovirus (CMV) promoter. None of the genotype 1 anti-El antibodies were able 
to recognise genotype 3 El. Three genotype 1 anti-E2 monoclonal antibodies recognised 
genotype 3 E2 and they all recognised epitopes in a highly conserved sixteen amino acid 
region. The genotype 3 glycoproteins localised to the ER and showed evidence of both 
aggregate and native complex formation as described for those of genotype 1. The 
relative mobilities of untreated and glycosidase-treated proteins confirmed the predicted 
glycosylation status of the E2 proteins of genotypes 1 and 3 but the genotype 3 El protein 
appeared to have one additional glycan compared to genotype 1 El. The deglycosylated 
genotype 1 El protein also seemed smaller than that of genotype 3. Neither of these 
observations was predicted from the sequence comparison. In contrast to genotype 1 E2, 
the recombinant genotype 3 E2 protein did not bind to human CD81, although 
interestingly, preliminary results on the ability of virions in human sera to bind CD81 
suggested that genotype 3 virions did bind but that genotype 1 virions did not. The ability 
of the PKR-eIF2a phosphorylation homology domain (PePHD) in the E2 protein to 
predict response to IFN treatment was not validated for genotype 3 and the proposed 
interaction of genotype 1 E2 with PKR was not confirmed, either by co-localisation or
immunoprecipitation. Therefore the role of E2 in mediating IFN resistance remains 
unclear.
In conclusion, the glycoproteins of both genotypes 1 and 3 behave similarly with respect 
to ER localisation and complex formation in this experimental system. Glycosylation 
status of the glycoproteins varies between the genotypes and further investigation is 
required to determine the true glycosylation status of genotype 3 E l . The lack of CD81 
binding of the genotype 3 E2 protein is intriguing. This will have to be confirmed with 
additional genotype 3 isolates but it does highlight the need to include representatives of 
other genotypes when analysing interactions between viral and cellular proteins.
Chapter 1
Chapter 1 
Introduction
1.1. Historical background
1.1.1. Viral hepatitis
Liver disease is often associated with yellowing of the skin and the whites of the eyes, 
otherwise known as jaundice. This clinical presentation of hepatitis was described in 
European literature dating back to the third century A.D but the infectious nature of some 
forms of hepatitis was recognised only in the early 1900s (Specter, 1999). The hepatitis 
viruses are so-called because the primary disease they cause is inflammation of the liver 
but taxonomically they are unrelated. What follows is a brief description of those viruses, 
which together with hepatitis C virus (HCV), make up the group of “hepatitis viruses”.
Hepatitis A virus (HAV) is transmitted primarily by the faecal-oral route and infections 
are often asymptomatic, especially in young children (reviewed by Cuthbert, 2001).
HAV is endemic in developing countries where most individuals are infected early in life. 
In first world countries, higher levels of sanitation led to a reduction in the overall rate of 
infection but initial exposure occurs at an older age and infection is more likely to be 
symptomatic. HAV is a member of the Picornaviridae family and has been assigned to a 
new genus, Hepatovirus, of which it is the only member. The virus is a spherical, 
nonenveloped particle with a diameter of approximately 27 nm. It contains a 7.5 kb 
single-stranded, positive sense RNA genome that has a single open reading frame (ORF),
1
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flanked by 5’ and 3’ noncoding regions (NCRs). The genome encodes a polyprotein that 
is cleaved to produce the structural and nonstructural proteins.
Hepatitis B virus (HBV) is transmitted primarily via sexual and blood to blood contact.
As with HAV, the majority of infections are asymptomatic but unlike HAV, a proportion 
of HBV-infected individuals fail to clear the virus and become chronically infected.
These individuals are at risk of developing cirrhosis and possibly hepatocellular carcinoma 
(HCC). HBV is a member of the family Hepadnaviridae which includes duck HBV 
(DHB V) and woodchuck HBV (WHBV), both of which have proved useful as models for 
HBV which only infects humans and chimpanzees. HBV has a spherical, enveloped 
virion of -42 nm, with the envelope consisting of host-derived lipids and the glycoprotein 
surface antigen (HBsAg). The encapsidated genome is a circular, partially double­
stranded DNA molecule o f-3.2 kb which encodes seven known viral products (Vyas & 
Yen, 1999).
Hepatitis D virus (HDV) is the only member of the genus Deltavirus within the 
Deltaviridae family. It is unique amongst animal viruses in that it relies on HBV to 
provide helper functions to establish an in vivo infection. Transmission is predominantly 
through parenteral routes. The HDV particle is 35-47 nm and consists of the viral RNA 
genome and the delta antigen (HDAg) enveloped by the surface antigen of HBV. The 1.7 
kb single-stranded, circular RNA genome is self-complementary and folds into a rod 
structure and has both self-cleavage and self-ligation activities (Smedile & Verme, 1999).
Hepatitis E virus (HEV) is transmitted by the faecal-oral route and causes a self-limiting 
disease. It has caused epidemics of hepatitis in adults in the developing world and has a 
notably high mortality in pregnant women (Aggarwal & Krawczynski, 2000). The HEV 
genome was first cloned in 1990 and identified as a single-stranded, positive sense RNA 
molecule of approximately 7.5 kb. It contains three overlapping ORFs flanked by short 
5’ and 3’ noncoding regions. The genome is enclosed in a nucleocapsid with icosahedral 
symmetry, measuring 32-34 nm in diameter. On the basis of its structural and
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physiochemical properties, HEV has been provisionally classified in the family 
Caliciviridae, genus Calicivirus.
Hepatitis G virus (HGV or GBV-C), like HCV, belongs to the family Flaviviridae 
although there is only 25% amino acid sequence homology between these viruses 
(Bowden, 2001). HGV was cloned from an infected tamarin, which had been inoculated 
with serum from a patient with chronic hepatitis. The genome was identified as a single­
stranded, positive sense RNA molecule of 9.4 kb with a similar gene organisation to that 
of HCV. HGV is transmitted by blood to blood contact but there is no conclusive 
evidence that it causes liver disease and the true site of replication has yet to be identified. 
It is increasingly being referred to by its original name, GBV-C.
1.1.2. Non-A, non-B hepatitis
The development of serological tests for HBV led to the introduction of blood donor 
screening for hepatitis B infection in the 1970s. This allowed for the evaluation of the 
role of this virus in transfusion-associated hepatitis (TAH). However, the removal of all 
HBV-positive blood donations from the supply did not eliminate cases of TAH. It 
became apparent that another blood-borne agent was responsible and these cases were 
defined as having non-A, non-B hepatitis (NANBH). Initially this was thought to be a 
mild disease but when long-term cases were analysed it was evident that chronic hepatitis 
often ensued with further progression to cirrhosis and liver failure.
Evidence of the transmissible nature of the NANB agent was shown when serum from 
patients with NANBH was administered intravenously to chimpanzees (Alter et al., 1978). 
The chimpanzees developed hepatitis but importantly, were negative for HAV, HBV or 
other hepatotropic viruses such as cytomegalovirus (CMV) and Epstein Barr virus (EBV). 
Ultrastructural changes, not reported in humans, were observed in the hepatocytes of the 
infected chimpanzees. The appearance of either cytoplasmic membranous tubules or 
intracellular particles of 20-27 nm or both were reported. Feinstone et al. (1983)
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demonstrated that the infectious sera were rendered non-infectious after treatment with 
chloroform, which suggested that the agent might be a virus with a lipid envelope.
1.1.3. Cloning of the NANB hepatitis infectious agent
Attempts at identifying the NANBH agent by conventional virological and immunological 
approaches failed, possibly due to insufficient concentrations of both viral antigen and 
viral antibody. The advent of recombinant DNA cloning technologies provided a new 
approach to identifying the nucleic acid of the agent. Choo et al. (1989) described the 
isolation of NANBH-specific nucleic acid by screening a bacterial cDNA library derived 
from chimpanzee plasma of high infectious titre. The plasma underwent 
ultracentrifugation to ensure isolation of a virus and both DNA and RNA were extracted 
from the resulting pellet. cDNA was synthesised using random primers and either DNA 
polymerase or reverse transcriptase and was cloned into the bacteriophage A,gtl 1 and 
expressed in Escherichia coli (E. coli). The library was screened for clones expressing 
viral antigen, using serum from a patient with chronic NANBH as a presumed source of 
antibodies. After screening approximately 106 recombinants, two positive overlapping 
clones were identified. The cDNA of these clones failed to hybridise to human and 
chimpanzee DNA therefore they were not derived from the host genome. However, total 
RNA from infectious chimpanzee liver did hybridise to the clones and no hybridisation 
was observed with RNA from an uninfected liver or after ribonuclease treatment of total 
nucleic acid. The authors concluded that the clones were derived from an exogenous 
RNA molecule associated with NANB hepatitis infection. Further analysis showed that 
this was a positive sense single-stranded RNA molecule, approximately 10 kb in length 
containing one continuous translational open reading frame (ORF). The binding of 
oligo(dT)-cellulose indicated the presence of either a 3’ terminal polyadenylated sequence 
or an A-rich tract elsewhere in the molecule. The NANB agent was named hepatitis C 
virus (HCV). Thereafter serological assays were developed (Kuo et al., 1989) and 
showed that HCV represented the predominant cause of transfusion associated hepatitis.
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1.1.4. Virus morphology
Before the identification of HCV, filtration experiments had shown that passage through 
an 80 nm filter did not have an effect of the infectious nature of the inoculum (Bradley et 
al., 1985). Further filtration experiments narrowed down the predicted diameter of the 
HCV virion to 30-60 nm (He et al., 1987). Subsequent to the identification of HCV, 
studies on the detailed structure of the virion have been hampered by the lack of a cell 
culture system and the low titres of infectious virus present in serum. More recently, 
electron microscopy, using immunogold staining of the putative envelope proteins, has 
identified spherical virus-like particles in human plasma. These particles were 55-65 nm 
in diameter and had spike-like projections of approximately 6 nm (Kaito et al., 1994). 
Similarly, Shimizu et al. (1996) described the appearance of 50 nm virus-like particles in 
the liver of an infected chimpanzee. The buoyant density of HCV virions is 
heterogeneous, possibly due to association with immunoglobulins or low-density 
lipoproteins. In highly infectious sera, HCV was detected in fractions of low buoyant 
density (<1.06 g/ml), equivalent to that of low density lipoproteins (LDL) (Hijikata et al., 
1993a). In contrast, virus complexed with antibody was detected in higher density 
fractions (-1.17 g/ml) and correlated with lower infectivity (Hijikata et al., 1993a). 
Chloroform treatment, which removes the lipid envelope, also resulted in particles with a 
buoyant density of 1.17 g/ml, thought to represent the HCV nucleocapsids (Hijikata et al., 
1993a).
1.1.5. Classification of HCV
The morphological characteristics of the HCV virion and the identification of a single­
stranded, positive sense RNA genome containing one ORF led to the suggestion that HCV 
was a member of the Flaviviridae family. This was confirmed following cloning and 
sequencing of the full-length genome, which showed regions of sequence identity with the 
pestiviruses and to a lesser extent with the flaviviruses (Choo et al., 1991). This also 
suggested a similar pattern of gene organisation with the structural genes in the N-terminal
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portion and the nonstructural genes in the remainder (Figure 1.1). Sequence comparison 
with other members of the Flaviviridae family also identified motifs that are characteristic 
of a serine protease, RNA helicase and RNA-dependent RNA polymerase (Miller & 
Purcell, 1990, Choo et al., 1991). Despite these regions of sequence homology, there is 
little overall amino acid sequence identity between HCV and the pestiviruses and 
therefore a third genus of the Flaviviridae family was proposed for classification of HCV 
(Robertson et al., 1998). This genus was named the Hepaciviruses and currently HCV is 
the only member.
1.2. The HCV genome and its replication
1.2.1. 5’ Untranslated region (5’ UTR)
The 5’ UTR is the most conserved region of the HCV genome (Bukh et al., 1992). This 
341 nt region is much longer than the 5’ UTRs of flaviviruses, which have an average 
length of 100 nt (Heinz, 1992) but is similar to that of pestiviruses such as bovine viral 
diarrhoea virus (BVDV) and classical swine fever virus (CSFV) (Brown et al., 1992).
The 5’ UTRs of these viruses all contain several AUG triplets upstream of the initiation 
codon and they are all predicted to form extensive secondary structure. The HCV 5’ UTR 
has four major structural domains, designated I to IV (Figure 1.2). Domains II and III are 
complex stem-loop structures, the latter containing an RNA pseudoknot. Domain IV 
contains the AUG initiation codon. This high degree of secondary structure and the 
multiple upstream AUG sequences is similar to the equivalent region in picomaviruses. 
Picomaviral genomes act as uncapped messenger RNAs and are translated by a 
mechanism which allows ribosomes to bind internally on the genome and initiate 
translation at a specific AUG sequence (Jackson et al., 1990). These internal ribosomal 
entry sites (IRES) are dependent on the highly ordered RNA secondary structure and 
allow translation in a cap-independent manner. An IRES element was identified in the 
HCV 5’ UTR by Tsukiyama-Kohara et al. (1992). Deletion analysis has mapped the
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Figure 1.2. Secondary RNA structure o f  the HCV 5 ’UTR 
and the start o f  the downstream open reading frame.
The region comprising the IRES extends from domain II to 
domain IV. The AUG start codon is highlighted.
(Taken from Honda et al., 1999).
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HCV IRES activity to between nucleotides 40 and 370 (Wang et al., 1993, Reynolds et 
al., 1995), therefore the 3’ boundary of the IRES lies in the coding sequence of the core 
protein, a feature unique to HCV. It has since been suggested that core may modulate the 
initiation of translation and Wang et al. (2000) have shown that the full-length core 
sequence suppresses translation and that this is a function of the core coding sequence not 
the core protein. The IRES has also been shown to bind cellular proteins such as PTB 
(Ali & Siddiqui, 1995) and La autoantigen (Ali & Siddiqui, 1997).
While the IRESs of HCV and the pestiviruses are structurally similar, their sequence 
differs by approximately 50%. However, most of these differences are concentrated in 
the stem-structures and base-pairing is maintained (Hellen & Pestova, 1999). There is 
strict conservation of sequence in the terminal loop (especially in domain II) and the 
internal bulges (Honda et al., 1999, Hellen & Pestova, 1999), which suggests that these 
regions may be involved in a direct interaction with conserved elements of the host 
translational apparatus. Pestova et al. (1998) have demonstrated specific interactions 
between these IRES structures and both the 40S ribosomal subunit and the eukaryotic 
initiation factor 3 (eIF3). eIF3 is essential for formation of the 80S ribosome and 
subsequent polypeptide synthesis. Two subunits of eIF2 (eIF2By and eIF2y) have been 
shown to be cofactors of HCV IRES-mediated translation (Kruger et al., 2000) but in 
contrast to other IRES elements, additional elFs, such as eIF4A, eIF4B or eIF4F, are not 
required (Pestova et al., 1998). Therefore the requirements for translation initiation in 
HCV are relatively simple and are so far unique in eukaryotes, being more similar to the 
situation in prokaryotes, with the IRES being comparable to the Shine-Dalgamo sequence. 
The HCV IRES functions by recruiting translation components to form an initiation 
complex and the highly ordered secondary structure orientates this complex such that the 
mRNA-binding cleft of the 40S subunit is positioned precisely at the initiation codon.
1.2.2. 3’ UTR
The 3’ UTR of HCV has 3 distinct regions -  a short variable sequence, a poly(U) tract of 
variable length and a highly conserved sequence of 98 nt termed the 3’X region (Figure
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1.3). The 3’UTR is predicted to fold into a stem-loop structure. The poly (U) region and 
the 3’X region but not the variable region have been shown to be critical for in vivo 
infectivity of HCV in chimpanzees (Yanagi et al., 1999b, Kolykhalov et al., 2000). Little 
is known about HCV replication (see section 1.2.9) but by analogy with other single 
stranded positive sense RNA viruses, transcriptional initiation by the RNA polymerase 
(see section 1.2.8) is predicted to occur at the 3’ ends of both negative and positive RNA 
strands. The poliovirus helicase has been shown to bind the 3’ terminal sequences of the 
negative RNA strand, possibly because it is required for unwinding the double-stranded 
structure formed after initiation of copying of the positive strand (Baneijee et al., 1997).
In contrast, the HCV helicase, NS3 (see section 1.2.5) has been shown to interact with the 
3’ UTR of both positive and negative RNA strands (Banjeree & Dasgupta, 2001).
Binding to the negative strand was specific for the stem loop structure at the extreme 3’ 
terminus, whereas binding to the positive strand required the entire 3’ UTR. Several 
cellular proteins have also been shown to interact with the 3 ’ UTR. Polypyrimidine tract- 
binding protein (PTB) binds to both the poly(U) tract and the 3’X region (Tsuchihara et 
al., 1997, Luo, 1999). Ito et al. (1998) have demonstrated that the 3’X region is able to 
enhance translation from the IRES and that this enhancement is reduced (but not 
abolished) when the PTB binding site is mutated. As mentioned in section 1.2.1, the 5’ 
UTR also binds PTB, suggesting a possible interaction of the 5’ and 3’ UTRs mediated by 
PTB. Other proteins that bind the 3’UTR include glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (Petrik et al., 1999), La autoantigen (Spangberg et al., 1999), 
heterogeneous nuclear ribonucleoprotein C (hnRNP C) (Gontarek et al., 1999) and human 
ribosomal proteins, L22, L3, S3 and mL3 (Wood et al., 2001). The functional relevance 
of these interactions remains unknown.
1.2.3. Processing of the HCV polyprotein
The HCV genome encodes a polyprotein that must be proteolytically cleaved to produce 
the 10 viral proteins (Figure 1.1). The structural proteins (core, E l, E2 and p7) are in the 
N-terminal region of the polyprotein. Processing of the structural proteins appears to be 
catalysed by host signal peptidases in the endoplasmic reticulum (ER) lumen, as cleavage
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in a cell-free assay is dependent on the addition of microsomal membranes (Hijikata et al., 
1991a). The cleavage of core and El from the polyprotein probably occurs 
cotranslationally, however, E2 is generated from an E2-p7-NS2 precursor. This is 
subsequently cleaved into NS2 and E2-p7. Final processing of E2 is inefficient and two 
stable proteins are produced, E2 and E2-p7 (Lin et al., 1994). Cleavage in the non- 
structural protein region is mediated by two viral protease activities located in the NS2- 
NS3 region. The NS2/NS3 junction is cleaved in cis by a zinc-dependent metalloprotease 
that encompasses NS2 and the N-terminal portion of NS3 (Hijikata et al., 1993b). The 
remaining non-structural proteins are cleaved by the action of the serine protease domain 
of the NS3 protein. Cleavage of NS3/NS4A junction occurs in cis and this is followed by 
trans cleavage of the NS5A/5B, 4A/4B and 4B/5 A junctions (Bartenschlager et al., 1995). 
A brief description of the non-structural proteins and their functions follows in this section 
and the structural proteins will be discussed in detail in section 1.4.
1.2.4. NS2
The mature NS2 is a transmembrane protein with its C-terminal region in the ER lumen 
and its N-terminal region in the cytoplasm (Santolini et al., 1995). As mentioned in 
section 1.2.3, together with the N-terminal third of NS3, NS2 has proteolytic activity that 
is responsible for cis cleavage at the NS2/NS3 junction. Although this portion of NS3 
contains the serine protease domain, it is not required for the 2/3 cleavage (Hijikata et al.,
1993b). The NS2-3 protease has been proposed to be a metalloprotease based on the 
observation that activity is inhibited by metal chelators such as EDTA and stimulated by 
exogenous zinc (Hijikata et al., 1993b), however there is no direct structural evidence to 
support this hypothesis. However, elucidation of the crystal structure of the NS3 serine 
protease identified a zinc binding site that is co-ordinated by 3 cysteine residues (Love et 
al., 1996), and the role of zinc ion appeared to be entirely structural. Mutagenesis of 
these cysteine residues significantly decreased serine protease activity and also had a 
measurable affect on the NS2-3 protease activity (Hijikata et al., 1993b), so it is possible 
that the two proteases share the same zinc binding site. Site-directed mutagenesis also 
identified His-952 and Cys-993 in NS2 as being important for enzymatic activity (Hijikata
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et al., 1993b), which led to the suggestion that the NS2-3 enzyme is a cysteine protease. 
Mutagenesis of the residues surrounding the cleavage site revealed that cleavage is 
inhibited only if the mutations alter the conformation of the region, suggesting that correct 
folding of the cleavage site and the protease is more important for activity than any 
particular amino acid side chain (Reed et al., 1995). At this time, the true nature of the 
protease remains unclear. NS2 has also been shown to be involved in regulation of NS5A 
phosphorylation (Liu et al., 1999).
1.2.5. NS3
The NS3 protein extends from amino acids 1027 to 1658 and has a molecular weight of 
approximately 70 kDa (Grakoui et al., 1993a). It is a multifunctional enzyme. In 
addition to its role as part of the NS2-3 protease described above, NS3 also has a serine- 
type protease function in the N-terminal domain and nucleoside triphosphate 
(NTPase)/helicase activity in the remaining portion of the molecule (Hijikata et al., 1993b, 
Suzich et al., 1993, Kim et al., 1995). These enzymatic activities are also functions of the 
flavivirus NS3 protein and the pestivirus p i25 protein, which therefore may be functional 
homologues of HCV NS3 (Ryan et al., 1998). NS3 may also play a role in the 
modulation of protein kinase A-mediated signal transduction (Borowski et al., 1996) and 
the N-terminal half of NS3 has been reported to transform NIH 3T3 fibroblasts (Sakamuro 
et al., 1995).
I.2.5.I. NS3 protease
The NS3 serine protease is responsible for cis cleavage at the NS3-4A junction and trans 
cleavage at the 4A-4B, 4B-5A and 5A-5B junctions. The minimal NS3 domain required 
for protease activity has been mapped to the N-terminal 180 residues (Bartenschlager et 
al., 1994) and a catalytic triad has been identified within this region based on sequence 
comparison with proteases of the trypsin superfamily. The residues involved are His- 
1083, Asp-1107 and Ser-1165 and mutation of these was shown to abolish cleavage at the 
NS3-4A, NS4A-4B, NS4B-5A and NS5A-5B junctions but not at the NS2-3 junction
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(Bartenschlager et al., 1993, Grakoui et al., 1993b). Processing at the NS3-4A junction is 
rapid and probably cotranslational. Thereafter, the order of cleavage is NS5A-5B 
followed by NS4A-4B and NS4B-5A (Bartenschlager et al., 1994).
The NS4A protein functions as an essential co-factor for the NS3 serine protease and is 
required for cleavage at the NS3-4A, NS4A-4B and NS4B-5A sites and enhances cleavage 
at the NS5A-5B site (Failla et al., 1994). NS4A forms a detergent-stable, non-covalent 
complex with the NS3 protease domain and this interaction requires the 22 N-terminal 
residues of NS3 and a 12-residue sequence in the centre of NS4A (Lin et al., 1995, Satoh 
et al., 1995). NS4A was thought to enhance protease activity by inducing conformational 
changes, which stabilise NS3 (Steinkuhler et al., 1996). The resolution of the X-ray 
crystal structures of NS3 revealed that, in the absence of NS4A, the N-terminal region of 
NS3 is loosely structured and extends away from the protein (Love et al., 1996). In the 
presence of NS4A, the N-terminal domain forms an 8-stranded p-barrel, with one strand 
contributed by NS4A (Kim et al., 1996). It was also shown that NS4 binding affects the 
spatial arrangement of the catalytic triad, as in the absence of NS4A, the His-1083 and 
Asp-1107 residues were positioned too far away from each other and the Ser-1165 residue 
to form a typical catalytic triad (Love et al., 1996). This explains the observed increase in 
protease activity in the presence of NS4A.
As mentioned in section 1.2.4., analysis of the crystal structure of the NS3 protease 
indicated the presence of a zinc binding site co-ordinated by three cysteine residues and 
(via a water molecule) a histidine residue (Love et al., 1996). Due to the close proximity 
of the zinc ion to the catalytic serine residue, it is predicted to have a structural rather than 
a catalytic role. This is supported by the report that zinc can be substituted by cadmium 
or cobalt ions with no affect on the protease activity (Stempniak et al., 1997). Also, in 
other enzymes where zinc is known to have a structural role, it is ligated by cysteine 
thiolates, as seems to be the case with NS3 (Berg & Shi, 1996).
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1.2.5.2. NS3 NTPase/helicase
Sequence motifs within the C-terminal two thirds of NS3 suggest that this region of the 
protein has both NTPase and RNA helicase activity. Suzich et al. (1993) demonstrated 
that HCV NS3 does possess NTPase activity in vitro and it has the same requirements for 
magnesium concentration and pH as do the equivalent flavivirus and pestivirus enzymes. 
NTPase activity is enhanced by the presence of polynucleotides, particularly poly(U).
The NS3 protein also contains a motif (DECH) which suggests it is a member of the 
DEXH subfamily of proteins. These proteins belong to the DEAD box family of RNA 
helicases and Kim et al. (1995) demonstrated that the carboxy terminal fragment of NS3 
possesses RNA helicase activity. This activity requires ATP and either magnesium or 
manganese ions. The helicase domain is able to unwind dsRNA, RNA/DNA 
heteroduplexes and dsDNA in a 3’ to 5’ direction, but this is dependent on a 3’ overhang 
region (Tai et al., 1996). The minimal requirement for both NTPase and helicase 
activities has been mapped to the C-terminal 465 amino acids of NS3 (Kim et al., 1997a) 
and mutations in either the ATPase or the helicase motifs affect both functions 
significantly (Kim et al., 1997b). The helicase activity has also been shown to be 
required for viral replication in chimpanzees (Kolykhalov et al., 2000).
The N-terminal protease domain and the C-terminal NTPase/helicase domain have been 
analysed independently and shown to be sufficient for their respective activities. There is 
no evidence of cleavage in vivo to separate these two domains and in other flavivirus 
proteins, the protease and helicase domains are also found on the same polypeptide. To 
investigate any potential cross-talk between these two domains, the protease, NTPase and 
helicase activities have also been analysed in terms of the full-length NS3 (Gallinari et al., 
1998). Once complexed with NS4A, the isolated domains and the full-length protein did 
not shown any significant differences in any of the three enzymatic activities. It was also 
shown that complete inhibition of the protease activity had no affect on the helicase 
activity. However, it has been shown that the protease domain is also involved in RNA- 
binding and that this leads to inhibition of protease activity, while ensuring optimal
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binding of RNA to the helicase domain (Gallinari et al., 1998). By this mechanism, there 
is potentially interplay between these two enzymatic domains.
1.2.6. NS4A and NS4B
Aside from its role as a cofactor for the NS3 serine protease (as discussed in section
1.2.5.1.), not much else is known about the 8 kDa NS4A protein. NS4A has an N- 
terminal hydrophobic domain, which has been shown to mediate localisation of NS3 to the 
ER membrane (Wolk et al., 2000). NS4A has also been reported to form a stable 
complex with the NS4B-5A polyprotein, which may be required for NS3-mediated 
cleavage at the NS4B-5 A junction (Lin et al., 1997). In addition, NS4A has been 
identified as a modulator of NS5A hyperphosphorylation and this is mediated by the 
central region of NS4A, which is also involved in the interaction with NS3 (Koch & 
Bartenschlager, 1999). A recent study has also identified an interaction between NS4A 
and NS2, although the functional role of this complex is unknown (Flajolet et al., 2000).
NS4B is the least well characterised of the HCV proteins. This hydrophobic 27 kDa 
protein localises to the ER membrane and displays properties of a cytoplasmically 
orientated integral membrane protein (Hugle et al., 2001). No function as yet been 
ascribed to the NS4B proteins of related pestiviruses, however the Kunjin flavivirus NS4B 
protein has been shown to be essential for viral replication (Khromykh et al., 2000). If 
this were true for HCV NS4B, it would support the suggestion that NS4B associates with 
the other non-structural proteins to form a replication complex. This was based on the 
observation that NS4A interacts with the NS4B-5A cleavage substrate (Lin et al., 1997) 
and that, like NS3 and NS4A, NS4B is also involved in the modulation of NS5A 
hyperphosphorylation (Koch & Bartenschlager, 1999).
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1.2.7. NS5A
The mature NS5A protein is a 56 kDa (p56) phosphoprotein but it also exists in a 
hyperphosphorylated form with a molecular weight of 58 kDa (p58) (Kaneko et al., 1994). 
Phosphorylation occurs mainly at serine residues and is mediated by a cellular kinase 
(Reed et al., 1997). Basal phosphorylation to produce p56 is independent of NS4A, 
however, hyperphosphorylation is dependent on the association of NS5A with NS4A 
(Asabe et al., 1997). Furthermore, Koch & Bartenschlager (1999) demonstrated that 
hyperphosphorylation occurs only when NS5A is expressed as part of a continuous NS3- 
NS5A polyprotein and that NS3, NS4A and NS4B are all involved in modulation of 
NS5A hyperphosphorylation. The NS2 protein also plays a role in the regulation of 
NS5A phosphorylation (Liu et al., 1999). Hyperphosphorylation of NS5A is a conserved 
feature among members of the Flaviviridae family but the role of the two different forms 
of the protein is unknown.
NS5A has been shown to form a multisubunit complex with NS3, NS4A and NS4B (Lin 
et al., 1997) and NS5A has been co-precipitated with the remaining two nonstructural 
proteins, NS2 and NS5B (Hijikata et al., 1993c). This suggests that the HCV 
nonstructural proteins form a replication complex as described for other single-stranded, 
positive sense RNA viruses (e.g. poliovirus). This complex is likely to be anchored on 
the intracellular membranes and NS5A is localised in the cytoplasmic membrane 
surrounding the nucleus (Tanji et al., 1995). A potential nuclear localisation signal has 
been identified in the C-terminus of NS5A but there have been no reports of NS5A in the 
nucleus (Ide et al., 1996). Apart from its putative role in virus replication, a region of 
NS5A (aa 2135-2331) has been shown to have transcription-activating activity (Kato et 
al., 1997). Two acidic motifs within this region are essential for this activity. It is not 
known whether NS5A acts as a transcriptional activator in vivo but if so, it could have a 
role in the development of hepatocellular carcinoma (see section 1.7.2.2.) in HCV-infected 
patients.
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NS5A has also been implicated as a mediator of viral resistance to interferon alpha (IFN) 
therapy. NS5A has been shown to bind to double-stranded RNA-dependent protein 
kinase (PKR) (Gale et al., 1997), which is induced by IFN and is a key component of the 
antiviral response. A 40 amino acid stretch, called the interferon sensitivity-determining 
region (ISDR), was identified in the central region of NS5A as being predictive of 
outcome to IFN therapy (Enomoto et al., 1995). However, this finding led to several 
conflicting reports and the proposed role of NS5A in IFN-resistance will be discussed in 
more detail in section 1.8.4.1.
1.2.8. NS5B
The 65 kDa NS5B protein has been shown to be an RNA-dependent RNA polymerase 
(RdRp) (Behrens et al., 1996). It contains the classical GDD motif, which is conserved in 
all RNA polymerases, and is essential for polymerase activity. The crystal structure of 
NS5B has been determined and reveals that the catalytic domain has the typical right- 
handed “fingers-palm-thumb” structure, with the RNA-binding groove lying between the 
“fingers” and “thumb” (Bressanelli et al., 1999). Further proof that the non-structural 
proteins form a replication complex is provided by the report that NS5B interacts with 
both NS3 and NS4A and this complex is localised to the endoplasmic reticulum (Ishido et 
al., 1998). NS5B expressed alone is also associated with intracellular membranes 
(Hwang et al., 1997), so it is likely that HCV replicates on intracellular membranes. A 
recombinant full-length form of NS5B has been shown to be capable of copying the full- 
length HCV RNA genome in vitro, without the need for addition factors (Oh et al., 1999), 
although additional viral or cellular factors are probably necessary for regulation of RNA 
synthesis. The HCV RdRp was shown to use the 3’X tail of both the plus and minus 
RNA strands as templates for RNA synthesis (Oh et al., 1999). This specificity for the 
3’X tail is thought to be due to the recognition of specific stem-loop structures in the 
3’UTR (Cheng et al., 1999). This is in accordance with the reports that both NS5B and 
the 3’X tail are essential for viral replication in vivo (Kolykhalov et al., 2000).
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1.2.9. Replication of HCV
Since the identification of HCV in 1989, the characterisation of the viral gene products has 
been relatively rapid. However, research into the viral life cycle has been severely 
hampered by the lack of suitable in vivo and in vitro systems for the study of HCV 
infection, replication and pathogenesis. As mentioned above, coprecipitation experiments 
have indicated that the nonstructural proteins probably form a replicase complex on the 
cytoplasmic side of the ER membrane (Ishido et al., 1998, Lin et al., 1997), which is 
analogous to what happens in related flaviviruses and pestiviruses. In its role as the 
RdRp, the NS5B protein is responsible for the synthesis of both plus- and minus-strand 
RNA, although the individual steps involved in this process are unknown. Numerous 
attempts have been made at propagating HCV in cell culture, through infection of either 
primary cells or established cell lines, or cultivation of primary cells from chronically 
infected patients (Lanford et al., 1994, Ito et al., 1996, Rumin et al., 1999, reviewed by 
Bartenschalger & Lohmann, 2001). These systems suffer from both poor efficiency and 
poor reproducibility and none permitted detailed analysis of the replication cycle. Recent 
progress has been made in this field with the development of subgenomic HCV RNA 
replicons which are capable of replicating successfully in the human hepatoma cell line 
(Huh7) (Lohmann et al., 1999). This system will be covered in more detail in section
1.2.9.2.
The search for a suitable animal model in which to study HCV replication has not been 
any more successful. The chimpanzee is the only known animal to support HCV 
replication but its use is limited by its scarcity, high maintenance costs and for ethical 
reasons. In the absence of a successful cell culture system, the chimpanzee has proved 
invaluable for the study of molecular clones of HCV, which contain all the necessary 
requirements for infectivity. The development of such clones will be discussed in the 
following section (1.2.9.1). A recent mouse model for HCV infection has been described, 
which relies on the transplantation of human hepatocytes into immunodeficient transgenic 
mice whose own hepatocytes degenerate spontaneously (Mercer et al., 2001). The 
resultant chimeric mouse/human liver could be infected with serum from an HCV-infected
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patient. The chimeric livers were able to maintain relatively high levels of HCV RNA (3 
x 104 to 3 x 106 copies/ml) for a period of 15-17 weeks. Although promising, this mouse 
model requires specialised techniques, which are unlikely to be available to most HCV 
researchers.
I.2.9.I. Infectious clones
In order to investigate the role of any specific viral product or domain in HCV replication, 
it would be useful to initiate the infection with RNA transcribed from a cDNA clone. If 
patient material is inoculated, the presence of a quasispecies (see sectionl.3.3.) of 
individual variants means that there is uncertainty over exactly which variants result in 
expression of viral proteins. RNA transcribed from a cDNA clone is advantageous as the 
infecting viral genome is then well defined and can be easily manipulated. Initial 
attempts at producing a clone that was infectious when RNA was injected directly into the 
liver of a chimpanzee were unsuccessful (Major & Feinstone, 2000). These clones were 
constructed by RT-PCR amplification of HCV RNA from patient material and PCR errors 
could have potentially rendered the virus incapable of replication. Additionally, the 
quasispecies nature of HCV could have meant that the selected clones contained natural 
mutations that were lethal for replication. To address this, a consensus clone was 
constructed from a total of six clones and intrahepatic injection of RNA derived from this 
clone resulted in HCV RNA levels of approximately 1 x 106 copies/ml (Kolykhalov et al.,
1997). In addition, serum aminotransferase levels, liver histology and the appearance of 
HCV-specific antibodies indicated that the chimpanzee was infected. Using the same 
strategy, infectious clones of genotypes la, lb and 2a (see section 1.3.1.) have been 
reported (Yanagi et al., 1997, Yanagi et al., 1998, Yanagi et al., 1999a, Beard et al., 1999, 
Lanford et al., 2001). Mutagenesis of these infectious molecular clones has demonstrated 
that NS2, NS3, NS4A and NS5B activities are all required for replication in vivo, as is the 
3’ X tail and poly(U) region of the 3’UTR (Kolykhalov et al., 2000, Yanagi et al., 1999b). 
The hypervariable region (HVR1) of E2 (see section 1.3.2) is not required for replication 
in vivo (Foms et al., 2000). These studies have provided crucial information about the
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essential viral genes required for HCV replication but the expense of such studies means 
that they are not practical for detailed analysis of the viral genome.
I.2.9.2. Subgenomic replicon system
The most recent breakthrough in the field of HCV replication has come from the 
development of selectable subgenomic replicons which can replicate to high levels after 
transfection into the human hepatoma cell line Huh7 (Lohmann et al., 1999) (Figure 1.4). 
Similarly to the construction of the infectious clones, a consensus genome (genotype lb) 
was constructed from material cloned from liver tissue of a chronically infected patient. 
The structural genes (and NS2) were replaced with the gene encoding the selectable 
marker neomycin phosphotransferase (neo) which confers resistance to the antibiotic 
G418. Translation of this gene was directed by the HCV IRES and an 
encephalomyocarditis virus (EMCV) IRES directed translation of the HCV NS genes. 
These bicistronic RNA transcripts were transfected into Huh7 cells and those cells 
harbouring the replicon were selected with G418. Low numbers of resistant colonies 
were obtained but Northern blot analysis demonstrated that such colonies contained large 
amounts of HCV RNA. The HCV proteins were detected by immunoprecipitation and 
immunostaining showed them to be closely associated with the ER, consistent with this 
being the site of replication.
This replicon system was validated by Blight et al. (2000) and their study also identified a 
series of adaptive mutations which arose during propagation of the cells containing the 
replicon. These mutations enhanced RNA replication, which increased the G418 
transduction efficiency. The adaptive mutations were clustered in a 30 amino acid region 
in the centre of NS5A and when they were transferred into the original replicon, there was 
increased cloning efficiency in Huh7 cells (Blight et al., 2000). Interestingly, only two of 
these mutations have been identified independently (Bartenschlager & Lohmann, 2001). 
Similarly, Krieger et al. (2001) reported the identification of a cell culture adaptive 
replicon that contained two mutations in NS3 and one in NS5A. These adaptive 
mutations were confirmed by replacement of the neo gene with the firefly luciferase gene
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Figure 1.4. Schematic representation of the method used to establish 
HCV-replicon-containing cell lines. The HCV genome is shown at the 
top and the subgenomic RNAs are shown below. They are composed of 
the HCV 5’UTR plus a small fragment of the core-coding region, the neo 
gene, the encephalomyocarditis virus IRES (E-I), NS2-5B or NS3-5B and 
the 3’UTR. Upon transfection of Huh-7 cells, only those supporting 
replication of the HCV RNAs amplify the neo gene and develop resistance 
against the drug G418. Therefore only these cells will form colonies. 
(Taken from Bartenschlager & Lohmann, 2000).
Chapter 1
in the replicon, which on transfection into Huh7 cells, showed increased levels of 
luciferase activity compared to the original replicon sequence (Krieger et al., 2001). It is 
not known if similar mutations would be seen in vivo or whether they are simply due to 
adaptation to the Huh7 cell line. So far this cell line is the only one shown to support the 
HCV replicon system, possibly due to factors unique to these cells. Another enigma is 
that the H77 clone, known to be infectious in chimpanzees, could not be established as a 
subgenomic replicon (Blight et al., 2000) and conversely, the isolate used to establish the 
replicon system has not been shown to cause infection in the chimpanzee. Although it is 
apparent that the structural proteins are not required for RNA replication, a full-length 
HCV replicon is required for analysis of the complete viral replication cycle. A recent 
report at an international meeting described the persistent replication of a selectable full 
length HCV genome in cell culture but there was no evidence of virion production, despite 
the presence of structural proteins (Pietschmann et al., 2001).
1.3. Genetic variability of the HCV genome
1.3.1. Genotypes
Soon after reporting of the prototype HCV isolate, HCV-1 (Choo et al., 1991), a number 
of sequences of other isolates were published and comparison revealed considerable 
diversity. Phylogenetic analysis of nucleotide sequences of complete genomes or 
subgenomic regions has led to the classification of six HCV genotypes (numbered 1 -6) 
(Simmonds et al., 1994) (Figure 1.5). Within each genotype are more closely related 
subtypes (a, b, c etc). Over the complete virus genome, genotypes differ from each other 
by more than 30%, subtypes by more than 20% and individual isolates of the same 
subtype, by less than 10% (Simmonds, 1995).
There are substantial regional differences in the distribution of HCV genotypes.
Genotypes 1, 2 and 3 have a broad world-wide distribution, although their relative
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Figure 1.5. Phylogenetic analysis of nucleotide sequences in 
part of the HCV NS5A region. They are classified into six 
genotypes and subtypes a, b, etc. (Taken from Simmonds, 1995).
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prevalence varies from one geographic area to another. In the United States and Western 
Europe, genotypes la  and lb are predominant (McOmish et al., 1994). In Southern and 
Eastern Europe there is more frequent infection with genotype lb (Simmonds, 1995) and 
in Japan, genotype lb accounts for up to 73% of infections (Takada et al., 1993). 
Genotypes 2a and 2b are commonly found throughout the United States, Europe and 
Japan. Genotype 3a is prevalent amongst intravenous (IV) drug users in the USA and 
Europe (Pawlotsky et al., 1995) and is the most common genotype in Thailand 
(Kanistanon et al., 1997). A wide variety of genotype 3 subtypes are found in Southern 
Asian countries (Tokita et al., 1994, Simmonds, 1995). Genotype 4 is prevalent in 
Middle Eastern countries and in Central Africa (Simmonds, 1995, Xu et al., 1994). 
Genotype 5 is confined to South Africa (Ohno et al., 1994) and genotype 6 is restricted to 
Southeast Asia (Simmonds et al., 1993).
The rate of nucleotide sequence change of HCV has been estimated as lO'Mo*4 
substitutions per site per year (Ogata et al., 1991, Smith et al., 1997a). Assuming this 
rate of change is maintained over long periods of time, it can be used to estimate the “age” 
of the individual genotypes and subtypes. Within subtype lb, variants were estimated to 
have diverged 70-80 years ago and the absence of any genotype lb specific country or 
region suggested that the initial spread was relatively rapid (Smith et al., 1997a). In 
Western countries, genotype 3a variants were estimated to have diverged only 40 years 
ago (Simmonds, 2001) and this is consistent with the epidemiological link between 
genotype 3a and illicit intravenous drug use (IVDU) and needle sharing, which has 
dramatically increased since the 1960s. In contrast, the genotype 2a, 2b and 2c variants 
are predicted to have diverged 90-150 years ago (Simmonds, 2001). Documentation of 
sequence variability is not as good in non-Westem countries but the wide range of 
subtypes in certain regions suggests that a particular genotype has been present in the 
human population for a long time and possibly that these represent the places of origin for 
a particular genotype. For example, genotype 2 shows considerable sequence diversity in 
Western African countries (Ruggieri et al., 1996), as does genotype 4 in Central Africa 
(Xu et al., 1994). The greatest diversity of genotypes 3 and 6 is found in Southern Asia 
(Simmonds, 2001).
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Genotypes of HCV also differ with respect to disease manifestation and response to 
interferon therapy, as will be discussed later in this chapter (sections 1.7.3. and 1.8.2.).
1.3.2. Variability in the HCV genome
The HCV genome shows various levels of sequence diversity along its length. The 
3’UTR and 5’UTR are highly conserved between genotypes, consistent with their roles in 
replication and translation. The core protein (see section 1.4.1) is the most conserved of 
the viral proteins with nucleotides in the core gene of isolates from all 6 genotypes having 
79.4-99% identity (Bukh et al., 1994). In contrast, the two envelope-encoding regions 
(El and E2) are highly divergent (Kato et al., 1992). The E2 protein has been found to 
have an unusually high degree of amino acid variation in its N-terminus (Hijikata et al., 
1991b, Weiner et al., 1991, Kato et al., 1992). This hypervariable region (HVR) is the 
most variable region of the HCV genome. The HVR, mapped to aa 384-411, appeared to 
be a target for anti-HCV neutralising responses (Zibert et al., 1995, Kato et al., 1993) and 
it has been suggested that this region is subject to immune pressure which leads to the 
selection of escape mutants (Weiner et al., 1992, van Doom et al., 1995).
1.3.3. Viral quasispecies
HCV variation is observed on four levels; genotypes, subtypes, quasispecies and the 
variants within a quasispecies. A quasispecies is defined as a population of viruses that 
share a common origin but which have distinct genomic sequences (Smith et al., 1997b). 
HCV circulates in a single individual as a population of different but closely related 
genomes and therefore can be described as having a quasispecies distribution (Martell et 
al., 1992). This quasispecies nature has been attributed to the RNA polymerase lacking 
proof-reading 3’-5’ exonuclease activity and therefore each round of replication is 
accompanied by the incorporation of mutations. The mutation rate of the HCV genome 
has been estimated to be ~10‘3-10'4 nucleotide substitutions per site per year (Ogata et al., 
1991, Smith et al., 1997a). However, as mentioned above, certain regions are more prone
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to a substitution than others, which has been interpreted as meaning that these regions are 
under selective pressure. The flavivirus, HGV is closely related to HCV and its 
polymerase is presumed to have a similar error rate to that of HCV. However, compared 
to the 30% sequence diversity between HCV genotypes, HGV isolates from around the 
world differ by only 14% (Smith et al., 1997c). Therefore the heterogeneous nature of 
HCV cannot be explained solely by the error prone RNA polymerase. This mixed virus 
population is thought to confer advantage to the virus in that it allows rapid selection of a 
variant that displays “better fitness” in response to a new environmental pressure. It has 
been suggested that the diversity of HCV quasispecies correlates with the progression of 
liver disease and contributes to the high level of chronicity seen in HCV-infected patients 
(Yuki et al., 1997) (see section 1.7.2.2). This might be due to the selection of variants 
which are able to evade the immune system and therefore establish a persistent infection.
A difficulty in interpreting the degree of variation from nucleotide sequence data is that 
most data were obtained from amplification of the viral RNA by RT-PCR. Both the 
reverse transcriptase and Taq DNA polymerase enzymes have high error rates themselves 
and therefore these errors could be incorrectly interpreted as virus heterogeneity. This 
needs to be taken into consideration when analysing the sequence diversity of a virus 
within an infected individual. To avoid this problem, it has been suggested that, rather 
than analysing cloned sequences, it is preferable to sequence the PCR product directly 
(Smith et al., 1997b). An error produced during PCR will be present only in a minority 
of products and will not be detected against the background majority.
1.4. The HCV structural proteins
1.4.1. Core
Core is the first peptide to be translated. It is cleaved from the polyprotein at residue 191 
to produce a 23 kDa product (p23) but the presumed mature form of core is produced by
22
Chapter 1
additional cleavage between residues 174 and 191 to give a 21 kDa species (p21) (Hussy 
et al., 1996). Processing of p21 and p23 is dependent on the presence of microsomal 
membranes, indicating that cleavage is mediated by membrane-associated proteases 
(Santolini et al., 1994). Core is highly conserved between the 6 genotypes and the 
hydrophobicity profile of core identifies 3 domains within the protein (Hope & 
McLauchlan, 2000) (Figure 1.6). Domain 1 (aa 1-122) contains a high proportion of 
basic residues and has two hydrophobic regions. Domain 2 (aa 123-174) is more 
hydrophobic than domain 1, while domain 3 (aa 175-191) is highly hydrophobic and acts 
as the signal sequence for E l, but is absent in p21 (Santolini et al., 1994). Electron 
microscopy indicated that the majority of core was associated with either the cytoplasmic 
face of the ER or with granular structures, which were subsequently identified as lipid 
droplets (Moradpour et al., 1996, Barba et al., 1997). There is also evidence of nuclear 
localisation of a form of p21 core, which is conformationally different from the 
cytoplasmic form (Yasui et al., 1998).
Core is presumed to form the viral capsid by its similar position in the genome and protein 
composition by comparison with the capsids of related flaviviruses and pestiviruses. 
However, very little is known about virus assembly as expression of the structural proteins 
in mammalian cells does not produce virus particles. Virus-like particles (VLPs) can be 
produced by infection of insect cells with recombinant baculoviruses (Baumert et al.,
1998) which express the HCV structural proteins. The core protein in the VLPs is the 
same size as that expressed in mammalian cells but because the VLPs are not released 
from infected cells, complete virus assembly cannot be analysed. In its role as the capsid 
protein, core is predicted to homo-oligomerise. Regions for oligomerisation have been 
identified in domain 1 (aa 36-91 and aa 82-102) (Matsumoto et al., 1996) and another 
potential region has been described in domain 2 but has not been confirmed (Yan et al.,
1998). In positive-sense RNA viruses (e.g. Sindbis virus, rubella virus), the capsid 
protein has been shown to bind specifically to the plus strand viral RNA, and likewise, 
core interacts specifically with the positive-sense HCV genome (Shimoike et al., 1999). 
VLPs produced in the baculovirus system have also been shown to encapsidate positive- 
sense HCV RNA (Baumert et al., 1998). There was a suggestion that core protein could
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modulate translation from the IRES (Shimoike et al., 1999) but this effect has since been 
attributed to the core coding RNA sequence and not the protein itself (Wang et al., 2000). 
One study has reported an interaction between core and El (Lo et al., 1996) but no other 
interactions with HCV proteins have been reported, probably because core is highly 
insoluble and membrane-bound following extraction from cells.
Core has been shown to bind to several cellular proteins. These include heterogeneous 
nuclear ribonucleoprotein K (hnRNP K) (Hsieh et al., 1998), lymphotoxin p receptor (LT- 
PR) (Chen et al., 1997), tumour necrosis factor receptor 1 (TNF-R1) (Zhu et al., 1998) 
and an RNA helicase from the DEAD box family of proteins (You et al., 1999, Owsianka 
& Patel, 1999). The functional significance of these interactions has been difficult to 
ascertain in the absence of a cell culture system for HCV. Core expression has been 
demonstrated to affect apoptosis (Ruggieri et al., 1997, Zhu et al., 1998), possibly as a 
result of its interactions with LT-pR and TNF-R1, both of which are known to be involved 
in apoptosis. Core has also been implicated in cellular transformation and the 
development of hepatocellular carcinoma (Ray et al., 1996, Moriya et al., 1998), 
transcriptional regulation (reviewed in McLauchlan, 2000), immune presentation (Large et 
al., 1999) and lipid metabolism (Moriya et al., 1997). It would appear that core has 
multiple functions but these need to be confirmed in a model system that reproduces viral 
replication and disease pathogenesis as seen in humans.
1.4.2. p7
p7 is located between E2 and NS2 in the genome. Processing of the polyprotein at the 
E2/p7 and p7/NS2 junctions is mediated by a host signal peptidase to release a highly 
hydrophobic 7 kDa product (Lin et al., 1994). However, cleavage at the E2/p7 junction is 
inefficient and leads to the production of two E2-specific species, E2 and E2-p7 
(Mizushima et al., 1994, Lin et al., 1994). Baumert et al. (1998) demonstrated that p7 is 
not required for VLP formation in insect cells. In a related pestivirus, bovine viral 
diarrhoea virus (BVDV), p7 is required for generation of infectious virus, although the E2- 
p7 product is not (Harada et al., 2000). The pestivirus p7 protein is known not to be a
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major structural component of the virion (Elbers et al., 1996) but its true function remains 
unknown. Similarly, the role of HCV p7 (and E2-p7) is unknown and awaits the 
development of a mammalian model system capable of generating virus particles.
1.4.3. E l and E2
Sequence comparison with related flaviviruses and pestiviruses suggested that El and E2 
were the viral envelope proteins (Choo et al., 1991). On expression of the polyprotein, 
El and E2 were identified as glycosylated proteins of approximately 30 kDa and 70 kDa 
respectively (Grakoui et al., 1993a, Selby et al., 1993). Cleavage of El from the 
polyprotein is mediated by an ER-associated host signal peptidase between amino acids 
191/192 and 383/384 (Hijikata et al., 1991a). Cleavage of the C-terminus of E2 is not as 
efficient and various E2 species have been described. These include E2, E2-p7 and E2- 
p7-NS2, which are released after cleavage between amino acids 745/746, 810/811 and 
1027/1028 respectively (numbering according to strain H77). The E2-p7-NS2 product is 
a short-lived precursor and is cleaved to release either E2 or E2-p7, which is stable and 
sometimes remains uncleaved (Lin et al., 1994, Dubuisson et al., 1994).
Both El and E2 are modified by V-linked glycosylation. This was determined by 
endoglycosidase digestion, which resulted in deglycosylated forms of El and E2 with 
molecular weights of approximately 21 kDa and 36 kDa respectively (Grakoui et al., 
1993a). From the amino acid sequence of genotype 1 (H77), El is predicted to have 5 
glycosylation sites with 11 in E2 (Miyamura & Matsuura, 1993). In the other strains and 
genotypes, the number of predicted glycosylation sites differs by up to 3. It was recently 
shown that the predicted 5th glycosylation site at position 325 in genotype la  El was not 
used (Meunier et al., 1999). Mutagenesis revealed that this was due to the presence of a 
proline residue immediately following the recognition sequence.
The HCV glycoproteins have hydrophobic domains in the C-termini which act as 
membrane anchors and gives the proteins a type I membrane topology (Rice, 1996). 
Deletion of the hydrophobic domain results in secretion of the protein and this allows the
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transmembrane domain (TMD) to be mapped to specific residues (Figure 1.7). The TMD 
of E2 maps to aa 718 to 746 (Cocquerel et al., 1998) and is composed of two hydrophobic 
stretches connected by a short hydrophilic segment (Cocquerel et ah, 2000). The TMD of 
El has a similar organisation and was initially mapped toaa311 to 383 (Michalak et al., 
1997). However, a study using chimeric proteins of the CD4 ectodomain fused to C- 
terminal hydrophobic sequences of E l, identified aa 353 as being the N-terminal limit of 
the El TMD (Cocquerel et al., 1999). It was suggested that El contained a second 
membrane anchor between aa 262 and 290 (Matsuura et al., 1994) but proteins truncated 
beyond these residues were still secreted, so it is unlikely that this region functions as a 
true membrane anchor. The TMDs of El and E2 are multifunctional. As well as 
anchoring the protein in the lipid membrane, their C-terminal halves act as ER signal 
sequences for E2 and p7 respectively and play a major role in subcellular localisation and 
assembly of the HCV envelope glycoprotein complex (see sections 1.4.4. and 1.4.5.).
1.4.4. HCV glycoprotein complexes
Expression of the HCV polyprotein and identification of the cleavage products revealed 
that El was coprecipitated by E2 antisera, implying that the El and E2 proteins interact to 
form a complex (Grakoui et al., 1993a). These E1E2 complexes were also identified in 
several other studies using both viral and non-viral expression systems (Lanford et al., 
1993, Ralston et al., 1993, Selby et al., 1994, Dubuisson et al., 1994, Deleersnyder et al., 
1997). Further characterisation of the E1E2 complex has relied on these expression 
systems because of the lack of a cell culture system that produces viral particles. The 
recent report of a full-length selectable replicon (Pietschmann et ah, 2001) paves the way 
for characterisation of the glycoprotein complex in the context of a replicating genome but 
unfortunately there is still no evidence of virus particle assembly in this system.
Initial characterisation of the E1E2 complex expressed using vaccinia virus recombinants 
provided contradictory reports, with Ralston et al. (1993) describing a non-covalently- 
linked complex, whereas Grakoui et al. (1993a) reported a complex linked by disulphide 
bonds. Subsequent studies using different HCV strains, expression vectors and cell lines
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showed that two forms of complex were detected in the same cell extract (Dubuisson et 
al., 1994, Dubuisson & Rice, 1996). They were a heterodimer of El and E2 stabilised by 
non-covalent interactions and a high molecular weight, disulphide-linked aggregate. The 
non-covalently associated E1E2 heterodimer might be the functional subunit of the HCV 
virion envelope. The structure of the glycoproteins on the virion envelope has not been 
determined but the heterodimer is commonly termed the “native” complex. This is 
formed by proteins following a productive folding pathway (Deleersnyder et al., 1997). 
Disulphide-linked aggregates are thought to be misfolded proteins that have followed a 
non-productive folding pathway (Dubuisson et al., 1994) (Figure 1.8). It is possible to 
distinguish between these two complexes with the use of non-reducing gel electrophoresis 
conditions and conformation-dependent antibodies. In the absence of reducing agents 
such as P-mercaptoethanol (p-ME) or dithiothreitol (DTT), the disulphide-linked proteins 
are retarded at the top of the gel, whereas the non-covalently linked proteins migrate as 
monomers. Deleersnyder et al. (1997) were able to distinguish between the two forms of 
complex by using a conformation-sensitive E2 antibody (H2) that selectively recognised 
the native complex. Another such antibody (H53) has also been used for similar purposes 
(Cocquerel et al., 1998). Other E2 or El antibodies used in studies on complex formation 
have recognised proteins involved in both aggregates and native complex. Interestingly, 
there are reports of human monoclonal antibodies that recognise both aggregates and 
native complex (Cardoso et al., 1998, Habersetzer et al., 1998). It has been suggested 
that aggregate formation is an artefact of high-level expression of the glycoproteins in cell 
culture but the isolation of these human antibodies suggests that both forms of complex 
are present in a natural infection.
I.4.4.I. Native E1E2 complexes
Kinetic studies have demonstrated that the formation of native complex is slow 
(Deleersnyder et al., 1997). Dubuisson & Rice (1996) determined the rate of 
intramolecular disulphide bond formation in El and E2 by analysing the appearance of 
denatured, oxidised forms of the proteins, which adopt a more compact structure due to 
accumulation of intramolecular disulphide bonds and therefore have greater mobility on
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Figure 1.8. A model for HCV glycoprotein assembly. After cleavage 
from the polyprotein, the glycoproteins can follow two different pathways. 
In the non productive pathway, El and E2 form heterogeneous aggregates 
stabilised by disulphide bonds. These aggregates can interact with the 
molecular chaperones BiP and calreticulin. In the productive pathway, El 
and E2 fold slowly and interact to form a noncovalent heterodimer. During 
their folding, HCV glycoproteins interact with calnexin, and E2 plays a 
chaperone-like role for E l.  Disulphide bonds are indicated by S-S.
(Taken from Dubuisson, 2000).
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the gel. Intramolecular disulphide bond formation for El was considerably slower than 
for E2, suggesting that this may be the rate limiting step for formation of native E1E2 
complexes. The conformation-sensitive antibody that specifically recognised E2 
associated with native complex, recognised both E2 and the unprocessed E2-p7 species 
(Deleersnyder et al., 1997), although it is not known if both E2 and E2-p7 are found in 
mature virions. Certainly for the BK strain of HCV (genotype lb), cleavage at the E2-p7 
junction is known to be efficient (Dubuisson et al., 1994) and therefore, for this strain at 
least, it is unlikely E2-p7 would be part of the native complex.
1.4.4.2. Aggregated E1E2 complexes
HCV glycoprotein aggregates are characterised by intermolecular disulphide bonds and a 
molecular mass greater than 158 kDa (Seong et al., 1998). It has also been shown that El 
and E2 form aggregates when expressed individually, therefore glycoprotein aggregates 
may contain intermolecular disulphide bonds between E1/E2, El /El and E2/E2 (Michalak 
et al., 1997). It appears that this is further complicated by the presence of non-covalent 
interactions as well as covalent interactions in the aggregate (Patel et al., 1999a). As 
mentioned earlier, it has been suggested that aggregate formation is an artefact of 
glycoprotein over-expression in cell culture. However, the appearance of such aggregates 
in cell lines where protein expression is tightly regulated, suggests that this is not the case 
(Duvet et al., 1998). Therefore aggregate formation may be an intrinsic property of HCV 
glycoproteins. It has been suggested that this may be a tactic employed by the virus to 
down-regulate particle formation and hence minimise exposure of viral antigens to the 
immune system (Choukhi et al., 1999). Foumillier et al. (1999) have also shown that the 
aggregate can induce antibodies that are able to neutralise binding of E2 to susceptible 
cells and furthermore, the native complex was unable to induce a significant antibody 
response. In conclusion, the glycoprotein aggregate may well play a functional role in the 
virus life cycle.
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1.4.4.3. Requirements for E1E2 complex formation
Deletion of the C-terminal transmembrane domain of E2 has been shown to abolish the 
formation of the E1E2 complex (Selby et al., 1994). Cocquerel et al. (1998) 
demonstrated that a chimeric protein consisting of the E2 ectodomain fused to the CD4 
membrane anchor was no longer able to interact with E l . Conversely, it was shown that a 
chimeric protein containing the TMD of E2 fused to the ectodomain of Herpes simplex 
virus (HSV) 1 gD was sufficient for interaction with El (Patel et al., 2001). The E2 TMD 
was also essential for correct folding of El and native complex formation. There is also a 
report that N-terminal regions in E2 and El are important for the E1/E2 interaction (Yi et 
al., 1997). The major El-interacting site on E2 was mapped to a discontinuous region 
within aa 415-500 and the highly conserved “WHY” tripeptide (aa 489-491) was crucial 
for this interaction. These data indicate that, in addition to an interaction via their TMDs, 
El and E2 may interact via regions in their ectodomains as well.
There is no apparent difference in the folding of E2 when expressed in the presence and 
absence of El but in the absence of E2, El does not fold correctly (Michalak et al., 1997). 
Using chimeric proteins, Patel et al. (2001) showed that it is the C-terminal domain of E2 
(containing the TMD) which is essential for ensuring correct folding of E l . Therefore E2 
has a “chaperone-like” role which is predominantly mediated by its TMD but may also 
involve regions in the ectodomain. A recent report also indicated that core was required 
for the correct folding of El (Merola et al., 2001). Dubuisson et al. (2000) have 
demonstrated that glycosylation of El is improved by the presence of E2 and membrane 
insertion of E2 has been shown to be stabilised by the presence of El (Cocquerel et al., 
2001). Therefore the maturation of the glycoproteins is tightly coupled. In addition, El 
and E2 have been shown to interact with molecular chaperones such as calnexin, 
calreticulin and BiP (Dubuisson & Rice, 1996, Choukhi et al., 1998), which promote 
folding of glycoproteins in the ER (see section 1.4.6).
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1.4.5. Subcellular localisation of HCV glycoproteins
The HCV glycoprotein complexes are retained in the ER, as demonstrated by their 
intracellular distribution, lack of complex glycans and the absence of cell-surface 
expression (Dubuisson et al., 1994). This was confirmed by Cocquerel et al. (1998) and 
the E2 protein expressed in the absence of El showed a similar intracellular distribution to 
the E1E2 complex and was not resistant to digestion with Endo H. This indicated that E2 
had not moved into the medial and trans-Golgi apparatus. Therefore an ER retention 
signal should be present in the ER. Replacement of the TMD of E2 with the membrane 
anchor sequence of CD4 (a protein normally expressed on the cell surface), resulted in 
expression of the E2 ectodomain on the cell surface and conversely, a chimeric protein 
containing the ectodomain of CD4 fused to the TMD of E2 was retained in the ER 
(Cocquerel et al., 1998). These data indicated that an ER retention signal is located in the 
C-terminal 29 amino acids of E2. Similarly, the use of chimeric proteins has identified an 
ER retention signal in the C-terminal 31 amino acids of El (Cocquerel et al., 1999, Flint 
& McKeating, 1999). ER retention was not due to misfolding of El in the absence of E2, 
as the chimeric proteins did not form aggregates and were recognised by a conformation- 
sensitive antibody (Flint & McKeating, 1999). It was concluded that the TMDs of El and 
E2 provided signals for ER retention of the glycoprotein complex. The highly conserved, 
charged residues between the two hydrophobic domains in the TMDs of El and E2 were 
shown to be crucial to ER retention (Cocquerel et al., 2000).
ER localisation could be due to retention in the ER or retrieval from the cis Golgi. To 
determine if the HCV glycoproteins can cycle between these two compartments, Duvet et 
al. (1998) examined the sensitivity of the glycoproteins to the glycosidase Endo D. If 
glycoproteins enter the cis Golgi, their oligosaccharides chains would be exposed to Golgi 
a-mannosidase I, which processes high mannose (Man9GlcNAc2) sugars to MansGlcNAc2 
(Komfeld & Komfeld, 1985). Molecules containing Man5GlcNAc2 should be sensitive to 
Endo D but the HCV glycoproteins remained Endo D-resistant, indicating that they did 
not cycle between the ER and cis Golgi departments. However, a recent study has 
provided contradictory evidence that the HCV structural proteins were located in the
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intermediate compartment and cis Golgi complex as well as the ER (Martire et al., 2001). 
In this study the HCV structural proteins were expressed from a stably transfected clone 
and were under the control of an inducible promoter. The authors proposed that this 
system prevented protein over-expression, which could lead to accumulation of misfolded 
proteins in the ER. Using confocal immunofluorescence microscopy, cell fractionation 
and immunoelectron microscopy, a small proportion of the proteins were localised to the 
intermediate compartment and cis Golgi region, while the majority were retained in the 
ER. The accumulation of complex V-linked glycans was not examined in this study, so 
these results cannot be directly compared to those of Duvet et al. (1998). Confirmation of 
the exact localisation on the HCV glycoproteins awaits the development of a model 
system in which to study virus particle assembly.
1.4.6. Association of HCV glycoproteins with folding proteins
The ER contains molecular chaperones, which associate specifically with incompletely 
folded proteins and increase the efficiency by which they acquire their correct 3- 
dimensional structure. They therefore play a role in quality control in that they prevent 
exit of misfolded proteins from the ER (see section 1.5.). The ER chaperone proteins 
include the immunoglobulin heavy-chain binding protein (BiP/GRP78), glucose regulated 
protein (GRP94), calreticulin and calnexin. An interaction with calnexin and/or 
calreticulin has been shown for several viral glycoproteins such as vesicular stomatitis 
virus G protein (Hammond & Helenius, 1994), Semliki Forest virus p62 and El and 
influenza haemagglutinin (Molinari & Helenius, 2000). The preference for glycoproteins 
is due to their lectin-like affinity for monoglucosylated V-linked glycans and binding and 
release of substrate glycoproteins depends on trimming and reglucosylation of the N- 
linked glycans (Herbert et al., 1995).
Calnexin, calreticulin and BiP have all been shown to interact with El and E2, whereas no 
interaction has been detected with GRP94 (Dubuisson & Rice, 1996, Choukhi et al., 1998, 
Liberman et al., 1999). Calnexin was shown to interact preferentially with monomeric 
HCV glycoproteins and native complexes, while calreticulin and BiP associated
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preferentially with aggregates (Choukhi et al., 1998). This indicated that calnexin was 
involved in the productive folding pathway of HCV glycoprotein complex formation, 
whereas calreticulin and BiP were involved in the non-productive pathway. The 
association of the HCV glycoproteins with calnexin and calreticulin was faster than with 
BiP but there was no appreciable difference between the kinetics of association with 
calnexin and calreticulin (Choukhi et al. 1998). This suggested that rather than 
interacting sequentially with the glycoproteins, calnexin and calreticulin recognise 
proteins that are in different states of folding. Over-expression of calnexin, calreticulin or 
BiP did not improve the formation of native E1E2 complexes (Choukhi et al., 1998), 
which suggested that a proper balance of chaperone activities is required for optimal 
folding.
The ER also contains other folding enzymes such as protein disulphide isomerase (PDI) 
and peptidyl proline isomerase (PPI). PDI catalyses the formation of disulphide bonds 
and PPI is involved in proline isomerisation (Gething & Sambrook, 1992). The 
conservation of cysteine and proline residues in the HCV glycoproteins suggests that these 
residues are important for folding, so the two afore mentioned enzymes are likely to be 
involved in folding of El and E2, but as yet this has not been documented.
1.5. Folding of glycoproteins in the ER
The lumen of the ER is a critical site for protein maturation. Newly synthesised 
membrane and secretory proteins are transported into the ER in a largely unfolded state. 
Specialised proteins within the ER facilitate optimal folding and assembly of the new 
proteins, which confers stability and determines their biological activity.
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1.5.1. Targeting proteins to the ER
Proteins that are destined for secretion or insertion into cellular membranes are targeted to 
the ER  during translation by a  signal peptide. This :signal sequence is characterised by its 
hydrophobic nature and is recognised by the signal recognition particle (SRP) as it 
emerges from tbe ribosome (Siegel, 1995). The ribosom e/nascent polypeptide chain/SRJP 
complex docks at the E R  membrane via the SRP receptor. Once boiund, SRP’ is; displaced 
and translation continues while the nascent polypeptide chain is simultaneously 
transferred into the translocon. The translocon is a m ultisubunit complex in the ER 
membrane. It form s a  membrane channel and i:s responsible for the transfe r o f 
polypeptide chains across the lipid bilayer (Figure 1.9). On the lumenal side o f the ER 
membrane, signal peptidase cleaves the signal peptide from  the polypeptide chain.
1.5.2. Gly cosy la tion
During translocation o f  the polypeptide chain, oligosaccharyl transferase (which is 
associated with the transl ocation machinery) adds N- linked glycan to the growing 
polypeptide chain as 14-residue oligosaccharides (Glc3M an9 GlcNAc2 ) (Parodi, 1999).
The oli gosacc harides axe added to the side chains o f asparagine residues in the consensus 
sequence N -X-S/T, where X is any amino acid e xc ept proline. Transfer o f the 
oligosaccharide occurs co-transLatiornally and can occur as soon as 12-14 aa residues o f the 
polypeptide chain have been transferred into the ER lumen, if a suitable acceptor site is 
present. Immediately follo wing addition o f G lcjM angGlcNA^, three glucose residues are 
removed sequentially by glucosi dase I (for the first glucose residue) and glueo sidase II 
(for the remaining two residues) to> yield Mang>GlcNAc2  (Parodi, 1999). During this 
process an interm ediate glycan (Glc]M an7 _9GlcNAc2) is formed and this is recognised by 
calnexi n and calreticulin, which bind and monitor folding o f  the protein (see section 
1.5.3). Once correctly folded, the chaperones are released. The high mannose 
oli gosaccharide m oieties are further trim m ed by ER mannosidase, yielding Mans; species. 
Transport to the Golgi compartments will result In further modification o f the glycans.
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Figure 1.9. ER signal peptides and SRP direct ribosomes to the ER 
membrane. The SRP binds to the exposed ER signal peptide and to 
the ribosome, thereby inducing a pause in translation. The SRP 
receptor in the ER membrane binds the SRP ribosome complex.
In a poorly understood reaction that involves multiple GTP-binding 
proteins, the SRP is released, leaving the ribosome on the ER 
membrane. A multisubunit protein translocation apparatus in the ER 
membrane then inserts the polypeptide chain into the membrane and 
transfers it across the lipid bilayer. (Taken from Alberts et al., 1994)
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1.5.3. Protein folding in the ER
Folding of proteins in the ER begins before translation is complete, although the time 
taken to reach the final conformational state varies between proteins. The ER contains 
specialised proteins which assist the newly synthesised protein in reaching its final 
conformational state. As mentioned earlier, folding enzymes such as PDI and PPI are 
responsible for catalysing disulphide bond formation and isomerisation of proline peptide 
bonds, respectively. These two folding steps may be rate-limiting. As well as forming 
native disulphide bonds, PDI is also involved in unscrambling wrong cysteine bridges into 
native ones (Braakman & van Anken, 2000).
The ER also contains a group of proteins termed molecular chaperones, which bind to 
unfolded and misfolded proteins to assist them in attaining their native state and prevent 
their exit from the ER. Two major classes of molecular chaperones have been identified. 
The first class includes members of the heat shock protein 70 class, which in the ER is BiP 
(grp78). BiP has an affinity for hydrophobic stretches of amino acids, which are usually 
exposed on unfolded or misfolded proteins. The second class consists of the lectin 
chaperones, calnexin and calreticulin. Both these chaperones bind to monoglucosylated 
forms of AMinked glycans present on the unfolded protein (Helenius et al., 1997). These 
are formed either during maturation of the oligosaccharide precursors as described in 
section 1.5.2. or as a result of reglucosylation of fully-trimmed oligosaccharides by the 
enzyme UDP-glucose:glycoprotein glucosyltransferase (GT) (Parodi, 1999). This 
enzyme is responsible for quality control, as reglucosylation results in renewed binding to 
calnexin and calreticulin. Therefore a cycle of glucose removal and addition is coupled to 
chaperone binding and release, during which the protein folds and is checked for structural 
quality (Figure 1.10). Calnexin and calreticulin can apparently bind to the same glycan, 
as demonstrated by folding of the influenza A virus HA molecule (Herbert et al., 1997) 
but they sometimes show specificity for particular glycans, which seems to depend on the 
location of the glycan in the newly synthesised protein. It has been shown that the 
presence of AMinked glycans within 50 residues of the N-terminus promotes association 
with calnexin/calreticulin rather than BiP (Molinari & Helenius, 2000). The association
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Figure 1.10. Schematic representation o f  the model proposed for 
the quality control o f  glycoprotein folding in the ER. Sad faces 
represent misfolded glycoproteins whereas happy ones are properly 
folded species. CNX: calnexin; CRT: calreticulin; OT: oligosacch- 
aryltransferase; GI: glucosidase I; GII: glucosidase II; GT: UDP- 
Glc:glycoprotein glucosyltransferase; D: degradation; G: golgi. 
(Taken from Parodi, 1999).
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Figure 1.11. Role o f  molecular chaperones in the endoplasmic reticulum 
(ER) in protein folding. During synthesis,secretory and membrane proteins 
are cotranslationally translocated into the lumen o f  the ER through an 
aqueous gated channel (1). They then bind to molecular chaperones (2) and 
begin the folding process, which is facilitated by the chaperones and by 
folding and processing enzymes (3). After completion o f  the folding and 
modifications (5), the proteins (7) dissociate from the chaperones (6) and are 
transported to the Golgi apparatus by vesicular transport. W hen folding or 
assembly o f  proteins is not completed successfully (4), the misfolded proteins, 
bound to the chaperones, are retained in the ER (8). This retention also signals 
the synthesis o f  new chaperones (12). The misfolded proteins may then be 
transported back out o f  the ER to the cytoplasm by retrograde translocation 
(9 & 10). They are then degraded in the cytoplasm (11).
(Taken from Kuznetsov & Nigam, 1998).
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of molecular chaperones with their substrates is normally short-lived but if the protein 
does not fold properly, this association may become stable and prolonged, thereby 
retaining the misfolded protein in the ER (Figure 1.11).
1.5.4. ER stress response
The accumulation of misfolded proteins in the ER would drastically affect the functioning 
of the cell, because approximately one third of all cellular proteins attain their proper 
tertiary structure in the ER. Eukaryotic cells have devised various mechanisms for 
relieving the ER stress induced by the accumulation of incorrectly folded proteins. These 
include transcriptional induction, translational attenuation (together known as the unfolded 
protein response (UPR)) (Patil & Walter, 2001) and protein degradation.
I.5.4.I. Transcriptional activation
When misfolded protein accumulate in the ER, a signal is sent across the ER membrane 
into the nuclear and cytoplasmic compartments. This results in transcriptional 
upregulation of a set of target genes (Kaufman, 1999). These genes include those that 
encode most of the chaperones and enzymes involved in protein folding in the ER. In this 
respect it is not unexpected to find that expression of HCV E2 leads to activation of the 
grp78 (encodes BiP) and grp94 (encodes GRP94) promoters (Liberman et al., 1999), 
presumably due to the accumulation of E2 aggregates in the ER. The number of known 
targets of transcriptional upregulation has increased greatly and includes proteins working 
at every stage of the secretory pathway.
The mechanism of the UPR was initially characterised in the budding yeast, 
Saccharomyces cerevisiae. IRE1 is a central component of the UPR and functions by 
sensing the accumulation of unfolded protein accumulation in the ER lumen and 
transmitting signals across the ER membrane. IRE1 is a type I transmembrane protein 
with a stress-sensing N-terminal domain in the ER lumen and a protein kinase C-terminal 
domain in the cytoplasm. In unstressed cells, the lumenal domain forms a stable complex
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with BiP. BiP is released on accumulation of misfolded proteins in the ER lumen and this 
converts IRE1 to an oligomeric active state (Bertolotti et al., 2000). This is accompanied 
by trans-autophosphorylation via its kinase domain, which in turn stimulates the 
endonuclease activity present in its most C-terminal domain. The IRE1 endonuclease 
splices out an intron from the HAC1U (uninduced) precursor mRNA, which encodes the 
basic leucine zipper transcription factor Haclp (Sidrauski & Walter, 1997). The 5’ and 3’ 
halves of the mRNA are rejoined by tRNA ligase Rlglp (Sidrauski et al., 1996), 
generating a new mRNA, HAC11, which encodes a functional Haclp. Haclp enters the 
nucleus and activates target gene transcription by binding to an upstream sequence called 
the unfolded protein response element (UPRE) (Cox & Walter, 1996) (Figure 1.12). 
Mammalian homologues of IRE1 include human IR Ela and mouse IRE1 p. IR Ela is 
expressed in all cell types, whereas IRElp expression is mainly confined to cells of the 
gut. Another mammalian protein has recently been identified, which shares homology 
with IRE1, IR Ela and IREip in its lumenal domain but its cytoplasmic domain lacks 
endonuclease activity and shares homology with eIF2a kinases (Figure 1.13a). This 
human protein is called PERK or PEK (Shi et al., 1998, Harding et al., 1999).
1.5.4.2. Translational attenuation
A notable feature of the UPR is the rapid repression of protein synthesis. This 
phenomenon is mediated by PERK (Harding et al., 1999). Its lumenal domain has been 
shown to be interchangeable with that of IRE1 (Bertolotti et al., 2000), so it is also 
responsible for sensing ER stress via an interaction with BiP. However, its cytoplasmic 
domain shows -40% homology to PKR, an eIF2a kinase. When active, PERK 
oligomerises and trans-autophosphorylates like IRE1 but its active kinase domain 
phosphorylates the translation initiation factor, eIF2a (Figure 1.13b). This causes a 
down-regulation in overall protein translation by preventing the association of mRNA 
with the ribosomal 60S and 40S subunits. Harding et al. (2000) showed that cells in 
which both copies of the PERK gene had been deleted (PERKT), have lost the ability to 
attenuate translation in response to accumulation of unfolded proteins and hence 
experience greater ER stress, as shown by increased levels of IR E la phosphorylation.
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Figure 1.12. Illustration o f  the unfolded protein response. IRE1 
senses the accumulation o f  unfolded protein in the ER lumen via its 
N domain. IRE 1 then oligomerises, trans-autophosphorylates via 
its kinase domain (K) and activates the endonuclease in the tail 
domain (T). The endonuclease cuts HAC1 mRNA at two sites, 
removing an intron. The two exons are rejoined by the ligase Rig 1 p 
and /T4C7'mRNA is translated into Haclp ', a transcriptional 
activator that upregulates expression o f  UPR target genes after 
binding to the UPRE in the promoters o f  genes encoding ER- 
chaperones and other proteins. (Taken from Patil & Walter, 2001).
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Figure 1.13. a) The domain structure o f  PERK, Irel and PKR.
SP: signal peptide, TM: transmembrane domain. The lumenal 
domain is cross-hatched and the predicted two lobes o f  the kinase 
domain, conserved between PERK and PKR, are shown in black. 
(Taken from H a rd in g ^  al., 1999).
b) Proposed mechanism for ER stress-induced translational 
attenuation. The N-terminal domain o f  PERK senses accumulation 
o f  unfolded proteins in the ER lumen. It oligomerises and auto- 
phosphorylates, which activates the kinase domain and results in 
phosphorylation o f  eIF2a at serine 51, leading to inhibition o f  
translation initiation. (Taken from Mori, 2000).
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Recently another human homologue of IRE 1 has been identified, which is also responsible 
for translational repression. This protein, hIREl p, which shows 76% identity with the 
previously identified mouse IREp, functions as a repressor of protein synthesis through 
cleavage of 28S ribosomal RNA during ER stress (Iwawaki et al., 2001). Therefore there 
appear to be two distinct pathways for attenuation of protein translation in response to ER 
stress. It is not yet known how the ER chaperones escape from this general inhibition of 
translation.
1.5.4.3. Protein degradation
After prolonged association with the molecular chaperones, particularly BiP, the 
misfolded proteins are targeted for degradation. It has been shown that these misfolded 
proteins can be extruded from the ER into the cytoplasm via the translocon, where they 
undergo ubiquitin- and proteasome-dependent degradation (Figure 1.11). This process is 
termed ER-associated degradation (ERAD) (Plemper & Wolf, 1999). It has been shown 
that ERAD and the UPR are intimately co-ordinated, as the degree of activation of the 
UPR correlates with the severity of the ERAD defect (Patil & Walter, 2001).
Certain viral proteins, such as human cytomegalovirus (HCMV) US2 and US11, and 
Human immunodeficiency virus (HIV) 1 Vpu can exploit this retrograde translocation to 
mediate export and degradation of ER-associated MHC class I and CD4 molecules, 
respectively (Plemper & Wolf, 1999). Accumulation of misfolded proteins in the ER is 
also responsible for the pathology of several diseases. This is due either to the protein not 
reaching its final destination, as in cystic fibrosis, or the accumulation of protein in the ER 
causing cellular damage, as in hepatocellular damage in patients with alpha]-antitrypsin 
deficiency (Kuznetsov & Nigam, 1998).
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1.6. Putative HCV receptors
1.6.1. Cellular tropism of HCV
The cellular tropism of a virus is important when considering candidates for the virus 
receptor. The principle site of HCV replication was thought to be the liver and therefore 
it seemed likely that the cellular receptor would be a hepatocyte-specific molecule. 
However there are also reports of both positive and negative strand HCV RNA being 
present in polymorphonuclear leukocytes, monocytes/macrophages and B-lymphocytes 
but not T-lymphocytes (Lerat et al., 1998). Replication in B-cells is an intriguing link 
with a lymphoproliferative disorder (mixed cryoglobulinaemia) which is associated with 
HCV infection (see section 1.7.2.3). There are also reports of high prevalence of HCV 
infection amongst patients with B-cell lymphoma (Dammacco et al., 1998), although this 
has not been confirmed. These data suggest that HCV may affect B-cell proliferation. 
Studies on HCV quasispecies have shown the presence of distinct variants between the 
liver and PBMC fractions (Okuda et al., 1999), which further suggests the possibility of 
extrahepatic sites of replication.
1.6.2. E2 mediates binding of HCV
Binding of HCV virions to a specific receptor is most likely to be mediated by the 
outermost proteins on the virion, in this case the envelope proteins El and E2. The lack 
of a model system in which virus particles are produced has meant that it has not been 
possible to study events involved in virus entry, such as attachment and penetration. 
Lagging et al. (1998) described the production of pseudotypic vesicular stomatitis virus 
(VSV) particles, which contained chimeric envelope proteins consisting of the HCV El 
and E2 ectodomains fused to the TMD and cytoplasmic tail of VSV G protein. The 
pseudotype virus was able to infect mammalian cells (HepG2 and BHK) and entry was 
inhibited by sera from chimpanzees which had been immunised with El and E2. This 
suggested that El and E2 could mediate infection of cells. It has subsequently been
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shown that cells expressing these same chimeric El and E2 proteins can induce cell fusion 
in a low pH-dependent manner, which suggests entry via an endosomal pathway 
(Takikawa et al., 2000).
The development of an assay for the binding of E2 to human cells was the first step 
towards the identification of a cellular receptor. This assay was based on the ability of 
antibodies or sera to prevent binding of E2 to the human MOLT-4 T-cell line, which was 
termed neutralisation of binding (NOB) (Rosa et al., 1996). E2 expressed in mammalian 
cells but not yeast, showed strong binding, while E2 expressed in insect cells showed 
weak binding. As well as binding MOLT-4 T cells, E2 also bound to hepatocarcinoma 
cell lines and human B-cells but not mouse cell lines or mouse hepatocytes. Sera from 
chimpanzees vaccinated with E1/E2 and protected from challenge were shown to inhibit 
binding of E2 to cells, suggesting that this could be a surrogate test for the presence of 
neutralising antibodies. Ishii et al. (1998) demonstrated the presence of antibodies 
capable of blocking E2-binding to cells in the sera of patients with chronic hepatitis C. 
Furthermore, the appearance of antibodies with high NOB titres coincided with viral 
clearance in those patients who resolved the infection naturally. Overall, these results 
strongly indicated that E2 is responsible for mediating binding of HCV to cells.
1.6.3. CD81
To identify the E2-binding molecule on human cells, Pileri et al. (1998) screened a cDNA 
library prepared from the MOLT-4 T-cell line and identified a clone which conferred E2- 
binding to mouse fibroblast cells on transient transfection. This clone encoded human 
CD81.
CD81 is a 26-kDa surface protein composed of four transmembrane domains and two 
extracellular loops (reviewed by Levy et al., 1998) (Figure 1.14). It shares this topology 
with the tetraspanin family of proteins, which are expressed in evolutionarily diverse 
organisms. CD81 is expressed on most human tissues with the exception of red blood 
cells and platelets, although most studies have concentrated on expression in lymphoid
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cells. On B-cells CD81 is present in a complex with CD 19, CD21 and Leu-13 (Fearon & 
Carter, 1995). This complex amplifies the signalling cascade generated through the B- 
cell receptor. Binding of anti-CD81 antibody induces anti-proliferative effects on B-cells 
and triggers aggregation (Levy et al., 1998). It is not known if these effects mimic those 
induced by the natural ligand of CD81 or if they are specific to the antibodies. CD81 is 
also found on the surface of T cells in association with CD4, CD8 and CD82 (Imai et al.,
1995) and may be involved in the maturation of T cells. It is likely that CD81 is part of a 
protein complex on the surfaces of non-lymphoid cells as well, but, as yet, these have not 
been characterised.
Binding of E2 was mapped to the large extracellular loop (LEL) of CD81 (Pileri et al.,
1998). This is the most variable part of the molecule but significantly, it is highly 
conserved in humans and chimpanzees, the only species permissive for HCV infection.
In accordance with this, E2 does not bind to murine, rat, hamster or African green monkey 
cells (Flint et al., 1999a). However, E2 does bind to rat cells transfected with human 
CD81, suggesting that additional human-cell-specific factors are not required for the E2 
interaction with CD81 (Flint et al., 1999a). African green money CD81 differs from 
human CD81 at only 4 residues. Mutation of these residues revealed that amino acid 186 
in human CD81 was crucial for interaction with E2 (Higginbottom et al., 2000). 
Additionally, the four cysteine residues in the LEL form two disulphide bridges, the 
integrity of which was necessary for the binding of E2 (Petracca et al., 2000). The 
species specificity of the E2/CD81 interaction appeared to correlate with susceptibility to 
HCV infection but the finding that E2 could bind to CD81 of tamarins (Allander et al., 
2000a, Meola et al., 2000), which are not permissive for HCV infection, puts this into 
doubt.
In an assay more relevant to the in vivo situation, recombinant human CD81 LEL attached 
to polystyrene beads has been shown to precipitate HCV virions from infectious 
chimpanzee plasma (Pileri et al., 1998, Hadlock et al., 2000). Pre-incubation of the 
plasma with sera from protected ElE2-vaccinated chimpanzees inhibited binding of 
virions to CD81, whereas no inhibition was seen with sera from unprotected, vaccinated
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chimpanzees. This indicated that antibodies capable of neutralising infection in vivo are 
also capable of inhibiting the interaction of HCV with CD81. Several studies have used 
antibodies with known epitopes to map the region of E2 involved in the CD81 interaction 
(Flint et al., 1999a, Yagnik et al., 2000, Patel et al., 2000, Owsianka et al., 2001). There 
is no absolute agreement from these studies but it is clear that the CD81-binding region on 
E2 is discontinuous and therefore conformational in nature. This was confirmed when it 
was shown that the aggregated form of E2 did not bind CD81 and interestingly, 
intracellular forms of E2 were bound with greater affinity than secreted forms (Flint et al., 
2000). The secreted forms of E2 were found to have acquired more complex glycans 
during passage through the secretory pathways of the cell, which suggests that 
glycosylation might affect the interaction with CD81. As yet, the type of glycans present 
on the glycoproteins in the HCV virion is not known. Despite the strong interaction 
between E2 and CD81, cell-surface expressed E2 does not induce fusion with CD81- 
positive cells (Flint et al., 1999b), which would be necessary for infection. It therefore 
seems likely that if CD81 is involved in viral attachment, other factors (cellular and/or 
viral) are required for virus entry.
1.6.4. LDL receptor
The LDL receptor has also been proposed as a candidate for HCV receptor because HCV 
particles have been shown to associate with low-density lipoproteins (LDLs) (Prince et al.,
1996). Indeed it has been shown that HCV is able to bind to COS-7 cells which express 
the LDL receptor (Monazahian et al., 1999). Moreover, Agnello et al. (1999) have 
reported that endocytosis of HCV and two other flaviviruses, hepatitis G virus and BVDV, 
is mediated by LDL receptors. Endocytosis of HCV correlated with LDL receptor 
activity and was completely inhibited in the presence of anti-LDL receptor antibody. 
However, small amounts of intracellular HCV were detected in LDL-deficient fibroblasts 
inoculated with HCV and could not be inhibited by anti-LDL receptor antibody, so viruses 
can enter these cells by some other means.
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In a recent study, Wunschmann et al. (2000) compared the characteristics of the LDL 
receptor and CD81 in terms of binding both HCV and E2. In agreement with previous 
reports, HCV binding and entry correlated with LDL receptor expression and was 
inhibited by the addition of LDL but not soluble CD81. In contrast, E2 binding was 
independent of LDL receptor expression and was inhibited by human soluble CD81 but 
not mouse soluble CD81 or LDL. There was no evidence of an interaction between E2 
and LDL or E2 and LDL receptor, so the mechanism by which HCV interacts with LDL 
or the LDL receptor remains unclear. The authors concluded that while E2 binds CD81, 
virus particles utilise the LDL receptor for binding and entry.
1.7. Natural history of HCV infection
1.7.1. Epidemiology and transmission
It is estimated that there are more than 170 million persons infected with HCV world-wide 
(World Health Organization, 1997). In developed countries the prevalence rate of HCV 
amongst the general population is less than 3% but higher prevalence rates are seen in 
parts of Africa and Eastern Europe (Naoumov, 1999). Egypt has a particularly high 
prevalence rate of 22%, which has been shown to be due to reuse of needles during a 
national campaign to treat schistosomiasis infections during the 1970s (Frank et al., 2000).
HCV is generally transmitted by the parenteral route, although cases of non-parenteral 
transmission have also been documented.
Parenteral Transmission of HCV 
There is more than an 80% chance of acquiring HCV infection when receiving blood from 
an HCV-positive blood donor (Thomas, 2000). However, the risk of transfusion- 
transmission of HCV has been substantially reduced since the introduction of blood donor 
screening for anti-HCV antibodies in 1989. Certain groups are particularly at risk for 
parenteral transmission of HCV. Prior to blood donor screening, haemophiliac patients
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and patients with immunoglobulin deficiency were at risk from contaminated batches of 
clotting factor and immunoglobulin, respectively (Heintges & Wands, 1997, Yap et al.,
1994). Health care workers are at risk through occupational exposure to blood and 
needle-stick injuries. Procedures such as tattooing, piercing and acupuncture are also 
associated with potential risk of HCV transmission. Illicit use of drugs, especially by 
injection, now accounts for the majority of HCV infections in developed countries. At 
least 60% of new HCV infections in the United States are due to intravenous drug use 
(IVDU) (Alter, 1999).
Non-parenteral Transmission of HCV
Cases of hepatitis C infection have been reported where there is no apparent evidence of 
parenteral exposure. Sexual transmission of HCV is infrequent, although co-infection 
with HIV seems to increase the risk of HCV sexual transmission (Lissen et al., 1993). 
Perinatal transmission of HCV is uncommon and most likely occurs at the time of 
delivery. A correlation has been shown between the risk of vertical transmission and the 
HCV RNA titre of the mother (Ohto et al., 1994).
1.7.2. Clinical features of HCV infection
The natural history of HCV infection has been difficult to assess because of the usually 
silent onset of the acute phase. Also, the interval between infection and the development 
of cirrhosis can exceed 30 years, which means there are few prospective studies.
I.7.2.I. Acute hepatitis C
The majority of patients with acute infection are symptom free but when symptoms are 
present, they develop an average of 7 weeks after exposure (Alter et al., 1992).
Symptoms usually consist of jaundice, malaise and nausea. The acute phase of HCV 
infection is characterised by elevated levels of serum alanine aminotransferase (ALT) 
released from damaged hepatocytes. HCV RNA becomes detectable by RT-PCR in
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serum 1-3 weeks after exposure (Farci et al., 1991) and anti-HCV antibodies appear 
within 3-20 weeks (Hoofnagle, 1997).
1.7.2.2. Chronic hepatitis C
Following acute infection it is estimated that only about 15-20% of patients will clear the 
virus. In the remaining 80%, HCV infection becomes chronic as demonstrated by the 
persistence of HCV RNA in serum. Serum ALT levels are abnormal or intermittently 
elevated in roughly two thirds of chronically-infected patients but remain normal in the 
other third (Theodore & Fried, 2000). Disease progression during chronic HCV infection 
is typically slow and less than 20% of patients develop cirrhosis of the liver within 20 
years post infection (Marcellin, 1999). The rate of progression of fibrosis towards 
cirrhosis can be predicted by the severity of hepatic fibrosis, as diagnosed by liver biopsy 
and certain factors such as alcohol intake, co-infection with HIV or HBV and older age 
can accelerate the development of fibrosis (Lauer & Walker, 2001). HCV-related end- 
stage liver disease is now a leading cause of liver transplantation (Marcellin, 1999) and 
cirrhosis may lead to hepatocellular carcinoma (HCC) in 0.4-2.5% of patients (Colombo,
1999).
1.7.2.3. Extrahepatic HCV-associated diseases
A variety of extra-hepatic manifestations have been associated with HCV infection. Most 
of these are immune complex-related diseases and include mixed cryoglobulinaemia 
(aggregation of immunoglobulins in blood vessels) and membranoproliferative 
glomerulonephritis (deposition of immune complexes in the capillaries of the glomeruli) 
(Manns & Rambusch, 1999). Porphyria cutanea tarda (alteration of iron metabolism) has 
also been associated with HCV as 60-80% of patients in one study had anti-HCV 
antibodies (Gumber & Chopra, 1995).
44
Chapter 1
1.7.3. Genotypes and natural history of HCV
The issue of whether pathogenicity of HCV infection varies according to genotype is 
controversial, as there are multiple other host and viral factors which could influence the 
disease. There have been reports that genotype lb was associated with a greater 
frequency of cirrhosis and the development of HCC than other genotypes (Dusheiko et al., 
1994, Bruno et al., 1997), while other studies have failed to show any relationship 
between disease severity and genotype (Benvegnu et al., 1997, Brechot, 1997). It has 
also been shown that patients infected with genotype lb are older than those infected with 
other genotypes (Zein et al., 1996) and therefore more severe disease may be a reflection 
of a longer duration of infection rather than a more pathogenic form of HCV (Zein, 2000). 
A recent report has described an association between genotype 3 and steatosis, a condition 
in which lipids accumulate in the liver (Rubbia-Brandt et al., 2001). The potential role of 
other risk factors such as obesity, alcohol abuse and IVDU was taken into account and the 
link was still found to be significant, although further studies await confirmation of this 
correlation.
1.8. Treatment and prevention of HCV
1.8.1. Interferon as a therapeutic agent for chronic hepatitis C
Before the identification of HCV in 1989, interferon (IFN) was shown to have beneficial 
effects against NANB hepatitis (Hoofnagle et al., 1986) and had been used successfully 
for the treatment of malignancies (Kaposi’s sarcoma, leukaemia) and viral infections due 
to HBV and human papillomavirus. Interferon alpha (IFNa) became the recommended 
therapy for chronic hepatitis C and a 6 month course of treatment led to normalisation of 
ALT levels, loss of detectable virus in blood and reduction of inflammation in liver 
biopsies in some patients. However, IFNa monotherapy showed a sustained response in 
a minority of patients and even when the duration of treatment was extended to 12
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months, only 13-25% of patients showed a sustained response (Poynard et al., 1996).
More recently, the nucleoside analogue, ribavirin, has been used in combination with 
IFNa and this has increased the efficacy of treatment. When used alone, ribavirin leads 
to a reduction in serum ALT levels but has no effect on HCV viraemia (Di Bisceglie et al.,
1995), but when used in combination with IFNa, the response rates increase to 38-43% 
for 48 weeks of treatment (Poynard et al., 1998, McHutchinson et al., 1998).
Combination therapy is also beneficial for patients who have relapsed after initial 
treatment with IFNa alone (Schalm et al., 1997). IFNa and ribavirin are currently the 
only licensed treatments for HCV in the UK (Booth et al., 2001). The efficacy of a 
pegylated form of IFN has recently been investigated. This involves attaching a large 
inactive molecule, polyethylene glycol, to the protein, which increases the half-life and 
allows larger doses to be given infrequently. Initial trials have shown that a combination 
of pegylated interferon and ribavirin leads to sustained response in approximately 60% of 
patients (Trepo et al., 2000) (Figure 1.15).
1.8.2. Predicting response to interferon treatment
The high cost of IFN treatment and the associated side effects mean that the identification 
of markers that are predictive of treatment outcome would be of great importance. Both 
host and viral factors have been identified as being predictive of response to IFN treatment 
but it is often difficult to assess the effects of these factors independently and none is 
sufficiently accurate to exclude a patient from IFN treatment. Host factors that have been 
reported as predictive of response are sex and age, with younger women having a more 
favourable outcome of treatment than older men (Booth et al., 2001). The better response 
in younger patients (<40 years) may be related to a shorter duration of infection and less 
severe liver disease. In fact, the absence of cirrhosis has been associated with an 
increased response to IFN therapy (Tsubota et al., 1994, Jouet et al., 1994).
Viral factors thought to be important in determining treatment response include genotype, 
level of viraemia and level of viral heterogeneity. Multivariant analyses have shown that 
genotype is an independent factor associated with treatment outcome, with genotypes 2
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and 3 being predictive of a better response than genotype 1 (Davis & Lau, 1997, Trepo,
2000). In a trial using IFNa and ribavirin, 69% of non-genotype 1 infected patients 
showed sustained response after 24 weeks of treatment compared to 16% of patients 
infected with genotype 1 (McHutchinson et al., 1998). Similar figures were reported by 
Poynard et al. (1998). If treatment was extended to 48 weeks, genotype 1 patients 
showed an increased response rate of around 30%, whereas the response rate of non­
genotype 1 patients remained the same. Therefore it is recommended that patients 
infected with non HCV-1 (mostly genotypes 2 and 3) should be treated for only 6 months 
(Booth et al., 2001). An inverse correlation between pre-treatment HCV RNA titre and 
response to IFN has been reported (Lau et al., 1993, Trepo, 2000). In the trials reported 
by McHutchinson et al. (1998) and Poynard et al. (1998), patients with <2x106 copies/ml 
of viral RNA showed a 44% response rate, compared to 27% for those with >2x106 
copies/ml. The degree of sequence heterogeneity has also been reported as predictive of 
IFN responsiveness (Kanazawa et al., 1994). It has been suggested that this is because 
the greater the diversity of variants, the greater the chance that IFN-resistant species will 
be present or escape mutants will be generated that will survive IFN treatment.
1.8.3. Antiviral action of interferon
Interferons comprise a family of cytokines secreted in eukaryotic cells in response to 
various stimuli, particularly viral infection. Upon binding to their specific cell surface 
receptors on target cells, IFNs trigger a cascade of intracellular reactions that culminate in 
the induction of a large number of genes. The protein products of these genes mediate the 
multiple effects of IFN, which include induction of an antiviral state in the target cells, 
immune stimulation and regulation of cell growth (reviewed by Goodboum et al., 2000), 
all of which serve to block virus replication and target infected cells for apoptosis to limit 
virus spread. There are two types of IFN. Type I IFNs include IFNa and IFNp and are 
produced by most cell types, in direct response to virus infection. Type II IFN consists of 
IFNy, which is produced by activated T lymphocytes and natural killer cells in response to 
their recognition of virus-infected cells (Goodboum et al., 2000).
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1.8.3.1. dsRNA-dependent protein kinase R (PKR)
Type I IFNs induce the synthesis of PKR, a serine/threonine kinase. PKR has an N- 
terminal regulatory domain that contains a dsRNA-binding site and a C-terminal catalytic 
domain. PKR is normally inactive and is activated on binding dsRNA. This induces a 
conformational change that triggers the catalytic activities of PKR. The active form of 
PKR is a dimer, with two PKR molecules binding one molecule of dsRNA. Once bound, 
PKR autophosphorylates and this renders the kinase domain active. Activated PKR 
phosphorylates the a  subunit of the eukaryotic translation initiation factor eIF2a, which 
results in inhibition of protein synthesis. Viruses that produce dsRNA during the course 
of their replication cycles have the potential to activate PKR, which in turn leads to a 
block in viral replication at the level of protein synthesis. Several viruses have evolved 
mechanisms to block the effects of PKR (Gale & Katze, 1998). Influenza virus activates 
a cellular inhibitor of PKR, which binds PKR and inhibits kinase activity (Polyak et al.,
1996). Influenza virus also encodes a protein, NS1, which blocks the dsRNA-mediated 
activation of PKR, possibly by sequestering dsRNA (Lu et a i, 1995). The vaccinia virus 
E3L protein acts via a similar mechanism (Chang et al., 1992). HIV, adenovirus and 
HSV also produce PKR inhibitors (Gale & Katz, 1998).
1.8.3.2. 2’-5’ oligoadenylate synthetase / RNAse L pathway
Type I IFNs induce the synthesis of 2’-5’ oligoadenylate (2-5(A)) synthetases. 2-5 (A) 
synthetases are activated by dsRNA and catalyse the synthesis of small oligomers, with a 
unique 2’-5’ linkage, from precursor ATP. These products bind to endoribonuclease L 
(RNAse L) and induce its activation via dimerisation. Activated RNAse L cleaves 
ssRNA, including mRNA and thereby inhibits protein synthesis. EMCV, HSV and HIV 
have all evolved strategies to counteract this pathway (Goodboum et al., 2000).
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1.8.3.3. Alternative antiviral pathways
The Mx proteins are also induced by IFNa. The human protein, MxA, inhibits the 
growth of several RNA viruses including members of the Orthomyxoviridae, 
Paramyxoviridae, Rhabdoviridae and Bunyaviridae (Pavlovic et al., 1990, Zhao et al., 
1996, Frese et al., 1996). Additional antiviral pathways also exist, as demonstrated by the 
generation of mice that are triply deficient in RNAse L, PKR and Mxl (Zhou et al., 1999). 
IFNa can also control viral infections indirectly, by activating the cellular immune system 
to destroy virus infected cells (Goodboum et al., 2000).
1.8.4. Mechanisms for HCV evasion of the interferon response
Some HCV-infected individuals do not respond to treatment and for patients with HCV 
genotype 1, over 50 % are resistant to IFNa therapy. This strongly suggests that HCV 
has evolved a mechanism or mechanisms to overcome the antiviral effects of IFNa. Two 
HCV proteins, NS5A and E2, have been implicated in mediating resistance to IFNa.
1.8.4.1. NS5A and ISDR
Enomoto et al. (1995) compared the full-length sequences of IFN-responsive and IFN- 
sensitive vimses from Japanese HCV genotype lb-infected patients and identified a region 
within NS5 A that corresponded with IFN responsiveness. This region was designated the 
interferon-sensitivity-determining region (ISDR) and patients who responded to IFN 
therapy were found to carry vimses that contained 4 or more amino acid residues that 
differed from the reference sequence HCV-J in this region. Many studies from North 
America and Europe subsequently reported conflicting data on the relationship between 
ISDR sequence and clinical resistance to IFN (Zeuzem et al., 1997, Khorsi et al., 1997, 
Hofgartner et al., 1997). These apparently discrepant results were difficult to interpret 
due to viral strain differences and differences in study design or treatment regimen. A 
recent statistical analysis of all the published ISDR sequences in the database has
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nonetheless demonstrated a positive association between ISDR sequence and IFN 
resistance (Withered & Beineke, 2001).
A mechanism for IFN resistance was first proposed by Gale et al. (1997) when it was 
demonstrated that NS5A is capable of interacting with PKR and inhibiting its 
phosphorylation of eIF2a. Moreover, PKR and NS5A interact directly via the ISDR 
domain and mutating the ISDR sequence to match that seen in responders in the Enomoto 
study, blocks the interaction (Gale et al., 1998). However, subsequent studies cast doubt 
on the role of the ISDR. Using a virus-rescue system, NS5A could rescue interferon- 
sensitive viruses from the antiviral effects of IFN in cell culture and the same effects were 
seen when using NS5A-deletion mutants lacking the ISDR domain (Polyak et al., 1999). 
More recently, Podevin et al. (2001) have used NS5A derived from responder and non­
responder patients and shown that NS5A can rescue IFN-sensitive viruses irrespective of 
the number of mutations in the ISDR or the phenotype of HCV from which the NS5A 
protein is derived. Therefore, while NS5A has been shown to block the antiviral effects 
of IFN, sequence differences in the ISDR may not be responsible for this activity. NS5A 
has recently been shown to induce the expression of interleukin-8 (IL-8), a cytokine that 
inhibits the antiviral action of IFN. Increasing levels of NS5A correlated directly with the 
increasing IL-8 concentrations and NS5A was shown to"activate the promoter of the IL-8 
gene (Polyak et al., 2001a). IL-8 alone was able to mimic the effects of NS5A on 
rescuing IFN-sensitive viruses in cell culture. Additionally, HCV-infected patients who 
did not respond to IFN treatment were found to have raised levels of IL-8 (Polyak et al., 
2001b). This suggests that as well as conferring IFN-resistance via an interaction with 
PKR, NS5A may also be involved in an alternative pathway, mediated by IL-8. This may 
explain why the ISDR sequence is not always predictive of sensitivity/resistance to IFN.
I.8.4.2. E2 and PePHD
Taylor et al. (1999) identified a 12 amino acid sequence in the E2 protein that has 
homology to several putative autophosphorylation sites within the N-terminal domain of 
PKR, as well as its natural substrate, eIF2a. This sequence was termed the PKR- eIF2a
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phosphorylation homology domain (PePHD). The PePHDs of the more IFN-resistant 
genotypes (la  and lb) show greater homology to PKR and eIF2a than those of the less 
IFN-resistant genotypes (2 and 3). Further investigation demonstrated that genotype la 
E2 interacted with PKR and the interaction was dependent on the PePHD. E2 was also 
shown to inhibit PKR activity in yeast and HeLa cells and the PePHD was required for 
this inhibition. The exact mechanism by which E2 inhibits PKR is not known but it is not 
thought to be due to E2 acting as a pseudosubstrate for PKR autophosphorylation sites 
(Taylor et al., 2001). Furthermore, PKR activity was not inhibited when the PePHD was 
mutated to resemble that of genotype 2 and 3 (Taylor et al., 1999). These results 
indicated that the PePHD might be responsible for the inherent resistance of genotype 1 
and sensitivity of genotypes 2 and 3. However, several clinical studies have shown that 
the PePHD is a highly conserved region and when mutations do occur, they are not 
predictive of response to IFN treatment for genotype 1 (Chayama et al., 2000, Berg et al., 
2000, Polyak et al., 2000) or resistance to IFN treatment for genotype 3 (Sarrazin et al., 
2000a, Puig-Basagoiti et al., 2001). Therefore the role of E2 in mediating IFN resistance 
remains to be established.
1.8.5. Prevention of HCV infection
There is currently no vaccine available for the prevention of HCV infection. Difficulties 
in HCV vaccine development include the heterogeneous nature of HCV, not only with 
respect to genotypes/subtypes but also because of its quasispecies nature, which leads to 
rapid changes within an infected individual, possibly due to immune selection. There is 
also no evidence of lasting immunity in individuals who resolve the infection, leaving the 
potential for reinfection with the same or different HCV isolate. The two main areas of 
vaccine development have included recombinant subunit proteins and nucleic acids as 
candidate vaccines. Vaccination of chimpanzees with purified El and E2 proteins 
resulted in protection from challenge with homologous virus in 5/7 vaccinees (Choo et al.,
1994). However, the same chimpanzees were not protected from challenge with a 
heterologous HCV strain, implying the absence of cross-neutralising antibodies 
(Houghton, 2000). The potential use of DNA vaccines has also been explored. DNA
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vaccines against other viruses (e.g. influenza, rabies, HSV1) successfully induce humoral 
and cellular immune responses (Ulmer et al., 1993, Xiang et al., 1994, Manickan et al.,
1995) and therefore potentially may result in both prevention of infection and 
immunotherapy of chronic infections. Immunisation of mice with naked plasmid DNA 
encoding HCV core can generate both humoral and lymphoproliferative immune 
responses (Lagging et al., 1995, Inchauspe et al., 1997). Plasmids encoding HCV E2 
have also been used successfully to induce anti-E2 antibodies in immunised mice and 
macaques (Nakano et al., 1997, Foms et al., 1999). As with most areas of HCV research, 
the development of an HCV vaccine is hampered by the lack of a susceptible, small 
animal model.
With no vaccine available, the most effective means of reducing the incidence of HCV 
infection is the screening of all blood donations and educating susceptible individuals, 
particularly IVDUs and hospital staff, on safe practices.
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1.9. Aims and objectives
The aim of this project was to amplify the HCV structural genes from the serum of a
patient infected with HCV genotype 3, to express the genotype 3 glycoproteins and to
compare their characteristics with those of genotype 1.
The following objectives were met:
1. To amplify the genotype 3 structural genes by RT-PCR and to obtain a majority 
sequence to compare with published genotype 3 and 1 sequences.
2. To express the genotype 3 El and E2 proteins and to investigate the reactivity of 
genotype 1 anti-El and anti-E2 antibodies against the genotype 3 proteins.
3. To compare the glycoproteins of genotypes 1 and 3 with respect to subcellular 
localisation, complex formation and glycosylation status.
4. To determine if genotype 3 E2 binds to human CD81, as reported for genotype 1
E2 (Pileri et al., 1998) and to investigate the ability of HCV genotypes 1 and 3 
virions in human sera to bind CD81.
5. To determine whether or not the PePHD within the E2 protein is predictive of 
response to interferon treatment in patients infected with HCV genotype 3. To 
investigate the proposed interaction of genotype 1 E2 with PKR (Taylor et al
1999).
53
Chapter 2
Chapter 2 
Materials and Methods
2.1. Materials
2.1.1. Bacterial Strains
Escherichia coli (E. coli) strain
DH5a
Top 10F’ (Invitrogen)
Epicurian Coli XL 1-Blue (Stratagene)
Phenotype
F'/endAX hsdRXl (rk"m+) supEAA thi\ 
recAX gyrA (Nalr) relAX A(lacZYA- 
argF) U169 (<\>S0dlac(lacZ)M\5)
F'{/acIq, Tn/0(TetR)} mcrA A(mrr- 
hsdRMS-mcrBC) (j)80/acZAM15A/acX74 
deoR recAX araDX39 A(ara-leu)l691 
gall] galK r;75L(StrR) endAX nupG
recAX endAX gyrA96 thi-X hsdRXl 
supEAA relAX lac [F’ pro AB  /<2cIqZAM 15 
Tn 10 (Tetr)]c
2.1.2. Vectors
pSFVl expression vector (Liljestrom & Garoff, 1991) Life Technologies 
pcDNA3.1(+) Invitrogen
pGEMl Promega
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2.1.3. Synthetic oligonucleotides
Oligonucleotides were initially synthesised “in house” by Alex Orr and Dave McNab 
and later ordered from MWG-Biotech (Germany).
2.1.4. Kits and enzymes for DNA/protein modification
Recovery Quick Flow Mini kit, Recovery Quick Flow Hybaid
Midi kit, DNA purification kit
Restriction Enzymes, CIP, T4 DNA ligase, NTPs Roche
SP6 RNA polymerase, m7G(5’)G RNA cap analogue,
Endoglycosidase H, PNGase F
QIAmp RNA extraction kit, SuperFect transfection reagent, Qiagen
Omni script reverse transcriptase
Superscript reverse transcriptase, RNase H Life Technologies
RNasin Promega
QuikChange Site-directed Mutagenesis kit Stratagene
Advantage 2 PCR kit, Advantage TaqPlus PCR kit Clontech
2.1.5. Mammalian cell lines and culture media
Proteins were expressed in baby hamster kidney (BHK) (clone C l3) cells and human 
hepatocellular carcinoma (Huh7) cells.
Glasgow minimal Eagles Medium (GMEM), Dulbecco’s modified Eagles Medium 
(DMEM), new bom calf serum (NBCS), foetal calf serum (FBS),
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penicillin/streptomycin, L-glutamine, non-essential amino acids and S.O.C medium 
were supplied by Life Technologies.
PBS, PBS(A), versene, trypsin, L-broth, 2YT broth, tryptose phosphate (TP) broth, and 
components of Eagles medium used during radiolabelling were produced “in-house” 
by the media department.
2.1.6. Human sera
Human sera used in this study were stored in the Regional Virus Lab at Gartnavel 
General Hospital, Glasgow. Informed consent for the use of the sera was obtained. 
Sera were separated within 4 hours of sampling by Carol-Anne Smith. Sera were 
stored in small aliquots at -20°C or in liquid nitrogen.
2.1.7. Radiochemicals
35S-L-Methionine lOpCi/pl Amersham
2.1.8. Antibodies
Monoclonal and polyclonal antibodies raised against A. Patel
HCV El and E2 (see Table 4.2.), anti-GST polyclonal
Conformational anti-E2 MAbs H30, H50, H53, H60 J. Dubuisson
H61.
Anti-calnexin polyclonal antibody 
Anti-calnexin monoclonal antibody
J. McLauchlan 
StressGen
Biotechnologies Corp.
Anti-PERK polyclonal antibody (N-18), 
Anti-PKR monoclonal antibody (B-10) 
Anti-PKR monoclonal antibody (71/10)
Santa Cruz, 
Biotechnology. 
A. Hovenessian
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Anti-mouse FITC raised in rabbit Dako Ltd.
Anti-rabbit HRP Diagnostics Scotland
Anti-mouse FITC raised in goat, anti-goat Cy3 raised Sigma
in rabbit, anti-mouse Cy5 raised in goat, anti-rabbit 
TRITC raised in goat, anti-mouse HRP, protein-A-HRP, 
rabbit anti-mouse IgG.
2.1.9. Chemicals
Unless otherwise stated, all chemicals were obtained from Sigma Chemical Co., BDH 
Chemicals Ltd or Prolabo.
ECL, Hybond nitrocellulose membrane Amersham
30% acrylamide, ammonium persulphate Bio-Rad
En Hance DuPont
Dried skimmed milk Marvel
Viraferon (interferon alpha-2b)
TMB substrate
SP(Brinny) Co., Ireland 
Zymed Laboratories
2.1.10. cDNA clones and proteins
The pSFVl clones of core, E l, E2 and E2 alone from strains H77 and Glasgow were 
provided by J. Patel. The pcDNA clone encoding El and E2 of strain H77 was 
provided by A. Patel. The extracellular loop 2 of human CD81, expressed as a GST 
fusion protein, was provided by A. Patel.
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2.1.11. Solutions
Agarose gel loading buffer 
Boiling mix
Cell Lysis solution 
Citrate phosphate buffer 
Eagles A 
Eagles B
Eagles (low meth)
Elution solution 
Equilibration solution
Fix solution
Immunoprecipitation 
(IP) buffer
L-broth
L-broth agar
Lysis buffer
Neutralisation solution
0.1M EDTA, 50% sucrose, lpg/ml bromophenol blue.
29% SGB, 6% (w/v) SDS, 2M 0-ME (excluded for non­
reducing conditions), 29% glycerol, 1 pg/ml 
bromophenol blue.
200mM NaOH, 1% SDS
0.1M citric acid / 0.2M Na2HP04 (pH 5.5).
1.5mM CaCl2.2H20 , ImM MgS04.7H20, 0.1ml 
concentrated HC1.
50% (v/v) salts/plus, 40% (v/v) amino acids/plus, 3.2% 
(v/v) vitamins (gassed with C 02 to pH 6.5).
7:1 (v/v) Eagles A: Eagles B (1/5 normal concentration 
of methionine), 2% (v/v) acetic acid in dH20.
1250mM NaCl, lOOmM Tris-HCl (pH 8.5).
600mM NaCl, lOOmM sodium acetate / acetic acid 
(pH 5.0), 0.15% Triton X-100.
50% methanol, 7% acetic acid in dH20.
50mM Tris-HCl (pH 7.6), 200mM NaCl, ImM EDTA, 
1% Triton X-100, ImM PMSF, 20mM NEM.
lOg NaCl, lOg Bactopeptone and 5g yeast extract per 
litre.
L-broth plus 1.5% (w/v) agar.
20mM Tris-HCl (pH 7.5), ImM EDTA, 20mM 
iodoacetamide, lOOmM NaCl, 0.5% Triton X-100.
3.2M potassium acetate / acetic acid (pH 5.5).
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PBS
PBS(A)
PBST
PBS(A) plus 6 .8 mM CaCl2 .2 H2 0  and 4mM 
MgCl2 .6H20.
170mM NaCl, 3.4mM KC1, lOmM Na2HP04, 1.8mM 
KH2PO4 , 25mM Tris-HCl (pH 7.2).
PBS(A) plus 0.05% (v/v) Tween 20.
Phosphate buffer 
Resolving gel buffer 
Resuspension solution 
Running gel buffer 
Stacking gel buffer 
TBE(IX)
Towbin buffer 
Trypsin solution 
Versene
0.2M Na2HP04 / 0.2M NaH2P 04.2H20  (pH 7.5).
1.5M Tris-HCl (pH 8.9), 0.4% SDS.
50mM Tris-HCl (pH 8.0), lOmM EDTA, lOOpg/ml 
RNase.
40mM Tris, 185mM glycine, 0.1% SDS.
0.5M Tris-HCl (pH 6.8), 0.4% SDS.
90mM Tris-HCl (pH 8.0), 90mM Boric Acid, ImM 
EDTA
25mM Tris-HCl (pH 8.3), 192mM glycine, 20% (v/v) 
methanol.
0.25% (w/v) Difco trypsin dissolved in PBS(A), 0.005% 
(w/v) phenol red.
0.6mM EDTA in PBS(A), 0.002% (w/v) phenol red.
Wash solution 800mM NaCl, lOOmM sodium acetate / acetic acid 
(pH 5.0).
2.1.12. Other materials and apparatus
X-Omat UV film was purchased from Kodak Ltd., as was developer and fixer for the 
KONICA. All tissue culture plasticware was supplied by Nunc. The immulon 
ELISA plates were purchased from Dynex.
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2.2. Manipulation of DNA and RNA
2.2.1. Purification of synthetic oligonucleotides
At the start of the project, oligonucleotides were synthesised “in-house” and were 
supplied with the DNA molecule covalently linked to a support matrix on a column. 
Oligonucleotides were removed from this column by pushing 1.5ml of ammonia 
through the column between two 5ml syringes at a rate of 0.5ml every 20 minutes.
The solution was mixed by pushing it back and forth through the column several times 
and was then transferred to a screw cap Eppendorf tube. To remove the amide 
protecting groups, the oligonucleotide was deprotected by incubating the solution at 
55°C for 5 hours and then cooled to room temperature. The oligonucleotide was dried 
under vacuum overnight to remove the ammonia and the pellet resuspended in 50pl 
deionised water. Oligonucleotides were stored at -20°C until required. In the latter 
stages of the project oligonucleotides were ordered from MWG-Biotech (Germany) 
and were supplied as lyophilised pellets.
2.2.2. Small scale preparation of plasmid DNA (minipreps)
The extraction of plasmid DNA from culture was performed using the Hybaid 
Recovery Quick Flow Mini Kit according to the manufacturers instructions. Briefly, 
single colonies of transformed bacteria were inoculated into 5ml of L-broth containing 
lOOpg/ml ampicillin and incubated with shaking overnight at 37°C. A 1.5ml aliquot 
of culture was centrifuged at 13000rpm for 30sec, the supernatant removed and the cell 
pellet resuspended in 50pl Pre-Lysis solution. This was followed by the addition of 
1 OOpl of Cell Lysis solution, which was mixed thoroughly until the solution was clear 
and viscous. 75pl of Neutralising solution was added before centrifugation for 3 min 
at 13000rpm. The supernatant was transferred to a Hybaid spin filter, 250pl of 
Binding buffer was added and the mixture centrifuged for 1 min before the addition of 
350pl of Wash solution and a further lmin centrifugation. The pellet was dried by a 
final lmin centrifugation and the DNA eluted by the addition of 50pl d ^ O  and a 
30sec centrifugation. The plasmid DNA was stored at -20°C.
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2.2.3. Large scale preparation of plasmid DNA (midipreps)
Large quantities of plasmid DNA were isolated from cells using the Hybaid Recovery 
Quick Flow Midi Kit as specified by the manufacturers instructions. 100ml of L- 
broth containing lOOpg/ml ampicillin was inoculated with bacteria and incubated with 
shaking overnight at 37°C. Cells were pelleted by centrifugation at 3000rpm for 20 
min at room temperature. The supernatant was removed completely and the cell pellet 
resuspended in 4ml of cold Resuspension solution (containing RNase). 4ml of Cell 
Lysis solution was added and mixed by inversion before leaving at room temperature 
for no longer than 5 min. 4ml of Neutralisation solution was added, immediately 
mixed by inversion and the cell debris removed by centrifugation at 12000rpm for 
30min at 20°C. The Hybaid columns were equilibrated with 10ml of Equilibration 
solution prior to the addition of the supernatant which was allowed to flow through the 
column by gravity. Two 10ml aliquots of Wash solution were applied to the column 
and the DNA was eluted by the addition of 5ml of Elution solution. The DNA 
solution was mixed with 3.5ml of isopropanol and the DNA precipitated by 
centrifugation at 12000rpm for 1 hour at 4°C. The DNA pellet was washed with 70% 
ethanol and centrifuged at 12000rpm for 30 min at 4°C. Finally, the DNA was air- 
dried and resuspended in lOOpl of dH20 and stored at -20°C.
2.2.4. Quantification of plasmid DNA and oligonucleotides
The He^iosa version 4.55 spectrophotometer was used to determine DNA 
concentrations by measuring the absorbance at 260nm, assuming 1 A260 equals 
50pg/ml for double stranded plasmid DNA and 1 A260 equals 20pg/ml for single­
stranded oligonucleotides. Purity of nucleic acids was determined by readings at 
260nm and 280nm (A260/A280), where a ratio of 1.8 indicated that the preparation was 
relatively free of protein contaminants.
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2.2.5. Restriction enzyme digestion of DNA
Restriction enzyme digestions and conditions as outlined by Sambrook et al. (1989) 
were adhered to, or adapted as required. All reactions were incubated at 37°C (or the 
temperature specified by the supplier) for 2-3 hours in a total volume of 20pl which 
contained 1OU of restriction enzyme per 1 pg of DNA in the buffer supplied for the 
enzyme. Digestion reactions were terminated by addition of lA volume of agarose gel 
loading buffer and resulting DNA fragments were analysed by agarose gel 
electrophoresis as described in 2.2.10.1.
2.2.6. Dephosphorylation of linearised plasmid DNA
Removal of the 5’ terminal phosphates of digested vectors was carried out using calf 
intestinal phosphatase (CIP). In a total volume of 50pl, the DNA was added to 5pi of 
lOx CIP buffer (Roche) and 1 unit of CIP per 5pg of DNA. The reaction was 
incubated at 37°C for 30 min and then another unit of CIP per 5pg of DNA was added 
and incubation continued for a further 30 min. The linearised, dephosphorylated 
vector was purified as described in 2.2.10.3 in preparation for ligation.
2.2.7. Extraction of RNA from human sera
RNA was extracted from human sera using the Qiagen QIAmp kit, as specified by 
manufacterers instructions. For lysis of virus particles, a 140pl aliquot of serum was 
combined with 560pl of AVL buffer containing carrier RNA and mixed by vortexing, 
then centrifugation for 1 min at 8000rpm. The mixture was incubated at room 
temperature for 10 min before the addition of 560pl of ethanol (100%) and further 
vortexing. A 630pl aliquot of the solution was added to a QIAmp spin column and 
centrifuged for 1 min at 8000 rpm. The filtrate was discarded and the remaining 
630pl applied to the column and the centrifugation step repeated. The filter was 
washed with 500pl of buffer AW1, centrifuged at 1 min at 8000rpm and the filtrate 
discarded. This wash step was repeated with 500 pi of buffer AW2 and centrifugation 
at 14000rpm for 3 min. The RNA was eluted by the addition of 60pl buffer AYE,
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incubation at room temperature for 1 min and centrifugation at 8000rpm for 1 min.
The viral RNA was stored at -20°C.
2.2.8. Reverse transcription of RNA
2.2.8.1. Superscript reverse transcriptase
Reverse transcription was performed using SUPERSCRIPT reverse transcriptase from 
Life Technologies. In a total volume of 12.5pl, 40 pmoles of primer (MS2) was 
added to 3 pi of viral RNA. Primer annealing occurred by heating to 70°C for 10 min 
and cooling to 4°C. This was added to a reaction mix containing 50mM Tris-HCl (pH 
8.3), 7.5mM KC1, 3mM MgCl2, 20 units of RNAsin, lOmM DTT, ImM each of dGTP, 
dATP, dTTP and dCTP, and 200U of SUPERSCRIPT reverse transcriptase to make a 
total reaction volume of 20pl. This was heated to 42°C for 50 min and 70°C for 15 
min before cooling to 4°C. To remove RNA complementary to the cDNA, 2 units of 
Ribonuclease H (RNAse H) was added and the reaction incubated at 37°C for 20 min. 
cDNA was stored at 4°C.
2.2.8.2. Omniscript reverse transcriptase
For the purposes of quantification, Omniscript reverse transcriptase (Qiagen) was used 
for the reverse transcription reaction. Briefly, 3 pi of RNA was added to 9.7 pi water 
and incubated at 65°C for 5 min then cooled to 4°C. To this was added a mix 
containing 2 pi of 10X RT buffer (Qiagen), 2 pi dNTP mix (5mM each dNTP), 40 
pmoles RT primer, 12U RNasin and 4U Omniscript reverse transcriptase. This mix 
was incubated at 37°C for 60 min and then 93°C for 5 min before cooling to 4°C
2.2.9. Polymerase chain reaction (PCR) amplification of cDNA
Amplification of HCV DNA was performed using “nested” PCR to increase the 
specificity and amount of DNA amplified. Two sets of primers were used, one set
63
Chapter 2
being internal to the other. The products from the first round of amplification were 
used as template for a second round of amplification using the internal primers.
2.2.9.1 Amplification of core, E l and E2
Both first and second round PCR reactions were performed using the Clontech 
Advantage 2 PCR kit which contained a polymerase mix which included AdvanTaq 
DNA polymerase, a small amount of a proofreading polymerase and TaqStart antibody 
to provide automatic hot-start PCR. For the first round PCR reaction, 4pl of cDNA 
was added to a 16pl reaction mixture containing 40mM Tricine-KOH (pH 9.2), 15mM 
KOAc, 3.5mM Mg(OAc)2, 3.75pg/ml BSA, 0.005% Tween20, 0.005% NP-40, 0.2mM 
each of dATP, dCTP, dGTP and dTTP, 16 pmoles of each primer and 0.4pl of the 
polymerase mix. PCR reactions were carried out under the following reaction 
conditions: a denaturation step of 94°C for 4 min and then thermal cycling of 94°C for 
90 sec (strand separation), 65°C for 90 sec (primer annealing) and 70°C for 3 min 
(strand elongation) for 25 cycles before cooling to 10°C. For the second round PCR 
reaction, 1 jul of the first round product was added to a 19pl reaction mixture containing 
the same components as for the first round reaction except, this time using the internal 
set of primers (16 pmoles of each). As for the first round, the reaction was heated to 
94°C for 4 min and then underwent thermal cycling of 94°C for 90 sec, 60-65°C 
(dependent on primer) for 90 sec and 70°C for 3 min for 25 cycles. Finally, the 
reaction was heated to 70°C for 7 min for a final extension step and cooled to 10°C.
For purification of the PCR product, the second round PCR reaction volume was 
increased to 50pl. All PCR reactions were carried out in a Biometra TRIO- 
Thermoblock.
2.2.9.2 Amplification of the PePHD region of E2
Extraction of RNA and reverse transcription were performed as described in 2.2.7 and
2.2.8.1. The PCR reactions were performed using the AdvanTaq Plus PCR kit from 
CLONTECH. This kit used a polymerase mix which contained AdvanTaq DNA 
polymerase and TaqStart antibody for automatic hot start PCR. For the first round 
PCR reaction, 4pl of cDNA was added to a 16pl reaction mixture containing 40mM
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Tricine-KOH (pH 8.0), 16mM KC1, 3.5mM MgCl2, 3.75pg/ml BSA, 0.2mM each of 
dATP, dCTP, dGTP and dTTP, 16 pmoles of each primer and 0.4pl of the polymerase 
mix. Following a 4 min denaturation step at 94°C, the reactions underwent thermal 
cycling of 94°C for 90 sec, 65°C for 90 sec and 68°C for 3 min for 30 cycles. For the 
second round PCR reaction, 1 jlxI of the first round product was added to a 19p i  reaction 
mixture containing the same components as for the first round reaction except, this 
time using the internal set of primers (16 pmoles of each). The second round cycling 
conditions were the same as for the first round except only 25 cycles were used and in 
addition, there was a final extension at 68°C for 7 min. For purification of the PCR 
product, the second round PCR reaction volume was increased to 50pl. All PCR 
reactions were carried out in a Biometra TRIO-Thermoblock.
2.2.9.3 Amplification of HCV cDNA for quantification purposes
For quantification purposes the cDNA was amplified by PCR using a Perkin Elmer 
Applied Biosystems 5700 sequence detection system and all PCR reagents and primers 
were obtained from Applied Bio systems. 1 pi of cDNA was added to a mix 
containing 12.5 pi of PCR mastermix (AmpliTaqGold DNA polymerase and dNTPs), 
7.091 pmoles of EMC HCV F primer, 1.225 pmoles of EMC HCV R primer and 5.1 
pmoles of EMCMGBP fluorescent probe. The cDNA was amplified with the 
following thermal cycling program: 50°C for 2 min, 95°C for 10 min and 40 cycles of 
95°C for 15 sec and 60°C for 1 min. All reactions were quantified against a HCV 
positive serum of known titre to generate a standard curve.
2.2.10. Electrophoretic separation and isolation of DNA
2.2.10.1. Agarose gel electrophoresis
DNA fragments produced by PCR or restriction enzyme digestion were resolved by 
agarose gel electrophoresis. A 1% (w/v) agarose gel was prepared in lx TBE buffer 
and contained a final concentration of 0.05pg/ml of ethidium bromide. Agarose gel 
loading buffer was added to each DNA sample prior to electrophoresis at 60-100V in
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lx  TBE buffer. An appropriately sized molecular weight marker (Roche) was 
included for comparison. Following electrophoresis, DNA was visualised under 
short-wave UV light or, for preparative gels, under long-wave UV light. Photography 
was carried out using the Bio-Rad Gel Doc 2000 Imaging system and accompanying 
software.
2.2.10.2. Purification of DNA from agarose gels
Agarose slices containing appropriate DNA fragments were excised from gels under 
long-wave UV transillumination. The DNA was recovered using the Hybaid 
Recovery DNA Purification Kit II, which uses a silica gel based system. The binding 
buffer containing the silica gel matrix was added to a spin column. The excised gel 
slice was added and incubated at 55°C until the gel had dissolved. The solution was 
applied to the column by centrifugation at 13000 rpm for 30 sec. DNA was washed 
with 500 pi Wash solution (containing ethanol) and the centrifugation step repeated. 
The pellet underwent further centrifugation for 1 min and the DNA was eluted by the 
addition of 10-20 pi DNAse-free water, gentle vortexing and a final centrifugation for 
30 sec.
2.2.10.3. Purification of linearised DNA and digested PCR fragments
Linearised plasmid DNA and PCR fragments were purified from solution using the 
Hybaid Recovery DNA Purification Kit II. The restriction enzyme digestion was 
mixed with binding buffer (provided by the supplier) which contains a silica gel matrix 
and added to a spin column. The solution was applied to the column by centrifugation 
at 13000 rpm for 30 sec. Thereafter, the procedure was the same as described above 
in 2.2.10.2.
2.2.10.4. Phenol/Chloroform extraction
Proteins were removed from bulk restriction enzyme digestions (containing more than
5pg DNA) by the addition of an equal volume of a 25:24:1 solution of
phenol:chloroform:isoamyl alcohol (Sigma). This mixture was mixed vigorously and
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centrifuged for 5 min at 13000rpm. This resulted in the organic layer containing the 
protein, being separated from the aqueous layer containing the nucleic acid. The 
aqueous layer was transferred to an equal volume of a 24:1 solution of 
chloroform:isoamyl alcohol to remove any residual phenol and the centrifugation step 
repeated. Finally, the aqueous layer was removed and the nucleic acid concentrated 
by ethanol precipitation as described in 2.2.10.5.
2.2.10.5. Ethanol precipitation
Nucleic acids were precipitated by the addition of 2 lA volumes of ethanol and 1/10 
volume of 3M sodium acetate. After mixing, the solution was placed on dry ice for 
15-30 min and the precipitated nucleic acids collected by centrifugation at 13000rpm 
for 10 min. The pellet was washed with 70% ethanol and centrifuged at 13000rpm for 
3 min. The pellet was then air-dried and resuspended in 10-50pl of dP^O.
2.2.11. Ligation reactions
Vector and “insert” DNA fragments, prepared by restriction enzyme digestion and 
purification, were ligated in a 1:3 molar ratio. In a total volume of 1 Ojul, the vector 
and insert DNA fragments were combined with lx ligase buffer and 10 units of T4 
DNA ligase. Reactions were incubated at 25°C overnight before transformation of 
competent E.coli as described in 2.4.
2.2.12. In vitro transcription of linearised DNA
Recombinant pSFV 1 constructs were linearised with Spel and purified by 
phenol/chloroform extraction and ethanol precipitation. 1 pg of this linearised 
template was added to a reaction mixture containing transcription buffer (40mM Tris- 
HC1 (pFl 8.0), 6mM MgCb, 2mM spermidine and lOmM DTT), NTP mix (ImM ATP, 
UTP and CTP, 0.5mM GTP), ImM m7G(5’)G RNA cap analogue, ImM DTT, 50 units 
ribonuclease inhibitor (RNasin) and 40 units of SP6 RNA polymerase (as described by 
Liljestrom & Garoff, 1991). The reaction was incubated at 37°C for 2 hours and 2pi
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of the reaction was analysed on a 1% agarose gel. The remaining RNA was used for 
electroporation into mammalian cells as described in 2.6.1.
2.2.13. Automated DNA sequencing
Automated DNA sequencing was carried out (by Lesley Taylor) using an ABI PRISM 
BigDye™ terminator cycle sequencing ready reaction kit. Sequencing was performed 
using an ABI PRISM™ 377 DNA Sequencer.
2.2.14. Site-directed mutagenesis
Site-directed mutagenesis was performed using the QuikChange Site-Directed 
Mutagenesis kit from Stratagene. A set of PCR primers, complementary to opposite 
strands of the plasmid and incorporating the mutation, were designed for each desired 
point mutation. All changes were made consecutively, apart from two, which were 
located close together and therefore done simultaneously.
The PCR reaction was carried out in a total volume of 50pl, including lOng of 
template plasmid, 125ng of each primer, lx buffer (lOmM KC1, lOmM (N H ^SO ^ 
20mM Tris-HCl (pH 8.8), 2mM M gS04, 0.1% Triton X-100, O.lmg/ml BSA), 0.2mM 
each of dATP, dCTP, dGTP and dTTP and 2.5 units of PfuTurbo DNA polymerase. 
The reactions were overlaid with mineral oil. PCR reactions were carried out as 
follows: denaturation at 95°C for 30 sec and then thermal cycling of 95°C for 30 sec, 
55°C for 1 min and 68°C for 12 min for a total of 12 cycles before cooling to 4°C.
PCR cycling conditions were optimised for each set of primers, usually by increasing 
the annealing temperature to 60°C or increasing the number of cycles to 18 or 24. 
Following the PCR, lOpl of the reaction was analysed on a 1% agarose gel to check 
that the PCR product was of the correct size. The remainder of the reaction was 
incubated with 10 units of Dpnl (to remove the parental plasmid) for 1 hour at 37°C. 
lp l of this reaction was then used to transform Epicurian Coli XLl-Blue 
supercompetent cells. Briefly, the cells were thawed on ice, the DNA added and the 
cells placed on ice for 30 min. The cells were then incubated at 42°C for 45 sec and 
placed on ice for a further 2 min before the addition of 500pl S.O.C medium and
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incubation at 37°C for 1 hour with shaking. 500pl of the culture was plated onto L- 
broth agar plates containing 100pg/ml ampicillin and incubated overnight at 37°C. 
Single colonies were inoculated into 5ml of L-broth (containing lOOjug/ml ampicillin) 
and incubated over night at 37°C with shaking. Plasmid DNA was isolated from the 
culture as described in 2.2.2. To ensure that no nicked plasmid DNA was transferred 
to the next mutagenesis reaction, the plasmid DNA was separated on a 1% agarose gel 
and the supercoiled plasmid DNA was cut out of the gel and extracted as described in
2.2.10.2. This DNA was used as a template for the next PCR reaction with a new set 
of mutagenesis primers.
2.3. Preparation of electrocompetent E.coli (DH5a) cells
To prepare electrocompetent bacteria, a 5ml overnight culture of E.coli strain DH5a 
was inoculated into 2 x 400ml 2YT broth. The cells were grown for 3-4 hours at 
37°C in a shaking incubator until the OD550 was approximately 0.6. The culture was 
chilled on ice for 15-30 min before centrifugation at 3000rpm for 10 min at 4°C. The 
cells were gently resuspended in 2 0 0 ml ice-cold deionised water, pelleted as before 
and resuspended again in 100ml water. Following a final centrifugation step, the cells 
were resuspended in 2ml 10% glycerol (in deionised water), aliquoted into 40pl 
volumes, frozen on dry ice and stored at -70°C.
2.4. Transformation of competent E.coli cells
2.4.1. Electroporation of DH5a cells
A 40pl aliquot of electrocompetent E.coli DH5a was thawed on ice before the addition 
of 2pl of the ligation reaction. This mixture was transferred to a chilled 
electroporation cuvette (0.1cm gap, Bio-Rad) and electroporated by a single pulse at 
1800V in a Hybaid Cell Shock apparatus. The cells were resuspended in 1ml of 
S.O.C. medium and incubated at 37°C for 1 hour to allow expression of the antibiotic 
resistance gene. One tenth of the culture was plated onto a L-broth agar plate 
containing 1 OOpg/ml ampicillin and incubated at 37°C overnight.
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2.4.2. Transformation of TOPI OF cells
Occasionally, commercially available chemically competent TOPI OF cells 
(Invitrogen) were used to obtain plasmid DNA. A 50pl aliquot of cells was thawed on 
ice before the addition of 2pl 0.5M P-mercapto ethanol and 2pl of the ligation 
reaction. This mixture was chilled on ice for 30 min and then incubated at 42°C for 
45 seconds to “heat shock” the bacteria and then chilled on ice for another 2 min prior 
to the addition of 950pl S.O.C. medium. The cells were incubated at 37°C for 1 hour 
in a shaking incubator and then plated onto agar plates as described before.
2.5. Maintenance of mammalian cells
2.5.1. BHK cells
BHK cells were cultured in Glasgow minimal Eagles Medium (GMEM) containing 
10% new bom calf serum (NBCS), 4% tryptose phosphate (TP) broth and 100 units/ml 
of penicillin/streptomycin at 37°C with 5% CO2 in 160cm2 tissue culture flasks. Cells 
were harvested at confluency, with a yield of 2-4x107 cells per flask.
2.5.2. Huh7 cells
Huh7 cells were cultured in Dulbecco’s modified Eagles Medium (DMEM) containing 
10% foetal calf serum (FCS), 4mM L-glutamine, IX non-essential amino acids and 
100 units/ml of penicillin/streptomycin at 37°C with 5% CO2 in 160cm2 tissue culture 
flasks. Cells were harvested at confluency, with a yield of 2-4x107 cells per flask.
2.6. Transfection of mammalian cells
2.6.1. Electroporation of recombinant SFV RNA
• 9 *Cells approaching confluency in a 160cm flask were washed with versene at room 
temperature and removed by trypsin treatment. The detached cells were suspended in 
10ml of cell medium and a single cell suspension was achieved by passing the cells
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through a narrow hole 5ml pipette several times. The cells were pelleted by 
centrifugation at 600rpm for 5 min at room temperature, resuspended in 30 ml of 
PBS(A), pelleted again and resuspended in a final volume of PBS(A) to give a
n
concentration o f -1x10 cells/ml. A 0.8ml aliquot of cells was placed in an 
electroporation cuvette (0.4cm gap, Bio-Rad) with the in vitro transcribed recombinant 
pSFVl RNA (2.2.12). The RNA/cell suspension was mixed by inversion and 
electroporated using the Bio-Rad Gene Pulser II apparatus. For BHK cells, the 
electroporation conditions were two pulses (with inversion between pulses) at 1.2kV 
and 25 pF at room temperature. For Huh7 cells the electroporation conditions were 
one pulse at 360V and 950pF at room temperature. The electroporated cells were 
transferred to 6ml of cell medium. Finally, 35mm tissue culture dishes were seeded 
with 2xl06 cells (in 3ml medium) and 13mm coverslips in 24-well plates were seeded 
with 1x10s cells (in 1ml medium). Cells were incubated at 37°C.
2.6.2. Transfection of pcDNA constructs
SuperFect transfection reagent (Qiagen) was used for transfection of Huh7 cells with 
recombinant pcDNA constructs. On the day prior to transfection, 2 x 105 cells were 
seeded onto 35mm plates or 5 x 104 cells onto coverslips in a 24-well plate. On the 
day of transfection the cells had grown to approximately 60% confluency. A pre­
determined amount of DNA (approximately 4pg per 35mm dish, depending on 
construct) was added to lOOpl of cell medium lacking FCS and antibiotics. The 
mixture was mixed thoroughly, incubated for 2-5 min at room temperature and mixed 
again by centrifugation at 13000rpm for a few seconds. A pre-determined amount of 
SuperFect transfection reagent (approximately 8 pi per 35mm dish) was added and 
mixed by pipetting. The mixture was incubated at room temperature for 5-10 min, 
during which time, the cells were washed once with PBS. 600pl of normal cell 
medium was added to each transfection reaction and the mixture added to the cell 
monolayer. The cells were incubated at 37°C for 2-3 hours and were then washed 
once with PBS before normal cell medium was added and incubation continued for 40- 
45 hours to allow for gene expression. When transfecting cells on 13mm coverslips, 
the relative volumes of transfection reagent and medium were reduced as specified by 
the manufacturers instructions.
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2.7. Radiolabelling of cells with 35S-methionine
Cells were radiolabelled with S-methionine 6-8 hours post electroporation. The 
medium was replaced with Eagles medium containing 1/5 normal concentration of 
methionine [Eagles (low meth)]. The cells were then incubated for a further 30 min at 
37°C before the medium was replaced with Eagles (low meth) containing 30pCi/ml 
S-methionine. Cells were radiolabelled for 14 hours at 37°C before harvesting.
2.8. Treatment of Huh7 cells with interferon-a
Cells were treated with Viraferon (interferon alpha-2b) to induce protein kinase R 
(PKR) expression. The medium was removed and replaced with Huh7 cell medium 
containing 1000 IU/ml interferon-a. The cells were incubated for 18 hours at 37°C 
before harvesting.
2.9. Preparation of cell extracts
2.9.1. Western blot analysis
Cells were washed twice with PBS and lysed in 250pl of boiling mix for 10 min at 
room temperature. The cell extract was collected into an Eppendorf and heated to 
100°C for 5 min. Cell extracts were stored at -20°C.
2.9.2. ELISA analysis
Cells were washed twice with PBS and lysed in 500pl of lysis buffer for 30 min at 
4°C. The extracts were collected and the cell debris removed by centrifugation at 
13000rpm for 5 min. The supernatant was stored at 4°C.
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2.9.3. Immunoprecipitation analysis
Cells were washed twice in PBS containing 20mM N-ethylmaleimide (NEM), an 
alkylating agent which blocks free sulphydryl groups on cysteine residues. Cells were 
lysed in 500pl of immunoprecipitation buffer (also containing 20mM NEM) for 10 
min at room temperature. The extracts were collected and the cell debris removed by 
centrifugation at 13000rpm for 5 min. The proteins of interest were isolated from the 
extracts according to the procedure in 2.10.
2.10. Immunoprecipitation
For immunoprecipitation, l-5pl of the appropriate antibody was added to cell lysates 
(prepared as described in 2.9.3) and the mixture incubated at 4°C overnight. Protein- 
A sepharose (7.5mg per precipitation) was equilibrated overnight in IP buffer at 4°C.
A bridging antibody, rabbit anti-mouse antibody (5 pi per precipitation) was added and 
allowed to bind to the protein-A sepharose overnight. The equilibrated protein-A 
resin was washed three times with IP buffer and resuspended in 1 OOXpl (where X was 
the number of precipitations) to achieve a 50% slurry. lOOpl of this protein-A resin 
was added to each precipitaion and protein-A-antibody binding was allowed to occur 
for 1-2 hours at 4°C on a rotator. The protein complexes were subsequently pelleted 
by brief centrifugation at 6000rpm and washed three times with 500pl of IP buffer. 
Bound proteins were eluted with 40pl of boiling mix.
2.11. Deglycosylation of proteins using Endo H and PNGase F
Proteins were immunoprecipitated as described above but were eluted and denatured 
with 0.5% SDS and 1% p-ME at 100°C for 15 min. The solution was cooled on ice 
and the sepharose beads pelleted by brief centrifugation. For endoglycosidase H 
treatment, citrate phosphate buffer (pH 5.5) was added to a final concentration of 
50mM, followed by 0.01 units of endo H. For PNGase F treatment, phosphate buffer 
(pH 7.5) (final concentration of 50mM), NP-40 (1% final concentration) and EDTA 
(final concentration of 2mM) were added, followed by 0.125 units of PNGase F.
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Reactions were incubated at 37°C for 2 hours. Finally, boiling mix was added and the 
deglycosylated proteins analysed by SDS-PAGE as described in 2.12.
2.12. Protein analysis by SDS-PAGE
Proteins were separated by electrophoresis through SDS polyacrylamide gels using the 
discontinuous buffer system (Laemmli, 1970) and the Bio-Rad Miniprotein II 
apparatus. The apparatus and glass plates (10 x 8cm) were assembled according to the 
manufacturers instructions using 1.5mm wide spacers. A 10% acrylamide resolving 
gel mix was used containing 3.6ml of 30% acrylamide solution (consisting of 
acrylamide and A^A’methylene bisacrylamide (ratio 37.5:1), 2.7ml of resolving gel 
buffer, 4.5ml of dP^O, 70pl of 10% ammonium persulphate (APS) and 5pl of 
TEMED. This solution was immediately poured into the gel assembly to 
approximately 2cm from the top of the plates. The resolving gel was overlaid with 
butan-2-ol to leave a smooth interface after polymerisation. After polymerisation, the 
top surface of the resolving gel was washed with resolving gel buffer. The stacking 
gel was prepared containing 1ml of 30% acrylamide solution, 1.5ml of stacking gel 
buffer, 3.5ml dh^O, 50pl 10% APS and 5jal TEMED. This was poured on top of the 
set resolving gel surface and a 1.5mm wide comb inserted to form loading wells for the 
protein samples. Following polymerisation, the comb was removed and the wells 
were washed with running buffer. The gel was placed in the electrophoresis apparatus 
and the reservoirs filled with running buffer.
Protein samples that were analysed under reducing electrophoretic conditions only, 
were denatured and reduced in boiling mix containing p-ME by heating to 95°C for 5 
min before loading. Alternatively, for analysis of proteins under both reducing and 
non-reducing conditions, samples were denatured in boiling mix lacking P-ME and 
heated to 95°C for 5 min. The samples were then divided into two parts and DTT (to 
a final concentration of 20mM) was added to one part. The reduction of disulphide 
bonds on proteins in this sample was further promoted by another incubation step at 
95 °C for 5 min. If reduced and non-reduced were analysed on the same gel, NEM to a 
final concentration of 20mM was added to each sample prior to loading to prevent 
reduction of non-reduced samples by diffusion of the reducing agent.
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Molecular weight markers (Amersham) were resolved alondside the samples to allow 
protein size determination. Gels were run at 100V until the bromophenol blue dye 
reached the bottom of the resolving gel. Thereafter, gels were removed from the 
apparatus and immersed in fix solution for 30 min, then in En Hance for 30 min and 
finally washed in water for 15 min. Gels were then dried under vacuum and exposed 
to Kodak X-Omat UV film for the detection of radiolabelled proteins. In the latter 
half of the project, the En Hance step was omitted and the gels were exposed to 
phosphorimager screens and later analysed using the Bio-Rad personal molecular 
imager FX and accompanying software. For non-radiolabelled proteins, the proteins 
of the gel were analysed by Western blot as described below.
2.13. Western blot analysis
2.13.1. Electroblotting to nitrocellulose membrane
Proteins were resolved by SDS-PAGE as described in 2.12 and were then transferred 
to nitrocellulose membrane in a Bio-Rad mini transblot apparatus, as described by 
Towbin et al. (1979). Briefly, a blotting sandwich was set up where the gel and 
nitocellulose membrane were placed, in contact with each other, between two pieces of 
Whatman 3mm paper which in turn were placed between two fibre pads. All 
materials were soaked in Towbin buffer prior to assembly of the sandwich and the 
sandwich was then transferred to the transblot apparatus and the reservoir filled with 
Towbin buffer. Electrotransfer was carried out at 100mA for 4 hours or 25mA 
overnight at 4°C.
2.13.2. Immunodetection
After transfer, membranes were blocked in 5% skimmed milk (Marvel) prepared in 
PBS(A) at 4°C overnight. Following three 10 min washes with PBS(A) containing 
0.05% (v/v) Tween-20 (PBST), membranes were incubated with the primary antibody 
(diluted in 1% BSA in PBST) for 4 hours. After three washes with PBST, the 
secondary antibody (either anti-mouse IgG or protein-A conjugated to horseradish 
peroxidase), diluted in 1% BSA in PBST, was added and incubated for lhour. The
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membranes were washed for a final three times and the proteins detected using the 
Amersham enhanced chemiluminescence (ECL) system. The two supplied reagents 
were mixed in a 1:1 ratio and placed on the membranes for 2 min with agitation. The 
membranes were then placed between two sheets of mellanine and exposed to Kodak 
XS-1 film for 10-60 seconds. All the washing and antibody incubation steps were 
performed at room temperature with shaking.
2.14. Enzyme linked immunosorbant assay (ELISA)
2.14.1. GNA capture ELISA
Immulon 2HB 96 well plates (Dynex) were coated with 125ng of Galanthus nivalis 
agglutinin (GNA), diluted in lOOpl of PBS(A), per well and left at room temperature 
overnight. The wells were washed with PBST three times before the addition of 
200jal of block solution (2% skimmed milk (Marvel) in PBST) for 2 hours. Wells 
were again washed with PBST and then 1 OOpl of two fold dilutions of cell extract 
expressing HCV E2 (prepared as described in 2.9.2) or a pre-determined dilution, was 
added and incubated for 1 Vz hours. The cell extracts were diluted in PBS(A). After, 
three more PBST washes, lOOpl of an anti-E2 antibody (diluted in block solution) was 
added and incubated for 1 Vz hours. Another washing step was followed by the 
addition of lOOpl of the secondary antibody (anti-mouse IgG or anti-rabbit IgG 
conjugated with horseradish peroxidase) diluted in block solution and incubated for 1 
Vz hours. After a final wash step, lOOpl of Tetramethyl benzidine (TMB) substrate 
was added to each well and incubated for 30 min with the plate covered in tin foil. To 
stop the reaction, 50pl of 0.5M H2 SO4 was added to each well and the absorbance 
reading of each well at 450nm determined using the Anthos Labtec IIT2 plate reader. 
All incubations were done at room temperature.
2.14.2. CD81 capture ELISA
The human CD81 used for the ELISA was the extracellular loop 2 of CD81, expressed 
as a GST fusion protein. The CD81 capture ELISA was performed exactly as 
described above for the GNA capture ELISA, except that the plates were coated with
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525ng of human CD81 per well (diluted in PBS(A)) instead of GNA. For the CD81 
capture ELISA in reverse, wells were coated with anti-E2 antibody (ALP98 at 1/1000), 
diluted in PBS (A). After washing and blocking as before, HCV E2 cell extracts were 
added and incubated for 1 Vz hours. This was followed by washing and the addition of 
525ng of human CD81 per well which was incubated for 1 Vz hours. After washing, 
CD81 was detected by the addition of a rabbit anti-GST antibody (diluted in block 
solution) which was incubated for 1 V2 hours. And after another wash step, anti-rabbit 
antibody conjugated with horseradish peroxidase (diluted in block solution) was added 
and incubated for a further 1 Vz hours. Following a final wash step, 1 OOpl of TMB 
was added to each well and incubated for 30 min with the plate covered in tin foil.
As, described above, the reaction was stopped by the addition of 0.5 M H2SO4 and the 
absorbance read at 450nm. All incubations were done at room temperature.
2.15. Immunofluorescence
Transfected cells on coverslips were fixed in ice-cold methanol and placed at -20°C for 
20 min. Cells were rehydrated by incubation with PBS for 15 min and then 
permeabilised with PBST for 15 min. The cells were then incubated with 200pl of the 
appropriate primary antibody (diluted in PBST) for 1 Vz hours with agitation at room 
temperature. Following three 5 min washes with PBST, the cells were incubated for 1 
Vz hours with 200pl of diluted secondary antibody, conjugated with either FITC, 
TRITC, Cy3 or Cy5. For double-labelling, cells were incubated with two primary 
antibodies and two secondary antibodies which were conjugated with different 
fluoresceins. Cells were then washed twice with PBST and twice with PBS before 
being rinsed in water, dried and mounted onto slides with 5 pi of Citifluor mounting 
fluid (supplied by Chem. Lab., Canterbury). The coverslips were sealed with nail 
varnish and stored at 4°C in the dark.
Fluorescence microscopy was performed using a Nikon MICROPHOT-SA microscope 
and confocal microscopy was performed using a ZEISS LSM 510 microscope and 
accompanying software.
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2.16. CD81 binding of virus particles
Glutathione agarose beads were coated with the human CD81-GST fusion protein or 
GST alone by incubation overnight at room temperature. The beads were then 
blocked with 2% BSA in TEN buffer (1M Tris-Cl pH 8.0, 50mM EDTA, 2M NaCl) 
for 1 hour at room temperature on a rotator, followed by 5 washes with 3 ml TEN 
buffer. A slurry was made with the addition of 0.5 ml TEN buffer and 50 pi aliquots 
of beads were transferred to eppendorf tubes for each reaction. After a brief 
centrifugation at 6000 rpm and removal of the supernatant, 200 pi of serum (either 
neat or diluted in TEN buffer) was added to the beads. The tubes were sealed with 
parafilm and incubated for 2 hours at 37°C on a rotator. The beads and serum were 
removed to a column and the beads washed 5 times with 5 ml of TEN buffer. After 
washing, the beads were removed to Eppendorf tubes, centrifuged briefly and the 
supernatant removed. Any bound virus was removed by the addition of 560 pi AVL 
buffer (Qiagen QIAmp kit) and incubation at room temperature for 10 min. RNA was 
then extracted as described in 2.2.7, reverse transcribed using Omniscript reverse 
transcriptase as described in 2.2.8.2 and amplified and quantified as described in
2.2.9.3.
2.17. Computer software
Sequences were initially analysed and edited using the Sequence Navigator program. 
Alignments and final editing of DNA and protein sequences were carried out using the 
programs FRAGMENT ASSEMBLY SYSTEM, PILEUP and PRETTY in the Genetic 
Computer Group sequence analysis package version 10.2. The Sequence Detector 
Software from Perkin-Elmer was used for detecting PCR product produced in the 
Perkin Elmer Applied Biosystems 5700 sequence detection system. An AGFA 
StudioScan II si scanner and Adobe Photoshop 5 and Adobe Illustrator 7.0 programs 
were used to process the figures. EndNote 3.0 was used for creating a bibliography.
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Chapter 3 
Cloning of HCV genotype 3 core, El and E2 from 
the serum of an infected patient
3.1. Introduction
Nucleotide sequence analysis of HCV isolates from around the world has revealed 
substantial variation over the viral genome. Phylogenetic analysis of nucleotide 
sequences of the complete genome or subgenomic regions (core, El and NS5B) has led to 
the classification of six distinct HCV genotypes (1 -6) which can be further divided into 
subtypes (a-h) (Simmonds et al., 1993 & 1994). Over the complete genome, the degree 
of nucleotide sequence identity between major genotypes ranges from 66-69% and from 
77-80% between subtypes (Simmonds, 1995). Genotype 3 was first identified by 
sequence comparison of subgenomic regions (Cha et al., 1992, Chan et al., 1992). The 
first full-length genome sequence for genotype 3 to be published was that of NZL1 
(accession no: D17763) which was isolated from a New Zealand blood donor (Sakamoto 
et al., 1994). When compared to the full-length sequence of other HCV isolates 
(genotypes la, lb, 2a and 2b), this isolate showed 65.7%-68.9% nucleotide homology, 
indicating that this isolate was distinct from those previously reported and hence was 
classified as a genotype 3a isolate. The HPCHK6 (accession no: D28917) isolate is the 
only other published full-length sequence of a genotype 3a isolate (Yamada et al., 1994) 
but two more unpublished sequences are available from the EMBL database, HCVCENS1 
(accession no: X76918) and an unnamed isolate (accession no: AF046866). These four
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are the only sequences covering the entire core, El and E2 genes from genotype 3a 
isolates.
Geographically, genotype 3 has a wide distribution although its prevalence varies from 
one geographic area to another. In Thailand it accounts for the majority of infections 
(Kanistanon et al., 1997) and a wide range of genotype 3 subtypes (3a-3f) has been 
reported in Nepal (Tokita et al., 1994). Subtypes 3c-3f have not been reported elsewhere, 
suggesting that they have evolved and stayed within Nepal, presumably due to the isolated 
position of the country. In Australia, genotypes 1 and 3 are the most commonly reported 
genotypes (Kaba et al., 1998). Genotype 3 is found throughout Western Europe and 
North America (along with types la, lb, 2a and 2b) and accounts for approximately 16% 
and 8% of infections respectively (Trepo & Pradat, 1999, Blatt et al., 2000). In Scotland 
the prevalence of genotype 3 is 47% (Sheila Cameron, Consultant Scientist, Regional 
Virus Laboratory, Gartnavel General Hospital, Glasgow). This figure was taken from all 
HCV positive patients (up to June 2000) who have had samples sent to the Glasgow 
laboratory but these patients reside all over Scotland and therefore this figure represents 
approximately 4/5 of Scotland with only the Edinburgh area being excluded. This high 
prevalence may be explained by the fact that genotype 3 is particularly common amongst 
intravenous (IV) drug users (Pawlotsky et al., 1995, Mihm et al., 1997) and in Glasgow an 
estimated 70% of IV drug users are HCV positive (Glasgow General Health Board report 
on HCV, 2000). Collecting the epidemiological data reported in the studies above is 
labour-intensive and expensive and therefore large studies are rarely undertaken. 
Additionally, the population being sampled should be carefully considered. Often this 
population is voluntary blood donors who are healthy adults. This obviously does not 
reflect the general population and leads to an underestimate in HCV prevalence and may 
misrepresent the true genotype distribution.
Whether or not genotype influences the clinical course of disease is controversial, as it is 
likely that host and other viral factors also play a role. Several studies have suggested an 
association between infection with genotype lb and the development of more severe liver 
disease including hepatocellular carcinoma (Dusheiko et al., 1994, Bruno et al., 1997).
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However, it has also been shown that genotype lb is significantly associated with older 
age and longer duration of infection and when these factors are taken into consideration 
there is no correlation between genotype and severity of disease (Martinot-Peignoux et al., 
1999, Mihm et al., 1997). Some manifestations of the disease do appear to be related to 
genotype. Steatosis is a condition in which lipids accumulate in hepatocytes. It has been 
shown to be significantly associated with genotype 3 (Mihm et al., 1997, Rubbia-Brandt et 
al., 2000). However, these studies were criticised as genotype 3-infected patients often 
have a past history of IV drug use and hence could have been exposed to other blood- 
borne infections. Also, accompanying alcohol abuse is not uncommon. In answer to 
these objections, Rubbia-Brandt et al. (2001) conducted a thorough study investigating the 
relationship with genotype independently from other known risk factors such as obesity, 
alcohol abuse and IV drug use and found that there was still a correlation between 
steatosis and genotype 3.
Genotype is also an established predictor of response to interferon (IFN) therapy. 
Numerous studies have shown that genotypes 2 and 3 are associated with a better response 
to treatment than genotype 1. This is true whether IFN is used alone (Martinot-Peignoux 
et al., 1995) or in combination with ribavirin (McHutchinson et al., 1998) or if the 
pegylated form of IFN is used (Zeuzem et al., 2000). The E2 and NS5A proteins have 
both been implicated in the response to IFN therapy and their involvement will be 
discussed in detail in Chapter 5. Suffice to say, the exact mechanisms behind the 
differing response to IFN and the development of steatosis remain unknown.
Although there are a large number of research groups around the world involved in 
analysis of the HCV proteins, by far the majority has concentrated on those of genotype 1 
only. Comparison of the characteristics of these proteins with those of other genotypes 
would surely further the current understanding of the virus life cycle and virus/host 
interactions. A conserved region between genotypes suggests that these regions are 
essential to the virus life cycle whereas a unique region may point to a function that is 
unique to that particular genotype. In this study these ideas were applied to the two 
putative envelope proteins, El and E2. There is no infectious clone available for
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genotype 3 so it was necessary to amplify the structural genes from the serum of a 
genotype 3 infected patient. I reasoned that by ensuring the PCR majority sequence is 
maintained in the clone, the expressed protein would function in the same way as that 
produced in the natural infection. Support for this is given by construction of infectious 
genotype 1 cDNA clones that were successful only when the cDNA sequence matched 
that of the PCR majority sequence (Kolykhalov et al., 1997, Yanagi et al., 1997). The 
encoded proteins could then be expressed and the similarities and differences between the 
type 1 and type 3 envelope proteins assessed.
3.2. Selection of patient serum
The criteria for selection of a suitable patient for this study were; infection with HCV 
genotype 3 and the availability of several aliquots of stored sera. The patient from whom 
serum was obtained was a 46-year-old former IV drug user. Informed consent was 
obtained at the times of blood sampling and approval for the study had been given by the 
West Glasgow Ethical Committee. The infecting HCV genotype was determined as 3a by 
restriction fragment length polymorphism (RFLP) and direct sequencing of the NS5A 
gene. A liver biopsy sample taken 12 weeks pre-treatment was given an Ishak score 
(Ishak et al., 1995) of 3 for inflammation and 1 for fibrosis. Following treatment in 1994, 
the patient was classified as a non-responder after failing to clear HCV RNA (as 
determined by RT-PCR) after 12 weeks of treatment with interferon alpha-2a (Roferon; 
Roche Products Ltd) at a dose of six million units thrice weekly. Aliquots of sera were 
available pre-treatment, during treatment and post-treatment. This same patient was 
chosen as part of a study on NS5A and the ISDR amino acid sequence was found to be 
identical to that of the prototype 3a sequence, NZL1 while the complete NS5A sequence 
was shown to have 95% homology to NZL1 (McKechnie et al., 2000). An immediate 
pre-treatment serum sample, from which the NS5A gene had been amplified in previous 
studies, was chosen for amplification of the HCV structural genes.
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3.3. Amplification of the HCV structural genes by 
RT-PCR
Oligonucleotide primers were designed to amplify the HCV genome from the end of the 
5’UTR to the beginning of NS2, thereby incorporating the core, El, E2 and p7 genes.
The sequences of these primers and the nucleotide positions at which they bind can be 
seen in Table 3.1. BamHl and Bglll restriction endonuclease sites were incorporated into 
the 5’ ends of the primers for second round amplification. This would facilitate future 
cloning. In addition, stop codons (one for each reading frame) were incorporated into the 
anti-sense primer for second round amplification. These stop codons would ensure that 
the correct size protein product was subsequently made. Following extraction from the 
infected serum, the viral RNA was reverse-transcribed using the MS2 primer. The 
resulting cDNA was then amplified, first with MS 1 and MS2 and then with the internal 
primers, MS3R and MS4R (Figure 3.1). The PCR product was resolved by agarose gel 
electrophoresis (Figure 3.2). Initially an annealing temperature of 65°C was used for both 
rounds of amplification, which resulted in a product of the correct size (2.5 kb) (Figure 
3.2A). Although there was no amplification of non-specific products, the overall amount 
of product was not optimal, so the annealing temperature was reduced in 2 or 3 degree 
increments for the second round of amplification (Figure 3.2B). Maximal amounts of 
product were seen with annealing temperatures of 58°C and 60°C (lanes 2 and 3 of fig 
3.2B), but 60°C was chosen for all future amplifications, as there were fewer non-specific 
products at this temperature.
3.3.1. Sequence comparison
For sequencing purposes, the PCR product was purified and initially sequenced using the 
inner PCR primers. The nucleotide sequence obtained with these primers was then used 
to design more sequencing primers which were specific for the PCR product. Therefore it 
was possible to obtain sequence of overlapping fragments which spanned the PCR product 
twice, once in each direction. An alignment of the full sequence (Gla-3a) with four
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T able 3.1. O ligonucleotide primers for nested RT-PCR o f  genotype 3 
structural genes.
Primer Sequence 5' to 3' Position Use
MSI (s) G C T T G C G A G T G C C C C G G G A G 3 0 1  - 3 2 0 PCR 1
MS2 (as) T G A C / T A A G G T A A A G A A G C C G 2 8 4 1  - 2 8 5 9 PCR 1 & RT
MS3R (s) G C G C G G A T C C A G A T C T G G G A G G T
C T C G T A G A C C G T G
3 1 6 - 3 3 5 PCR 2
MS4R (as) G C G C G G A T C C A G A T C T T C A T T T A T
T T A A G A A G C C G A A G A G G A C C A A G
2 8 2 9  - 2 8 4 8 PCR 2
Nucleotide numbering according to NZL1 (Sakamoto et al., 1994). 
s = sense, as = antisense 
HCV sequence is shown in red.
BamHl restriction sites are shown in blue.
Bglll restriction sites are shown in green.
Stop codons are underlined.
RNA extracted from HCV 
genotype 3-infected patient
Reverse transcription with 
MS2 primer and reverse 
r transcriptase
M S 2
J J J J J ___________________________________
cDNA amplified by PCR with 
outer primers, MSI and MS2, and 
Tag DNA polymerase
cDNA
<
HCV viral ~  
RNA
M S 2
cDNA
First round PCR 
product
M S I
1
5 ’U T R  c o r e  E l E 2 N S 2
Second round PCR amplification 
with inner primers, MS3R and 
MS4R and Tag DNA polymerase
M S 4 R
<
M S 3 R
i  _
E S303 0 i
CO CO
i
CO 3
=  X
Second round 
PCR product
C o r e E l E 2
Figure 3.1. Illustration o f  the am plification o f  the core, E l and E2 genes 
from the serum o f  a HCV genotype 3 infected patient by reverse 
transcription o f  viral RNA and am plification o f  cDNA by nested PCR.
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Chapter 3
genotype 3a reference isolates is shown in Figure 3.3. Overall, the five nucleotide 
sequences for core, El and E2/p7 showed 83.8% homology. Further analysis showed 
90.4% homology for core, 85.6% for El and 80% for E2/p7.
In Figure 3.4, the derived amino acid sequence of Gla-3a was aligned with that of the four 
genotype 3 isolates. For comparison, the genotype la  reference strain (H77) was also 
included. Analysis of the genotype 3 protein sequences revealed 93.2% homology in 
core, 91.6% homology in El and 80.9% homology in E2/p7. By comparison with 
genotype la  (H77), Gla-3a showed 92.7% homology in core, 70.7% in El and 72.6% in 
E2/p7. The El protein of both genotypes 1 and 3 was 191 amino acids in length and there 
were 8 conserved cysteine residues at positions 207, 226, 229, 238, 272, 281, 304 and 306 
(indicated with Proline residues were also conserved in both genotypes at positions 
224, 228, 244, 295, 310, 328 and 341 of El. Additional prolines were found at positions 
208 and 254 in H77, position 241 in all four type 3 isolates and position 283 in HPCHK6.
The E2 protein of genotype la was 355 amino acids in length whereas E2 of genotype 3 
was 361 amino acids. The insertions in genotype 3 occurred at positions 480, 571 and 
579-582. There were 19 cysteine residues in E2 that were conserved between genotype 1 
and 3 and one in the p7 protein (indicated with Genotype 1 had an additional 
cysteine at position 740. There were 21 proline residues in E2 and one in p7 that were 
conserved in both genotypes. All 5 genotype 3 isolates had an additional proline residue 
at position 461. There were another 8 proline residues that were not conserved within the 
genotypes, including two in the hypervariable region (HVR1). The HVR1 is highlighted 
in yellow and consists of the first 27 amino acids of E2. It was evident that the degree of 
variation in this region was substantially higher than elsewhere in E2, and was not related 
to genotype. This sequence was expected to differ between the different quasispecies 
present in the one isolate and therefore no interpretation could be made from the sequence 
of the HVR1 seen here, which presumably represented that of the majority sequence.
When comparing Gla-3a to the four previously published genotype 3 isolates, there were 
positions in both El and E2 where Gla-3a differed from the other four. There were 3
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Chapter 3
such differences in E l; T223A (i.e threonine in consensus and alanine in Gla-3a at 
position 223), D232V (although this was an asparagine in AF046866) and P241S. 
Ignoring the hypervariable region and any position where there was no consensus, there 
were 13 positions in E2 where Gla-3a differed from the other four. They were E43ID, 
I433L, F442I, F464S, P480S (although this was an alanine in HCVCENS1), A491P, 
I497T, A532G (this was glutamic acid in NZL1 and HCVCENS1), T559S, F586L,
Q668L, K721R and K787R.
Four predicted glycosylation sites at positions 196, 209, 234, and 305 (underlined in 
Figure 3.4) in the El protein were present in both genotypes 1 and 3. A fifth site was 
predicted at position 325 but it had previously been demonstrated that only 50% of such 
sites (with a C-terminal proline) were used (Gavel & von Heijne, 1990). The E2 protein 
had 7 predicted glycosylation sites that were conserved between H77 and all type 3 
isolates, at positions 417, 423,430, 448, 476, 557 and 651. Two further glycosylation 
sites at positions 533 and 629 were present in H77 and all type 3 isolates except NZL1. 
Due to the insertion present in genotype 3, the glycosylation site at position 578 in 
genotype 1 was disrupted in genotype 3 but an alternative had been introduced at position 
581. H77 had an additional site at position 541 that was not present in genotype 3.
3.4. Cloning of the HCV structural genes into the SFV 
vector
The Semliki Forest Virus (SFV) expression system was chosen for the purposes of 
producing the protein products of the HCV structural genes. The pSFVl expression 
vector, which forms the basis of the SFV expression system, contains a polylinker cassette 
with a BamHl restriction site downstream of the transcription initiation site (Figure 3.5). 
This site was used for insertion of the PCR product encoding core, El and E2. As 
mentioned previously, BamHl sites were added to the 5’ ends of the PCR primers and 
hence into the PCR product as well. Both the PCR product and the pSFV 1 vector were 
cleaved with BamHl, purified and then ligated together and electroporated into E.coli.
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o f  the PCR product encoding the HCV structural genes. The 
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Clones were selected for presence of the inserted PCR product by digestion with BamHl 
or Bglll (internal to the BamHl sites on the PCR product). This released a 2.5 kb 
fragment. The orientation of the insert within the vector was determined by cleavage 
with Smal. From the PCR nucleotide sequence, three Smal sites were identified and with 
one site present in the vector, it was possible to determine orientation of the insert by 
simple restriction endonuclease digestion. It was noticed that only 20% of the clones 
analysed had an insert in the correct orientation. The selected clone was named 
pSFVF2cEiE2. As with the PCR product, the clone was sequenced across the length of 
the insert. The derived amino acid sequence, which was aligned with that of the PCR 
product, is shown in Figure 3.6. There were 9 differences between these two sequences.
3.5. Site -directed mutagenesis of pSFVF2CEiE2
The nine amino acid mutations found in pSFVF2cEiE2 were all due to single nucleotide 
exchanges with one in core, two in El, five in E2 and one in p7 (Figure 3.6). To correct 
these by site-directed mutagenesis, it was first necessary to subclone the HCV structural 
genes into another smaller vector to reduce the chances of introducing mutations into the 
SFV vector. The selected vector for this purpose was pGEM-1 (Figure 3.7). Due to the 
size of the HCV coding region, it was decided to divide this in two at the Pstl site within 
the E2 gene. Therefore pSFVF2cEiE2 was cleaved with Xbal, Hindlll (both in the vector) 
and Pstl to release two fragments of 2022 bp and 1960 bp (Figure 3.8). These were 
cloned into pGEM-1 at the appropriate sites to create pMSl and pMS2 respectively. 
pMSl contained exchanges 1, 2 and 3 and pMS2 contained exchanges 4,5,6,7,8 and 9 and 
these plasmids were the templates for site-directed mutagenesis.
The strategy for site-directed mutagenesis was that employed by the “QuikChange” kit 
from Stratagene (Figure 3.9). Oligonucleotide primers designed against both DNA 
strands and containing the desired mutation were made for each exchange. As exchanges 
4 and 5 were situated close together, one pair of primers containing both mutations was 
designed. These mutations were obviously made simultaneously whereas the remainder 
were made consecutively. Following denaturation of the template plasmid, the specific
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Figure 3.9. Illustration o f the strategy used for site-directed 
m utagenesis, using the QuikChange kit from Stratagene.
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primer pair was annealed and extended by Pfu Turbo DNA polymerase, which resulted in 
nicked, circular DNA strands. This was repeated for 12-24 cycles to amplify the mutated 
DNA. An example of the PCR product obtained during mutagenesis of mutation 9 in 
pMS2 can be seen in Figure 3.10. To remove the parental plasmid, the PCR product was 
digested with Dpnl, which is a 4 bp cutter and specifically cleaves methylated DNA.
Only the parental DNA, which originated from E.coli would be methylated. The 
remaining, mutated DNA was transformed into E.coli where the nicked DNA was 
repaired. This plasmid DNA was then used as template for the next mutation, however I 
found that it was beneficial to ensure that this template consisted of supercoiled plasmid 
only as amplification of both DNA strands did not occur when nicked plasmid DNA was 
present. Therefore the plasmid DNA was first separated by gel electrophoresis and the 
supercoiled DNA extracted and purified before being used as template for the next round 
of mutagenesis.
After mutagenesis, the repaired HCV genes were reconstructed and cloned back into 
pSFVl (Figure 3.8). The 2022 bpXbaVPstl fragment from pMSl and the 1240 bp 
Pstl/BamHl fragment from pMS2 were ligated together along with the 10271 bp 
XballBamHl fragment of pSFV 1. The resulting SFV clone was named pSFVR3cE] E2 . 
This repaired clone was nucleotide sequenced over core, El and E2 to confirm that 
mutations 1-9 had been repaired and that no other mutations had been introduced. The 
derived amino acid sequence is shown in Figure 3.11 and was aligned with the amino acid 
sequence of Gla-3a. The amino acid sequence of the genotype la  infectious clone, H77 
(Yanagi et al., 1997) was included in the alignment as this would be used for the 
expression of the representative type 1 proteins for comparison with those of Gla-3a. The 
derived amino acid sequence of the repaired clone was identical to that of the Gla-3a PCR 
majority sequence. The predicted transmembrane domains (TMD), which are responsible 
for ER retention, are boxed. The C-terminal halves of the El and E2 TMD sequence are 
thought to function as signal sequences for E2 and p7 respectively (Cocquerel et al., 1998 
& 1999) and are underlined in Figure 3.11. Amino acids within these TMDs, which were 
identified by Cocquerel et al. (2000) as being fully conserved between HCV variants, 
were also conserved in Gla-3a (indicated with “*”). These included charged residues in
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the hydrophilic region between the two hydrophobic regions. Specifically, a lysine 
residue at position 370 in El and aspartic acid and arginine residues at positions 734 and 
736 of E2 which had been shown to be crucial for the maintenance of structure and 
function of the TMDs (Cocquerel et al., 2000), were all present.
3.6. Construction of genotype 3 E2 SFV clone
For some purposes it was necessary to observe the characteristics of E2 in isolation and to 
compare them to the clone expressing E2 in the context of E l . Therefore the E2 gene was 
subcloned from pSFVR3cEiE2 into the pSFVl vector (Figure 3.12). Previous experience 
with expression of the HCV genotype 1 structural proteins with the SFV system had 
shown that the authentic HCV start codon and the sequence surrounding it, was required 
for good expression levels of any of the downstream genes (J. McLauchlan, personal 
communication). Therefore the strategy for subcloning E2 had to include the first few 
amino acids of core. Conveniently there were Smal sites in pSFVR3cEiE2 which cleaved 
the nucleotide sequence at positions equivalent to 24 amino acids into core and at the end 
of El but before the E2 signal sequence. Cleavage with Smal resulted in four fragments 
of 163 bp, 692 bp, 1577 bp and 11127 bp as shown in Figure 3.12. The 11127 bp 
fragment was dephosphorylated and ligated to the 1577 bp fragment to form pSFVR3E2. 
The orientation of the E2 gene within the vector was confirmed with EcoRN and Pvull 
digestions.
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3.7. Discussion
There are four complete genome sequences available for HCV genotype 3a in the EMBL 
database. They are NZL1 (Sakamoto et al., 1994), HPCHK6 (Yamada et al., 1994) and 
two unpublished sequences (AF046866 and HCVCENS1). A few other published 
sequences are available for genotype 3a core and El but none for the complete E2 gene 
and there are no reports of detailed analysis of the E2 gene from the different genotypes. 
When the PCR majority derived amino acid sequence of Gla-3a is compared to the four 
reference isolates (Figure 3.4), the percentage homology in the El protein is 91.6%. 
According to Bukh et al. (1993) this amino acid identity within El is consistent with these 
isolates being of the same genotype. In contrast, the 69.1% homology in El between Gla- 
3a and the genotype la  reference strain, H77, confirms that these two isolates are different 
genotypes. The degree of homology in the core and E2 proteins (93.2% vs 80.9%) 
between the five genotype 3 isolates, is consistent with previous data showing that core is 
one of the most conserved regions of the genome whereas E2 is one of the most variable 
(Simmonds, 1995).
The derived E 1 amino acid sequence shows that the unmodified proteins of genotypes 1 
and 3 are identical in length and also share all 8 cysteine residues, which are likely to be 
involved in the formation of disulphide bonds and hence in maintenance of the correct 
conformational structure of the protein. Proline residues are also considered important 
for protein structure and are conserved in both genotypes in 7 positions, although 
additional prolines in some isolates could reflect structural differences. The unmodified 
E2 protein of genotype la  is 6 amino acids shorter than that of genotype 3. Two of the 
insertions in genotype 3 involve a proline residue, which could alter the structure of the 
protein, although these residues are not conserved in all 5 of the genotype 3 isolates 
reported here. As with E l, the E2 proteins of genotypes 1 and 3 share several cysteine 
residues that are crucial for the correct conformation of the protein. Genotype 1 E2 has 
an additional cysteine residue, which could lead to differences in the structure of the E2 
proteins of genotypes 1 and 3 through differences in disulphide bond formation. Proline 
residues are also highly conserved in E2 but genotype 3 has an additional conserved
89
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proline residue which is absent in genotype 1 and there are other prolines which are not 
conserved within the genotypes. Therefore variation in E2 structure is expected, even 
between isolates of the same genotype, however the highly conserved nature of some 
residues between genotypes implies that conservation of structure in certain regions is 
necessary for protein function.
The HCV envelope proteins are heavily modified by V-linked glycosylation. The degree 
of glycosylation could alter the ability of El and E2 to interact with cellular proteins due 
to steric hindrance. Therefore, differences in glycosylation states between genotypes 
could impart different functional characteristics on the proteins. Both genotype 1 and 
genotype 3 El have four (or five) predicted glycosylation sites. The situation with E2 is 
more complicated, but if the two absent sites in NZL1 are ignored, genotype 3 has 10 
predicted glycosylation sites and genotype 1 has 11. This is in agreement with that 
reported by Miyamura & Matsuura (1993) for genotype 1. The site in genotype 1, which 
is disrupted by the insertion in genotype 3, is reintroduced in the insertion implying that 
glycosylation in this region of E2 is important for protein function.
As the characteristics of the E2 protein expressed from Gla-3a will be analysed as a 
representative type 3 E2, it is important to note any amino acids which differ from the four 
other type 3 isolates. Possibly the most significant of these differences are those that 
involve proline residues, at positions 241, 480 and 491. At position 241 the consensus is 
a proline but this is a serine in Gla-3a. At position 480 the consensus residue is also a 
proline but it is also a serine in Gla-3a and an alanine in HCVCENS1. Interestingly this 
residue is absent in genotype 1. At position 491 the consensus residue is alanine and this 
is a proline in Gla-3a as well as in genotype 1. The structure of proline is very rigid due 
to the side chain being covalently bonded to the nitrogen atom of the peptide backbone. 
This prevents rotation and therefore has a significant effect on the conformation of the 
protein around these residues. It is likely that these differences at positions 241, 480 and 
491 do induce a structural change in this region of E2.
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Following cloning of the PCR product into pSFVl, the resulting clone, pSFVF2cEiE2 was 
sequenced across the core, El and E2 genes and 9 amino acid differences were discovered 
between the clone and the PCR product (Figure 3.6). These were all due to single 
nucleotide exchanges and were present throughout the insert, with exchange 1 in core, 
exchanges 2 and 3 in E l, 4-8 in E2 and exchange 9 in p7. Exchanges 2, 3, 5 and 6 all 
involve proline residues, which could have an effect on the protein structure as described 
previously. In addition exchanges 2, 6 and 7 abolish conserved glycosylation sites. 
Exchange 5 in E2 removes a conserved proline residue. Therefore I predicted that these 
changes would have an effect on the overall structure of El and E2. Construction of the 
infectious H77 clone revealed that to be infectious, the injected RNA transcripts had to 
match the consensus sequence (Yanagi et al., 1997). These authors reported finding a 
high proportion of clones which were either defective for protein production or had 
multiple amino acid mutations. There are several reasons for the differences in our clone. 
They could have been introduced during the RT-PCR procedure due to the infidelity of the 
Taq polymerase. The cloned product could also represent a variant that was present as a 
minority in the patient serum, although if this were the case it would be unexpected to find 
no differences in the HVR1. In a report directly relevant to this study, in which the 
genotype 1 structural region was amplified from serum and expressed, Foms et al. (1997) 
reported that there was evidence for selection of defective genomes during the cloning 
procedure. All of their clones were dysfunctional for polyprotein production. It was 
unlikely that such a high proportion of defective genomes was present in the viral 
population and the authors concluded that the explanation was due to spurious translation 
from within the HCV sequence, resulting in a protein product that is toxic to E.coli. By 
introducing extra nucleotides directly upstream of the HCV start codon, the proportion of 
functional clones was increased. It is not known if the same explanation is relevant to 
this present study as too few clones were analysed for protein expression. In fact, in our 
study, it was the ability to obtain a clone with an insert in the correct orientation that was 
more problematic. This could also reflect the bias of E.coli for translationally defective 
clones.
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Having corrected all 9 differences and cloned the inserts into pSFV 1 once again, the 
resulting construct, pSFVR3cEiE2, was sequenced across core, El and E2. All nine 
amino acid differences had been corrected and no other exchanges had been introduced. 
Therefore this construct could be used confidently for the purposes of expressing the 
genotype 3 HCV structural proteins encoded by the genome circulating as the majority in 
this particular patient.
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Chapter 4 
Expression and characterisation of the HCV 
genotype 3 glycoproteins
4.1. Introduction
The Semliki Forest virus (SFV) expression system directs high levels of expression of a 
heterologous gene product in a wide range of animal cell hosts (Liljestrom & Garoff, 
1991). It has advantages over other eukaryotic expression systems, such as the 
baculovirus and vaccinia systems, in that it does not rely on the construction of 
recombinant virus stocks. SFV can infect a broad range of cultured mammalian cells, 
including human, so this expression system is appropriate for the expression of 
mammalian viral glycoproteins.
The SFV vector, pSFV 1, is a modified cDNA copy of the viral genome. The region 
encoding the structural proteins (produced by the 26S RNA) has been replaced by a 
polylinker containing a BamHl-Xmal-Smal polylinker sequence and three stop codons 
downstream of the 26S promoter (Figure 3.5). The gene of interest is inserted into one of 
these unique restriction sites. The recombinant SFV genome is synthesised by in vitro 
transcription and electroporated into cells. The 5’ and 3’ untranslated regions and the 
nsPl-4 genes, which encode the RNA replicase complex, are retained and can therefore 
drive the replication and transcription of recombinant SFV RNA. The translational 
machinery of the host cell is responsible for protein synthesis and, due to the high RNA
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levels produced by the SFV replicase complex, synthesis of the viral proteins overtakes 
host protein synthesis, with levels of the heterologous protein reaching 25% of total 
cellular protein 75 hours post infection (Liljestrom & Garoff, 1991). The SFV expression 
system has been used successfully for the expression of human, murine, avian, bovine, 
bacterial and viral proteins (Liljestrom & Garoff, 1991, Ciccaron et al., 1993, Sjoberg et 
al., 1994). Viral proteins include herpes simplex virus-encoded DNase (Kehm et al., 
1998), influenza nucleoprotein (Berglund et al., 1999), HIV gpl20 and gp41 (Altmeyer et 
al., 1999), human papilloma virus E6 and E7 proteins (Daemen et al., 2000) and the HCV 
genotype 1 structural proteins (Patel et al., 1999a & 2001).
Numerous studies have reported complex formation between the HCV glycoproteins, El 
and E2 (Grakoui et al., 1993a, Ralston et al., 1993, Selby et al., 1994). Due to lack of a 
cell culture system for HCV and the low levels of virus particles in patient sera, the only 
means to study the glycoprotein complexes has been through expression from recombinant 
cDNA templates in a variety of systems. These include vaccinia virus (Ralston et al., 
1993, Dubuisson et al., 1994), Baculovirus (Baumert et al., 1998) Sindbus virus 
(Dubuisson et al., 1994) and Semliki Forest virus expression systems (Patel et al., 1999a). 
All of these studies have reported the presence of two forms of the E1E2 complex. They 
form a heterodimer that is stabilised by non-covalent interactions and a high molecular 
weight, disulphide-linked aggregate (Dubuisson et al., 1994). The non-covalent 
interactions are thought to be authentic and represent the native prebudding form of the 
glycoprotein complex (Deleersnyder et al., 1997). The aggregate is thought to be formed 
by the misfolding of the proteins but it is unclear if these complexes are formed during the 
natural HCV life cycle or whether they are an artefact of the expression systems used. 
These observations are all based on analysis of genotype 1 El and E2 proteins and before 
firm conclusions can be drawn on the authentic formation of the glycoprotein complex in 
the virion, it is important to see if these findings apply to other genotypes.
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4.2. Reactivity of genotype 1 antibodies against 
genotype 3 glycoproteins
4.2.1. Expression of genotype 3 structural proteins using the 
SFV system
For expression of recombinant proteins with the SFV system, the gene of interest is first 
cloned into the SFV plasmid vector, pSFV 1. This process was described in chapter 3 for 
the construction of pSFVF2cEiE2, pSFVR3cEiE2 and pSFVR3E2, which encode the 
genotype 3 proteins. For comparative purposes, SFV constructs encoding the equivalent 
genotype 1 proteins were kindly provided by Janisha Patel (MRC Virology Unit, 
Glasgow). These constructs are pSFVH77cEiE2 and pSFVH77E2, which encode the 
structural proteins of the infectious genotype la  clone, H77 (Yanagi et al., 1997) and 
pSFVGlaCEiE2 which encodes the structural proteins of a local genotype la  strain known 
as HCV-la Gla (Gla) (Patel et al., 1999a & 2000). A summary of these constructs and 
the proteins they encode can be seen in Table 4.1.
In preparation for in vitro transcription, the SFV constructs were linearised by cleavage 
with restriction endonuclease SpeI. There was a unique SpeI site beyond the BamHl 
cloning site in pSFVl (see Figure 3.4) and there were no Spe I sites in the genes encoding 
the structural proteins of either genotype 1 or 3. This linearised DNA served as a 
template for in vitro synthesis of recombinant RNA directed by SP6 RNA polymerase. 
One twelfth of the total recombinant RNA was analysed by agarose gel electrophoresis 
(Figure 4.1). The template plasmid DNA was visible as a faint band at approximately 
13.5 kb for the recombinant plasmids (lanes 1 and 2) and 11 kb for the SFV vector (lane 
3). The brighter bands below this were the transcribed RNA molecules and the smear 
below this main RNA band was due to RNA degradation products. The remainder of the 
transcription reaction was electroporated into mammalian cells for expression of the 
recombinant protein. Initially Baby Hamster Kidney (BHK) cells were used, as these
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Table 4.1. Summary of SFV constructs.
SFV
construct
Encoded
protein
Genotype Strain comment
pSFVF2cEiE2 Core, El, E2 3a Gla-3a 9 aa differences 
from R3
pSFVR3cEiE2 Core, El, E2 3a Gla-3a Corrected 
sequence 
matches PCR 
majority 
sequence
pSFVR3E2 E2 3a Gla-3a Subcloned from 
pSFVR3cEiE2
pSFVH77cEiE2 Core, El, E2 la H77 From infectious 
clone
pSFVH77E2 E2 la H77 From infectious 
clone
pSFVGlaCEiE2 Core, El, E2 la Gla
1 2 3
DNA—
(13.5 kb)
RNA—
Figure 4.1. In vitro transcribed RNA from pSFVR3cEiE2 
(lane 1), pSFVH77cEiE2 (lane 2) and pSFV l (lane 3). 
Linearised plasmid DNA was transcribed in vitro from an 
SP6 prom oter and 2 pi o f the reaction was separated on a 
1% agarose gel. A small amount o f  the DNA tem plate is 
visible along with the transcribed RNA. The sm ear 
underneath the main RNA band is indicative o f  degradation 
products. The rem ainder o f  the transcription reaction was 
electroporated into cells for protein expression.
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were the cells used in the first description of this expression system by Liljestrom & 
Garoff (1991). However, human hepatocytes are a more relevant cell type for the 
expression of HCV proteins and hence, conditions were adjusted to allow electroporation 
of the constructs into the human hepatocellular carcinoma cell line, Huh7.
4.2.2. Recognition of genotype 3 E2 by genotype 1 E2 
antibodies
There have been no previous reports describing expression of the genotype 3 envelope 
proteins and as far as is known, there are no genotype 3 specific antibodies available. A 
large panel of genotype 1 specific antibodies to El and E2 had been generated by Dr 
Arvind Patel (MRC Virology Unit, Glasgow) (Patel et al., 2000, Owsianka et al., 2001) 
and these were kindly made available for this study. The majority of these antibodies 
were raised against the Gla strain proteins and not all recognised strain H77 E2 (A. Patel, 
personal communication). Attention was focussed on those antibodies that did recognise 
H77 E2, as RNA from this strain had been shown to be infectious. Three genotype 1 anti- 
El antibodies, raised against the Gla strain, were also available. Details of the antibodies 
tested are shown in Table 4.2. The reactivity of these genotype 1 antibodies against 
genotype 3 was analysed in a variety of immunological assays.
Western blot analysis identified four antibodies that recognised both type 1 and type 3 E2 
(Figure 4.2A). They were ALP98 (a), AP266 (b), ALP1 (c) and R646 (d). All four 
antibodies recognised a protein of approximately 66 kDa which was specific to cells 
expressing the structural proteins, not being seen in the lanes containing the SFV vector 
only (lane 5) or Huh7 cells only (lane 6). Interestingly, ALP1 failed to recognise F2 E2 
and AP266 had less affinity for F2 E2 when compared to R3 E2. The polyclonal 
antibody, R646, had more activity against the type 1 proteins (H77 and Gla) than the type 
3 proteins (R3 and F2) and many additional cellular proteins were also recognised by this 
antibody. This was possibly due to over-exposure to allow for detection of genotype 3 
E2. In addition to the main protein band, ALP98 also recognised protein bands at
96
Table 4.2. Details o f genotype 1 El and E2 antibodies used in this study
Antibody Type Epitope
Type
Specificity Dilution Original
Source
ALP98* Mouse
monoclonal
linear E2 (aa 650-657) 1:1000 A. Patel
AP266* Mouse
monoclonal
linear E2 (aa 650-657) 1:10 A. Patel
ALP1* Mouse
monoclonal
linear E2 (aa 654-665) 1:10 A. Patel
AP320* Mouse
monoclonal
linear E2 (aa 464-471) 1:500 A. Patel
AP33* Mouse
monoclonal
linear E2 (aa 412-423) 1:500 A. Patel
R646§ Rabbit
polyclonal
linear E2 1:1000 A. Patel
H30# Mouse
monoclonal
conform­
ational
E2 1:200 J. Dubuisson
H50# Mouse
monoclonal
conform­
ational
E2 1:200 J. Dubuisson
H53# Mouse
monoclonal
conform­
ational
E2 1:200 J. Dubuisson
H60# Mouse
monoclonal
conform­
ational
E2 1:200 J. Dubuisson
H61# Mouse
monoclonal
conform­
ational
E2 1:200 J. Dubuisson
AP21.010* Mouse
monoclonal
linear El (aa 213-235) 1:500 A. Patel
API 19* Mouse
monoclonal
linear El (aa 235-260) 1:500 A. Patel
R528* Rabbit
polyclonal
linear El 1:1000 A. Patel
* raised against HCV strain Gla (Patel et al., 2000, Owsianka et a l 2001) 
§ raised against HCV strain H77 (Owsianka et a l 2001)
# raised against strain HCV-H (Cocquerel et al., 1998)
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approximately 97 kDa and 30 kDa (although to a much lesser extent). These bands were 
specific to E2-expressing cells. The ~21 kDa protein band was present in all 6 lanes, 
indicating it was a cellular protein. Neither AP266 nor ALP1 recognised any additional 
proteins. Close inspection of the migration patterns of the E2 proteins, revealed that there 
may be slight differences in mobility between the E2 proteins of different constructs.
Two antibodies that recognised only genotype 1 E2 are shown in Figure 4.2B. Western 
blot with AP320 (a) indicated a major protein band in the type 1 E2-expressing cells only. 
There was a minor band at the same position in all the other lanes, which indicated 
recognition of a cellular protein. AP33 (b) recognised only H77 E2. The antibody was 
raised against Gla E2 and did recognise this protein as well but the pSFVGlacEiE2 
construct used here had a tag that disrupted the epitope recognised by AP33.
Western blot analysis detects antibodies that recognise denatured proteins. Some 
antibodies may recognise an epitope that is conformational and would be destroyed when 
the protein is denatured. To detect reactivity of such an antibody, an alternative assay, 
such as immunofluorescence can be used, in which the native structure of proteins may be 
retained. To verify the reactivity of the antibodies identified by Western blot analysis, 
they were also analysed by indirect immunofluorescence and the results are summarised in 
Table 4.3. The results were consistent with those for Western blot analysis. Those 
antibodies (AP320 & AP33) which did not recognise type 3 E2 by Western blot did not 
recognise type 3 E2 by immunofluorescence either. The patterns of recognition by 
ALP98 and R646 are shown in Figure 4.3 A and B, respectively. ALP98 recognised E2 
of R3 (a), F2 (b) and H77 (c) but no specific fluorescence was visible in cells expressing 
the SFV proteins only (d) or Huh7 cells only (e). The pattern of fluorescence was 
cytoplasmic and had a web-like nature. Similar fluorescence patterns were seen with all 
reactive antibodies. In Western blot analysis, R646 showed more reactivity to type 1 E2 
and this was even more pronounced in immunofluorescence assays (Figure 4.3B). In fact, 
the reactivity against type 3 E2 was scored as negative (a). If the concentration of the 
antibody was increased, the same cytoplasmic staining pattern could be seen with type 3 
E2 through the general high background fluorescence. It was concluded that R646 was 
not an optimal antibody for detecting type 3 E2 in an immunofluorescence assay.
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Table 4.3. Summary of reactivity of genotype 1 E2 antibodies against 
both genotype 1 and genotype 3 E2 as determined by indirect 
immunofluorescence.
Antibody Genotype 1 E2 Genotype 3 E2
H77 Gla R3 F2
ALP98 (MAb) ++ ++ ++ ++
AP266 (MAb) ++ ++ ++ ++
ALP1 (MAb) ++ ++ ++ -
AP33 (MAb) ++ - - -
AP320 (MAb) ++ ++ - -
R646 (PolyAb) ++ ++ +/- +/-
Table 4.4. Summary of reactivity of genotype 1 E l antibodies against 
both genotypes 1 and 3 El as determined by indirect immunofluorescence.
Antibody Genotype 1 El - Gla Genotype 3 El -  F2
21.010 ++ -
API 19 ++ -
R528 ++ -
“++” indicates positive reactivity 
indicates negative reactivity
Figure 4.3A Reactivity o f anti-E2, ALP98, against genotype 1 and 
genotype 3 E2 by indirect immunofluorescence in Huh7 cells. Huh7 cells 
were electroporated with in vitro transcribed RNA from pSFVR3cEiE2 (a), 
pSFVF2cEiE2 (b), pSFVH77cEiE2 (c) and pSFV l (d). Panel (e) shows 
m ock electroporated cells. Cells were fixed in m ethanol and prepared for 
indirect imm unofluorescence with ALP98 and anti-m ouse FITC. Images 
were captured with a 63X oil immersion lens.
Figure 4.3B Reactivity o f anti-E2, R646, to genotype 1 and 
genotype 3 E2 by indirect im m unofluorescence in Huh7 cells. Huh7 
cells were transfected with pSFVR3cEiE2 (a), pSFVH77cEiE2 (b) or 
pSFV 1 (c) and fixed in methanol before being prepared for indirect 
imm unofluorescence with R646 and anti-rabbit Cy3. Panel (d) 
shows mock transfected cells. Im ages were captured using a 63X oil 
imm ersion lens.
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The reactivity of three genotype 1 El antibodies against genotype 3 El was also analysed 
by immunofluorescence (Table 4.4). Neither of the monoclonal antibodies (21.010 and 
API 19) nor the polyclonal antibody (R528) were able to recognise type 3 E l .
As a final test of antibody reactivity, both native and denatured forms of E2 were captured 
by GNA and the ability of the antibodies to recognise the different forms was analysed by 
ELISA. In addition to those constructs expressing all the structural proteins (i.e. core, El, 
E2), the constructs expressing E2 only were also included to examine whether antibody 
reactivity was modified by the presence or absence of core and E l . Galanthus nivalis 
agglutinin (GNA) is a lectin that captures the carbohydrate portion of the glycoprotein. 
Prior to GNA capture, half of the E2-expressing cellular extract was treated with SDS and 
DTT to denature the protein. Both native and denatured E2 were bound to GNA and 
antibody reactivity was measured in terms of absorbance at 450 nm. These figures were 
plotted for each E2 construct and are shown in Figure 4.4 A and B. The ELISA results 
for those antibodies that were previously shown not to recognise genotype 3 E2 are shown 
in Figure 4.4A. For both AP320 (a) and AP33 (b), the absorbance readings for the 
genotype 3 proteins (R3 and F2) were in the same range as those of the SFV vector or 
cells only. Therefore, as with the Western blot and immunofluorescence assays, AP320 
and AP33 did not recognise genotype 3 E2 in ELISA. The reactivities of those antibodies 
that were previously shown to recognise type 3 E2 are shown in Figure 4.4B. As before, 
ALP98 (a), ALP1 (b) and AP266 (c) recognised both genotype 1 and genotype 3 E2 in 
ELISA. ALP98 showed similar levels of reactivity to E2 of both genotypes, whether 
expressed alone or along with core and El. ALP1 did not recognise genotype 3 F2 E2, 
which agreed with the previous Western blot and immunofluorescence findings. With 
ALP1, similar absorbance readings were seen for the equivalent genotype 3 (R3) and 
genotype 1 (H77) constructs, whereas with AP266, higher readings were seen with 
genotype 3 than genotype 1. The same cell extracts were used for all ELIS As in this 
figure, therefore the degree of reactivity of different antibodies against proteins of the 
same construct could be compared. With both ALP1 and AP266, the absorbance readings 
for E2 expressed alone were lower than for E2 co-expressed with core and E l . This 
applied to both type 1 and type 3 but it was not possible to guarantee that the expression
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levels of all the constructs were equivalent. The results shown in this figure were from 
one experiment but this was repeated 3 times from the protein expression stage. As 
equivalent levels of expression could not be ensured, the results of these 3 experiments 
could not be incorporated into one figure but the other experiments all showed similar 
trends to those reported above.
None of the antibodies tested above displayed any tendency towards recognising 
conformational epitopes only. It would be of interest to know if a conformation- 
dependent antibody would be able to recognise both genotypes 1 and 3 E2, even if there 
are differences in the primary sequence. Small quantities of known conformation- 
dependent E2 antibodies were available from J. Dubuisson. These were raised against 
genotype 1 (strain HCV-H) E2 as described by Deleersnyder et al. (1997). The reactivity 
of these antibodies against native forms of both genotypes 1 and 3 E2 was analysed by 
ELISA (Figure 4.5). A non-conformation-dependent antibody, AP266, was included and 
reactivity with all E2-expressing extracts indicated that expression levels were optimal. 
However, the conformational antibodies recognised only H77 E2. Reactivity was higher 
with H50, H53 and H60 than H30 and H61. Due to limitations on the quantities of these 
antibodies, it was only possible to repeat this experiment twice, each from the protein 
expression stage. Both experiments showed reactivity with H77 E2 only.
The epitopes of some of these antibodies had been mapped by Arvind Patel, using 
peptides (Figure 4.6) based on the amino acid sequence of the HCV genotype la  strains 
Gla or HCV-H (personal communication). The amino acid sequences of El and E2 of 
genotype 1 (H77) and genotype 3 (R3) are aligned in Figure 4.6. The proposed antibody 
epitopes were marked on the sequence and distinction was made between those antibodies 
that recognised both types 1 and 3 and those that recognised only type 1. The epitopes of 
ALP98 and AP266 (aa 650-657) were identical and conserved between R3 and H77.
ALP1 recognised an overlapping epitope (aa 654-665) and there was one difference 
between R3 and H77 within this region. R3 had an isoleucine residue at position 660 
compared to a leucine residue in H77. There was also only one amino acid difference in 
the epitope recognised by AP33 (aa 412-423). This was a lysine residue at position 415
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Figure 4.5. Reactivity o f  genotype 1 conform ation- 
dependent antibodies against genotype 1(H77 &Gla) 
and 3 (R3) E2. E2-expressing cell extracts were prepared 
by electroporating BHK cells with in vitro transcribed RNA 
from pSFVR3cEiE2 (type 3), pSFVH77cEiE2, pSFVGlaCEiE2 
(both type 1) and pSFV 1. Native E2 was captured in GNA- 
coated wells and linear-epitope antibodies (AP266) or 
conform ational-epitope antibodies (H30, H50, H53, H60 
& H 6 1) were added. Antibody reactivity was m easured by 
the addition o f anti-mouse HRP conjugate and TMB 
substrate. The reaction was stopped by the addition o f 
H2S 0 4 and the absorbance m easured at 450 nm.
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in R3 and an asparagine residue in H77. The epitope recognised by AP320 (aa 464-471) 
was more variable and there were 3 such differences. At position 464 there was a serine 
in R3 and an aspartic acid in H77; at position 466 there was an arginine in R3 and an 
alanine in H77 and finally, at position 471 there was a serine in R3 and a proline in H77. 
The epitopes of the El antibodies had not been mapped down to the minimum number of 
amino acids, therefore just the general region recognised by each antibody is shown. It 
was evident that these epitopes for AP21.010 and API 19 were highly variable between 
genotype 1 and 3. These antibodies were only tested against the genotype 1 Gla isolate 
and it has since been shown that API 19 does not recognise H77 El (A. Patel, personal 
communication). There are only two differences in the H77 sequence that could account 
for this loss of reactivity, a valine at position 242 instead of a methionine and a lysine at 
position 252 instead of an arginine (compare epitope tested to H77 sequence in Figure
4.6).
4.3. Localisation of genotype 3 E2
The immunofluorescence data suggested that genotype 3 E2 showed a similar staining 
pattern to genotype 1 E2 (Figure 4.3A) which had been shown to localise to the 
endoplasmic reticulum (ER) (Dubuisson et al., 1994). Calnexin is an ER chaperone 
protein and can therefore be used as an ER marker. To investigate whether genotype 3 
E2 was localised to the ER, Huh7 cells expressing genotypes 1 and 3 E2 were probed with 
both anti-E2 (ALP98) and anti-calnexin antiserum in an indirect immunofluorescence 
assay. Localisation of the two proteins was analysed by confocal microscopy (Figure
4.7). The red staining indicated E2 and the green staining indicated calnexin. The E2- 
expressing cells in panels c, g and k were probed for E2 only, whereas those in panels d, h 
and 1 were probed for calnexin only, however both secondary antibodies were used in all 
reactions. The fact that no staining was visible in panels g and d ensured that there was 
no cross-reaction of antibodies which could have led to false positives. Cells expressing 
type 3 E2 (panels a, e and i) and type 1 E2 (panels b, f  and j) were probed for both E2 and 
calnexin and the merged images are shown in panels i and j. The yellow staining 
indicated regions where E2 and calnexin were found in the same area of the cell i.e.
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regions of colocalisation for E2 and calnexin. Extensive colocalisation was seen for both 
genotypes 1 and 3 E2 with calnexin.
4.4. Interaction of genotype 3 E l and E2
4.4.1. Analysis of glycoprotein complex formation
Two methods have been described for distinguishing between the two forms of HCV 
glycoprotein complex. Some studies have made use of a conformation-sensitive E2 
antibody that selectively recognises the native complex (Deleersnyder et al., 1997, 
Cocquerel et al., 1998). The majority of studies have utilised non-reducing 
electrophoresis conditions to differentiate between the aggregate and native forms of 
glycoprotein complex (Dubuisson et al., 1994, Dubuisson & Rice, 1996). In the absence 
of reducing agents such as p-mercaptoethanol or dithiothreitol (DTT), the disulphide- 
linked aggregates remain at the top of the gel, while the non-covalently linked proteins, 
which constitute the native complex, migrate as monomers.
The genotype 3 (R3 and F2) and genotype 1 (H77) structural proteins were expressed in 
Huh7 cells and proteins were labelled with S-methionine. This was particularly 
necessary for detection of genotype 3 El for which there was no available antibody. 
Radiolabelled type 3 El could be detected upon immunoprecipitation with anti-E2 
antibody, as opposed to detection with anti-El antibody by Western blot analysis. 
Radiolabelling also allows for detection of all forms of the protein, some of which may 
not be recognised by a certain antibody. The E2 protein and any interacting proteins, 
were immunoprecipitated from the cellular extracts with an anti-E2 antibody (ALP98).
For analysis of the two forms of glycoprotein complex, the precipitated proteins were 
divided into two equal portions and one portion was treated with the reducing agent, 
dithiothreitol (DTT) which reduces disulphide bonds. The remaining precipitated 
proteins were not treated to allow for distinction between the aggregates and native 
complex. These reduced and non-reduced proteins were separated by SDS-PAGE and are
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shown in Figure 4.8. In lanes 1-3 of the non-reduced samples there was a strong protein 
band at the top of the gel, which was thought to be the aggregate. Below this, bands 
representing the monomeric forms of E2 at approximately 66 kDa and El at 
approximately 30 kDa were visible. The El and E2 proteins of the different constructs 
appeared to be slightly different sizes and this will be discussed further in section 4.4.2. 
This also provided the first proof of El expression from the genotype 3 constructs, R3 and 
F2. In spite of the addition of DTT, this high molecular weight aggregate was still visible 
in lanes 1-3 of the “reduced” samples. The monomeric forms of El and E2 were also 
visible but there appeared to be a greater amount present here than in the non-reduced 
samples (compare lane 1 of “non-reduced” with lane 1 of “reduced”). An additional 
protein band of approximately 97 kDa was present in both non-reduced and reduced 
samples and the size suggested it was the E1E2 complex. With all three HCV constructs 
there was a fainter protein band visible below the dominant El protein band. This could 
be the oxidised form of El that migrates faster than the reduced form (Dubuisson & Rice,
1996). The ability of the recombinant proteins expressed from the SFV vector to shut off 
host protein synthesis is evident from the lack of cellular protein in lanes 1-4 compared to 
lane 5.
The data presented above were obtained from proteins expressed in Huh7 cells.
However, when this was repeated in BHK cells, it was noted that there was considerably 
less formation of native complex. In order to assess this difference properly, the 
immunoprecipitation experiment was performed in duplicate, in Huh7 cells and BHK cells 
(Figure 4.9). The non-reduced protein samples are shown in (a) and the DTT-treated 
reduced samples in (b). In lanes 1-3 of the non-reduced samples expressed in Huh7 cells, 
the protein bands representing the E1E2 complex (~97 kDa), E2 (-66 kDa) and El (-30 
kDa) were clearly visible. However, in the equivalent lanes for BHK cells, the bands 
representing E1E2 and E2 were barely visible. The El protein bands were more evident 
but were much fainter than those from the Huh7 cells. Aggregates were present in both 
cell types. In the reduced samples, there was no apparent difference between the 
intensities of the protein bands in Huh7 and BHK cells. In addition to the R3 (genotype 
3) and H77 (genotype 1) constructs that were previously analysed in Figure 4.8, this
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Figure 4.8. Im munoprecipitation o f E l and E2 with anti-E2, 
ALP98. EIuh7 cells were electroporated with in vitro transcribed 
RNA from pSFVR3cEiE2 (lane 1), pSFVF2cEiE2 (lane 2), 
pSFVH77cEiE2 (lane 3) and pSFV l (Lane 4). Lane 5 contains 
extract o f  m ock electroporated cells. Proteins were radiolabelled 
with 35S-methionine and imm unoprecipitated with anti-E2 
attached to protein A sepharose beads via rabbit anti-m ouse IgG. 
Bound proteins were removed and half o f the sample was treated 
with DTT (reduced samples) while the other h a lf rem ained 
untreated (non-reduced samples). The proteins were separated 
on a 10% polyacrylamide gel. The positions and sizes o f  E l and 
E2 are indicated.
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experiment included the other genotype 1 strain, Gla (lane 3). This strain also shows 
evidence of both native complex and aggregate complex formation.
4.4.2. Comparison of E l and E2 glycosylation states between 
genotypes 1 and 3.
The difference in sizes of E2 between the different constructs was first noted during 
Western blot analysis (Figure 4.2). However it became more evident in the 
immunoprecipitation experiments that E2 of the F2 construct migrated faster than that of 
the R3 construct which in turn migrated faster than E2 of H77 (Figure 4.8). The size of 
the El protein also differed between the constructs with El of F2 migrating fastest and El 
of R3 the slowest (Figure 4.8). As the El and E2 proteins were known to be heavily 
modified by TV-linked glycosylation, the most likely explanation was that the proteins had 
different glycosylation states. As discussed in chapter 3, the protein sequence predicted 5 
glycosylation sites in El for R3 and H77 and 4 for F2. E2 had 10 predicted glycosylation 
sites for R3, 11 for H77 and 9 for F2. To analyse these differences, the proteins were 
immunoprecipitated as before and were treated with glycosidases (Endo H and PNGase F) 
before separation by SDS-PAGE (Figure 4.10). These enzymes should remove the 
carbohydrate portion from the protein and therefore the protein band should represent that 
of the protein backbone alone. In lanes 1-3 of the glycosidase-treated samples, the 
unglycosylated form of the E1E2 complex was seen at approximately 60 kDa. Two 
forms of the unglycosylated E2 protein were seen, a 41 kDa form and a 36 kDa form.
The larger protein was probably the uncleaved E2/p7 protein whereas the smaller was the 
fully cleaved E2 protein. In the PNGase F-treated samples, the unglycosylated form of 
El was approximately 18 kDa in all three constructs. This applied to the Endo H-treated 
forms of El for the R3 and F2 constructs as well but the Endo H-treated form of H77 El 
migrated slightly faster.
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Figure 4.10. Immunoprecipitation o f glycosylated and 
unglycosylated forms o f El and E2 with anti-E2. Huh7 cells 
were electroporated with in vitro  transcribed RNA from 
pSFVR3cEiE2 (lane 1), pSFVF2cEiE2 (lane 2), pSFVH77cEiE2 
(lane 3) and pSFVl (lane 4). Proteins were radiolabelled and 
immunoprecipitated as described in Fig. 4.8. Samples were 
divided into three equal parts and proteins treated with 
glycosidases (Endo H or PNGase F) or left untreated. Proteins 
were separated on a 10% polyacrylamide gel. The positions 
and sizes o f  the different forms o f El and E2 are indicated.
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4.5. Discussion
Of the 11 anti-E2 antibodies tested which recognised genotype 1 (H77) E2, only 4 
(ALP98, AP266, ALP1 and R646) were able to recognise genotype 3 E2 as well.
Western blot analysis (Figure 4.2) shows that the E2 protein is approximately 66 kDa for 
both genotype 1 and 3 isolates, with slight differences in migration detectable. These 
differences will be discussed in detail later but generally the size of genotype 3 E2 is in 
agreement with that of genotype 1 which has been reported as 68 kDa (Dubuisson et al., 
1994). In ELISA analysis of ALP98 reactivity (Figure 4.4B), there is evidence of more 
reactivity with the construct expressing both El and E2 than that expressing E2 alone but 
this is only evident with R3 and not H77. Also it is not possible to ensure that the 
expression levels of these constructs are equivalent, therefore the degree of reactivity is 
not directly comparable. The epitope on E2 recognised by ALP98 (Figure 4.6) is fully 
conserved between genotype 3 and genotype 1 and therefore it is not surprising that 
ALP98 recognises both types 1 and 3 E2. This epitope also contains one of the conserved 
cysteine residues and a conserved glycosylation site. The epitope recognised by AP266 
has been mapped to the same position as that of ALP98 but Western blot analysis does not 
show an identical pattern of protein recognition (Figure 4.2). This may be simply because 
more antibody was present for ALP98 (which was used in its concentrated form) and 
therefore stronger activity is seen here than with AP266. Alternatively, it suggests that 
the complete epitopes recognised by these antibodies are different. Comparison of the 
reactivity of these antibodies by ELISA (Figure 4.4B) indicates that AP266 recognises 
denatured E2 better than native E2, whereas ALP98 recognises both equally well. This 
increased activity with ALP98 may reflect recognition of additional proteins as 
demonstrated in Western blot analysis. A second possibility is that the epitope recognised 
by ALP98 is equally accessible on the denatured and native protein, whereas the epitope 
recognised by AP266 is more accessible on the denatured form of E2 than the native form. 
This is speculative. Suffice to say there is no difference in reactivity of these antibodies 
with genotype 1 and genotype 3 E2.
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ALP1 does not recognise E2 of the genotype 3 F2 construct in Western blots, 
immunofluorescence or ELISA. It does however recognise E2 of the genotype 3 R3 
construct. Within the epitope recognised by ALP1 (Figure 4.6) is one of the amino acids 
that is mutated in R3 (mutation 8 in Figure 3.6). There is a glycine residue at position 
661 in F2 and a glutamic acid residue in R3. This is the only difference between these 
constructs in this region and therefore must account for the difference in reactivity with 
ALP1. Glutamic acid has a larger side chain than glycine, so the loss of reactivity may be 
due to this local structural change. There is an additional amino acid difference between 
genotype 1 and genotype 3 within this epitope but it does not have an effect on reactivity. 
Genotype 1 has a leucine residue at position 660 and in genotype 3 this is an isoleucine. 
These residues are similar and there is no significant difference in the size of the side 
chain, which probably explains why there is no loss of reactivity with ALP 1. It is 
interesting that the only monoclonal antibodies that recognise genotype 3 E2 all recognise 
epitopes within a 16 amino acid region. There are several stretches of conserved regions 
between genotypes 1 and 3 but interestingly, there are no antibodies specific to these 
regions. The only other antibody that showed potential for recognising genotype 3 E2, 
was the polyclonal R646. However, this could only be demonstrated in Western blot 
analysis (Figure 4.2). In immunofluorescence (Figure 4.3B) and ELISA (data not 
shown), the true reactivity was difficult to distinguish from the high background levels, 
though E2-specific staining was visible in immunofluorescence which is an advantage of 
this technique over ELISA. The activity of this antibody against type 3 E2 is therefore 
much less than with type 1 E2 but it is not absent. As with the data from the monoclonal 
antibodies, this indicates that there are differences between the epitopes on the type 1 and 
type 3 E2 proteins.
The epitopes have been mapped for two of the antibodies that recognise only genotype 1 
E2 (Figure 4.6). Within the epitope recognised by AP33 there is only one amino acid 
difference between type 1 and type 3, a lysine residue in R3 and an asparagine residue in 
H77. Lysine has a larger side chain than asparagine. This could mean that the antibody 
is not able to bind and would explain the loss in reactivity. Apart from this residue, the 
epitope is conserved between R3 and H77, including a glycosylation site. This lysine
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residue is also present in the genotype 3 HCVCENS1 isolate (accession no: X76918) but 
in the remaining published genotype 3 isolates there is an asparagine at this position as in 
H77 (Figure 3.4), therefore it is possible that AP33 would recognise these genotype 3 
isolates. In contrast, AP320 recognises an epitope that is quite variable. Of the 3 
positions where the sequence of R3 differs from that of H77 in this region (Figure 4.6), 
possibly the most influential is the change from a proline to a serine at position 471. As 
discussed in chapter 3, proline affects the local protein structure due to its rigid nature and 
loss of this structure could lead to loss of antibody reactivity. Additionally, the arginine 
residue at position 466 in R3 is much larger than the alanine in H77, which could also 
explain the loss of reactivity to type 3 E2. The epitopes of the conformation-dependent 
E2 antibodies have not been determined and therefore no conclusions can be drawn from 
their lack of reactivity to genotype 3 E2, other than it is likely to be due to a structural 
difference. Interestingly, the E2 protein of the genotype 1 Gla isolate is also not 
recognised by these antibodies, so even between isolates of the same genotype, the 
structure may differ.
None of the three El antibodies tested were able to recognise genotype 3 E l . Judging 
from the degree of variability of the sequence between type 1 and 3 within the epitopes 
recognised by AP21.010 and AP119 (Figure 4.6), this is not unexpected. However, the 
fact that even the polyclonal antibody (R528) does not show any reactivity with type 3 El, 
suggests that the exposed regions of the El proteins are quite variable.
The cytoplasmic staining of genotype 3 E2-expressing cells seen in immunofluorescence 
with ALP98 (Figure 4.3A), was comparable to that of genotype 1 E2-expressing cells.
This suggested that, as described for type 1 E2 (Dubuisson et al., 1994), type 3 E2 is 
localised to the endoplasmic reticulum. Evidence of colocalisation between both 
genotypes 1 and 3 E2 with the ER marker, calnexin, indicates that genotype 3 E2 does 
localise to the ER (Figure 4.7). Typical reticular-like staining is seen for both E2 and 
calnexin. Comparison of the co-localisation patterns for genotypes 1 and 3 shows that 
with genotype 3 there is more evidence of E2 expression on the cell surface than with 
genotype 1. This could be followed up by analysing the medium of expressing cells for
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evidence of E2 secretion or by creating a 3-dimensional image of the expressing cell, 
using the Z-stack function during confocal microscopy analysis. The co-localisation 
pattern also confirms that there must be an ER retention signal for type 3 E2. The ER 
retention signal for genotype 1 has been identified (Cocquerel et al., 1998 & 2000) and the 
conservation with genotype 3 is shown in Figure 3.11.
Immunoprecipitation with the anti-E2 antibody, ALP98, confirmed that genotype 3 El and 
E2 interact with each other, as determined by the appearance of 66 kDa and 30 kDa 
protein bands representing E2 and El respectively (Figure 4.8). This is true for both R3 
and F2 constructs, indicating that none of the 9 mutations in F2 have an effect on the 
E1/E2 interaction. Yi et al. (1997) mapped the region of E2 involved in the El 
interaction to amino acids 415-500, although the actual binding regions are thought to be 
discontinuous. Within this region there are two amino acid differences between F2 and 
R3 (Figure 3.6) at positions 496 and 499 but the immunoprecipitation results suggest that 
these residues are not important for the E1/E2 interaction. Furthermore, it was shown that 
the amino acid residues “WHY” from 488-490 are critical for E2 interaction with El (Yi 
et al., 1997) and these residues are fully conserved between all genotype 3 isolates and 
genotype 1 (Figure 3.4), confirming the functional importance of these residues. The 
region of El involved in interacting with E2 has only been restricted to the N-terminal part 
(aa 192-238) (Yi et al., 1997) in which there is one amino acid difference (at position 236) 
between F2 and R3, but again this does not appear to affect the E1/E2 interaction. This 
would suggest that the El and E2 proteins interact via their ectodomains. However, this 
is complicated by the fact that it has been shown that the native E1/E2 interaction is 
abolished when truncated forms of El and E2 are expressed (Michalak et al., 1997) and 
Patel et a l (2001) have also demonstrated that the TMD of E2 is critical for correct 
folding of El and hence native complex formation. Truncated forms of genotype 3 El 
and E2 have not been analysed so it is not known if a similar function can be attributed to 
the type 3 TMDs.
Two different forms of the E1E2 complex have been widely reported. The heterodimer is 
stabilised by non-covalent interactions and is considered to be the native form of the HCV
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glycoprotein complex (Deleersnyder et al., 1997). In contrast, the aggregate contains 
intermolecular disulphide bonds and is thought to represent misfolded proteins (Dubuisson 
et al., 1994). Both non-reduced and DTT-reduced proteins were analysed to determine 
the ability of the genotype 3 glycoproteins to form these different complexes (Figure 4.8). 
The presence of monomeric El and E2 in the non-reduced samples indicates that these 
proteins formed a non-covalently-bonded complex, as complexes containing covalent 
interactions remained intact and did not migrate through the gel. The 97 kDa heterodimer 
of El and E2 was also visible. Therefore, as described for genotype 1, the genotype 3 
glycoproteins formed both aggregate and native complex. In addition, formation of 
native complex has been reported to be accompanied by an oxidised form of El which 
migrated faster (Dubuisson & Rice, 1996) and this form was visible for both genotype 3 
constructs. A similar protein pattern was seen for the reduced samples except that the 
amounts of E2 and El monomer were greater than in the non-reduced samples. This was 
because as well as the proteins from the native complex, there were also proteins present 
which originated from the aggregated complex which was reduced by the addition of 
DTT. However, this explanation is over-simplified as Patel et al. (1999a) demonstrated 
that the aggregate also contained non-covalent interactions, as proteins expressed in the 
presence of DTT continued to precipitate as monomers under non-reducing conditions. 
This interpretation was based on the observation that the majority of complexes 
synthesised by the genotype 1 Gla strain were aggregated and under non-reducing 
conditions, very few monomeric forms of El and E2 were seen. These proteins were 
expressed in BHK cells using the SFV system and when I repeated this, the same 
observation was made (Figure 4.9a, lane 3, BHK). The same applied to genotype 1 H77 
(Figure 4.9a, lane 2, BHK) and genotype 3 R3 (lane 1). In other words, evidence of 
native complex was indicated by the presence of faint bands representing El monomers 
but the neither the E2 monomer nor E1E2 complex was visible on the non-reducing gel. 
However, when the proteins were expressed in Huh7 cells, there was clear indication of 
both El and E2 monomers as well as the native E1E2 complex with all three constructs 
(Figure 4.9a, Huh7). No significant differences were observed between the proteins 
expressed in BHK and Huh7 cells when analysed under reducing conditions (Figure 4.9b). 
The reason for the different appearances of the “native” El and E2 monomers when
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expressed in BHK and Huh7 cells and analysed by non-reducing SDS-PAGE is not clear. 
This difference was not been reported by a study using other expression systems. 
Dubuisson et al. (1994) examined complex formation of HCV glycoproteins expressed 
from recombinant vaccinia viruses in a human hepatoma cell line (HepG2), porcine 
kidney cells (PK-15) and BHK cells and reported similar results for all three cell types. 
They also examined formation of glycoprotein complexes when El and E2 were 
expressed from recombinant Sindbis viruses, which is related to SFV, in BHK cells only 
and no differences were observed between this system and the vaccinia virus expression 
system. Whatever the reasons, the differences observed in this study are a side-issue to 
the main objective, which was to determine if the genotypes 1 and 3 glycoproteins 
behaved similarly in terms of complex formation. In conclusion, genotypes 1 and 3 
glycoproteins are able to form both aggregates and native complexes.
It is evident from Figures 4.8 and 4.9, that both the El and E2 proteins of the genotype 3 
and genotype 1 isolates have different mobilities. It is known that genotype 1 E2 is 6 
amino acids shorter than genotype 3 E2 (section 3.3.1) but this does not agree with the 
observed differences in migration and the most likely explanation is differing 
glycosylation states. Analysis of the E2 protein sequences has shown that R3 has 10 
predicted glycosylation sites, H77 has 11 (Figure 3.4) and F2 has 9 due to the mutation at 
position 558 which abolishes a glycosylation site (Figure 3.6). This is in agreement with 
the observed mobilities of the untreated E2 proteins (Figure 4.10), with F2 E2 migrating 
fastest and H77 E2 migrating slowest. After glycosidase treatment, the unmodified E2 
proteins all co-migrate; indicating that differing glycosylation states was responsible for 
the different mobilities. The E2-p7 product is indistinguishable from the E2 product in 
the untreated samples, however, once the A-linked sugars are removed, the uncleaved 
E2p7 is visible as a slower migrating protein above the fully cleaved E2 product (Figure 
4.10). This larger product was first described by Grakoui et al. (1993a) but was only 
identified as E2p7 by Lin et al. (1994) and Mizushima et al. (1994). This work confirms 
that as with genotype 1, the cleavage at the E2/p7 site is incomplete in genotype 3.
The El protein has 5 predicted glycosylation sites in R3 and H77 and 4 in F2 (due to 
mutation at position 236). However, in genotype la  it has been shown that the site at
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position 325 is not glycosylated due to the presence of a proline immediately after the 
tripeptide recognition sequence (Meunier et al., 1999). This proline residue is present in 
genotype 3 as well, so this site may also be precluded from glycosylation in genotype 3 
E l. The relative mobilities of the untreated El proteins of R3, F2 and H77 (Figure 4.10) 
suggests that R3 has an additional glycosylation site or conversely, that H77 has one less. 
Possibly, the 5th glycosylation site is used in R3 but not in H77. Although, if  this site is 
used in R3, it would also be used in F2 which would mean that both H77 Eland F2 El 
have 4 glycosylation sites and should co-migrate but they do not. Similar differences in 
mobility of the H77 and Gla El proteins were reported by Patel et al. (1999a) and are also 
seen in Figure 4.9 but are not explained by differing glycosylation states. There is also a 
discrepancy in the mobility of H77 El in the reduced and non-reduced samples (Figures 
4.8 and 4.9), with the non-reduced El migrating faster than the reduced E l . This 
suggests that the El proteins in the native complex and aggregate may be processed 
differently or that El in the native complex has a more compact conformation due to 
reshuffling of disulphide bonds as proposed by Dubuisson and Rice (1996). This is not 
observed with either the genotype 1 Gla isolate or the genotype 3 isolate. Treatment with 
peptide 7V-glycosidase F (PNGase F) resulted in co-migration of El from R3, F2 and H77 
but when treated with endoglycosidase H (Endo H), H77 El migrated marginally faster 
than El of R3 and F2 (Figure 4.10). The reason for treating the proteins with both Endo 
H and PNGase F is that it provides additional information on the subcellular localisation 
of these proteins. Endo H removes the high-mannose A-linked sugars but not the 
complex forms. In contrast, PNGase F removes both high-mannose and complex sugars. 
Resistance to Endo H digestion but not PNGase F digestion indicates that the protein has 
left the ER and is in the medial or trans Golgi, where complex sugars are added. There is 
no evidence of resistance to Endo H digestion in any of the constructs, which confirms 
that El and E2 are retained in the ER. These data would therefore not support any 
proposed surface expression of R3 E2 as suggested by the calnexin co-localisation data. 
There is a difference in mobility between Endo H- and PNGase F-treated H77 El. 
Dubuisson et al. (1994) reported a similar observation with the genotype lb HCV-BK 
strain but not with the genotype la  HCV-H strain which is most similar to H77. There is 
no obvious explanation for this other than perhaps one of the glycans on H77 and BK El
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is resistant to PNGase F digestion. These results do suggest that the unmodified El 
protein of H77 is smaller than that of R3 or F2. This is not predicted from the sequence 
so may possibly be attributed to differences in disulphide bonding which creates a more 
compact structure, although all 8 cysteine residues are conserved in both genotype 1 and 
3.
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Chapter 5 
Interaction of HCV E2 with 
PKR and PERK.
5.1. Investigation of HCV E2 interaction with Protein 
Kinase R (PKR).
5.1.1. Introduction
The most established functional difference between HCV genotypes 1 and 3 to date is that 
patients infected with genotype 3 have a much higher response rate to interferon 
treatment, either alone or in combination with ribavirin (McHutchison et al., 1998, 
Zeuzem et al., 2000). The mechanism behind this remains unclear but two HCV proteins, 
NS5A and E2, have been implicated in the evasion of the interferon (IFN) response 
through inhibition of protein kinase R (PKR) activity (Gale & Katze, 1998). PKR is a 
critical component of the IFN-induced antiviral response and several viruses have evolved 
mechanisms to block its activity. The high failure rate of IFN therapy in HCV infected 
individuals suggests that HCV has also developed such a mechanism. Most studies have 
focused on the role of the NS5A protein since Enomoto et al. (1995 &1996) identified an 
IFN-sensitivity determining region (ISDR) within NS5A of genotype lb. If there were 
four or more amino acid “mutations” in the ISDR, it was reported that all patients 
responded to IFN therapy. Several groups have attempted to confirm the predictive value 
of the sequence within the ISDR but this has proved controversial as, at first, most studies
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from outside Japan were unable to show such a correlation (Zeuzem et al., 1997, Khorsi et 
al., 1997, Hofgartner et al., 1997). More recently, some European studies have reported a 
correlation between “mutant” type lb isolates and sustained response (Saiz et al., 1998, 
Sarrazin et al., 1999) and suggested the discrepancy is due to the relatively low prevalence 
of genotype lb isolates in Western countries compared to Japan. Genotype la  has a high 
prevalence in the United States and Europe and shows the same response rates as 
genotype lb, however no correlation between response and mutations in the ISDR of type 
la  isolates has been demonstrated (Sarrazin et al., 2000a, Zeuzem et al., 1997).
Likewise, no correlation has been reported for genotype 3a (Saiz et al., 1998, McKechnie 
et al., 2000, Sarrazin et al., 2000b).
The biological significance of the ISDR appeared to be confirmed when Gale et al. (1997) 
demonstrated that NS5A interacted with and inhibited PKR in a yeast expression system 
and that deletion of the ISDR abolished this ability. In addition to the ISDR, an 
additional 26 amino acids downstream of the ISDR were required for PKR-binding and 
introduction of multiple mutations in the ISDR (as found in IFN-responsive isolates) 
abrogated the NS5A/PKR interaction and inhibition (Gale et al., 1998). The same 
laboratory was able to show that NS5A from genotype 3a nonresponder was also able to 
inhibit PKR in the yeast assay (personal communication, C. Blakely). This was the same 
patient (and serum sample) as was used in this present study but is the only known 
information on a non-genotype 1 NS5A effect on PKR. Despite this evidence, there is 
still doubt over the role of the ISDR in combating the antiviral effects of IFN. Several 
studies have shown that expression of NS5A confers partial resistance to IFN, allowing 
growth of IFN-sensitive viruses such as encephalomyocarditis virus (EMCV) (Paterson et 
al., 1999, Polyak et al., 1999, Song et al., 1999). However, the expression of a mutant, in 
which the entire ISDR was deleted, retained this ability (Polyak et al., 1999) and Paterson 
et al. (1999) reported that NS5A clones derived from a responder patient were more 
inhibitory than those from a nonresponder, indicating that the effects of NS5A in vitro do 
not correlate with the clinical response. Following on from these studies, Francois et al. 
(2000) examined the inhibitory effect of the entire HCV genotype 1 a polyprotein and 
reported that it conferred partial resistance to IFN as measured by the growth of EMCV.
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However, they also reported that there was no evidence that PKR activity was affected by 
the expression of the HCV proteins.
The development of a subgenomic replicon system for HCV allowed investigation of the 
effect of IFN on HCV replication. The levels of both replicon RNA and HCV proteins 
are reported to decline after IFN treatment, in a dose-dependent manner (Frese et al., 
2001). Interestingly, Blight et al. (2000) have identified an adaptive mutant which lacks 
the entire ISDR, but both this mutant and the wild type replicons were highly sensitive to 
IFN treatment. Similarly, Gou et al. (2001a) reported sensitivity to IFN in replicons 
derived both from IFN-resistant and -sensitive cDNA clones from patients. However, 
HCV replicons persisted even at high concentration of IFN and long-term treatment failed 
to select IFN-resistant variants. Subsequently, IFN has been reported to “cure” cells from 
replicons and this process is dependent on cellular factors, but not PKR. or RNaseL (Guo 
et al., 2001b). To date, there have been no reports on the effect of the HCV replicon on 
PKR activity and none of the replicons, even if including the HCV structural genes, form 
virus particles (Pietschmann et al., 2001), so it is still not possible to observe the effects of 
IFN in terms of the complete virus life cycle.
The involvement of E2 in mediating IFN resistance was first suggested by Taylor et al. 
(1999). Within E2, the authors identified a 12 amino acid sequence which shares 
homology with the autophosphorylation sites of PKR and the phosphorylation site of its 
substrate, eIF2a (Figure 5.1). This region was named the PKR- eIF2a phosphorylation 
homology domain (PePHD). The PePHD regions of the IFN-sensitive genotypes (2 and 
3) were noted to have less homology to PKR than the more resistant genotypes (la  and 
lb) and this was proposed as an explanation for the differing responses to IFN therapy.
The authors suggested that NS5A may be involved in the development of resistance over 
the course of IFN treatment as demonstrated by the appearance of different NS5A 
quasispecies, whereas E2 is responsible for the intrinsic resistance or sensitivity of an 
HCV genotype. Genotype 1 E2 was shown to interact with PKR in an in vitro assay and 
the PePHD region was required for this interaction. PKR activity was also inhibited by 
genotype 1 E2 in yeast and mammalian cells (in a PePHD-dependent manner) and this
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Figure 5.1 Amino acid sequence o f  the PePHD region for 
genotype lb (HCV-J), genotype la (HCV-H) and genotype 
3a (NZL1). The sequence surrounding the PKR 
phosphorylation site o f  eIF2a and the autophosphorylation 
sites o f  PKR are shown in comparison. The phosphorylation 
sites are indicated w ith“*”. In the PePHD alignment, 
represents an identical amino acid. Taken from Taylor 
et al. (1999).
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was abolished when the PePHD was mutated to resemble that of genotypes 2 and 3. In a 
follow-up study, it was shown that this inhibition is not due to E2 acting as a 
pseudosubstrate for PKR autophosphorylation sites (Taylor et al., 2001).
5.1.2. Sequence analysis of the PePHD region of genotype 3 E2 
in patients with differing responses to interferon therapy.
There are extensive clinical data to show that HCV genotype 3 is more sensitive to IFNa 
than genotype 1. However, a proportion of genotype 3-infected individuals do not have a 
sustained response to treatment. In the paper describing identification of the PePHD 
region in E2, Taylor et al. (1999) indicated that the blocking of IFNa through PKR 
occurred only when the sequence matched that of genotype 1, and that this was abolished 
when the sequence was mutated to resemble that of genotype 2 or 3. Therefore, those 
genotype 3-infected individuals who are found to be resistant to IFNa treatment may 
harbour a PePHD variant similar to that of genotype 1.
A visiting worker, Alexandra Cochrane, performed the following study in collaboration 
with Alexander Orr and myself. RNA was extracted from serum, reverse-transcribed and 
the PePHD region amplified by PCR from 14 genotype 3-infected patients. The patients 
showed a range of treatment outcomes which included sustained responders (SR), non­
responders (NR), relapsers (REL) and breakthrough (BT) patients (see Figure 5.2 for 
definitions). The breakthrough patients were of particular interest, as due to the 
quasispecies nature of HCV, it is possible that a PePHD variant exists as a minority at first 
and then undergoes positive selection during the course of interferon treatment. In view 
of this, the PePHD regions of the BT and REL patients were sequenced from serum 
samples collected both before treatment and during (patients 5 and 6) or after (patients 4, 8 
and 9) treatment (for simplicity these are referred to as post treatment samples).
Following RNA extraction, the viral RNA was reverse transcribed and the cDNA was 
amplified through two rounds of PCR. After purification, the PCR products were 
sequenced and the derived amino acid sequences (position 617-707) and the response to
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Figure 5.2 Diagrammatic representation o f  the response 
definitions for IFN treatment o f chronic hepatitis C.
SR = sustained responder, Rel = relapse, BT = breakthrough 
and NR = non-responder.
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therapy for each patient is shown in Figure 5.3. The PePHD region in genotype 3 is from 
aa 665-677 (numbering according to NZL1) and is highlighted in yellow. Only one 
patient (a non-responder) had a PePHD variant which differed from the consensus 
genotype 3 sequence. This variant had a single amino acid change towards the genotype 
lb sequence. Incidentally, the patient is the same one whose serum was used for 
amplification of the structural genes of genotype 3 HCV (see chapter 3). The 30 amino 
acids downstream of the PePHD region showed no variation. Some variation was 
observed in the upstream sequence but this showed no correspondence to either treatment 
response or the time of sample collection.
In conclusion, in this study of 14 genotype 3 infected patients there were no consistent 
differences between responders and non-responders and there was no evidence for positive 
selection of PePHD variants in the breakthrough or relapser patients.
5.1.3. Localisation of E2 and PKR within the cell
5.I.3.I. Cloning of H77 E2 into pcDNA 3.1
For the purposes of studying the effect of E2 on endogenous cellular proteins, it was 
necessary to express the E2 protein in a system other than the SFV system in which there 
is shutdown of host cell protein synthesis. The pcDNA 3.1 vector (Figure 5.4) was 
chosen as a suitable vector where the expression of E2 is under the control of a 
cytomegalovirus (CMV) promoter. A construct encoding H77 El and E2 in the pcDNA 
vector (Pc H 7 7 e ie 2 )  was available from Dr A.Patel (MRC Virology Unit, Glasgow). The 
strategy for subcloning E2 from this E1/E2 construct is illustrated in Figure 5.5. The 
plasmid was first cut with the restriction endonuclease Ncol which cleaved at the end of 
El but before the signal sequence for E2. This released a fragment of approximately 
1.5Kb including the E2 gene and part of the vector. The 5’ overhang was filled in with 
Klenow DNA polymerase to create a blunt end and the fragment was then cleaved with 
the restriction endonuclease Xbal which cuts in the vector portion. The resultant
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fragment was inserted into the pcDNA vector which had been cleaved with the EcoRN 
and Xbal restriction endonucleases. This construct was named pcH77E2.
5.1.3.2. Treatment of cells with interferon a
This work was done by Suzanne Barnard (Division of Virology, University of Glasgow), 
using the same batch of interferon which was used in the PKR study. A cis-reporter 
plasmid, containing a consensus interferon-stimulated response element (ISRE) upstream 
of the luciferase gene, was used to assess the ability of this particular batch of interferon-a 
to activate transcription of the reporter gene. The plasmid was transfected into 2fTGH 
cells, which have been shown to have an intact IFN-signalling pathway (Pellegrini et al., 
1989) and following treatment with IFNa, the cells were assayed for luciferase activity. 
The results, with increasing concentrations of IFNa, are shown in Figure 5.6. Luciferase 
activity increased with increasing concentrations of IFNa up until 2500 U/ml where it 
started decreasing, probably due to saturation of the system. This indicated that this batch 
of IFNa was active.
5.1.3.3. Effect of interferon treatment on PKR expression
It has been widely reported that exposure of cells to IFN type I results in an increase in 
levels of PKR as a result of transcriptional activation of the gene (Meurs et al., 1990).
Two monoclonal antibodies directed against PKR were obtained for the purpose of 
studying the putative interaction of PKR and E2. One of these PKR antibodies (71/10) 
has been well characterised (Laurent et al., 1985) and was a gift from A.G. Hovanessian 
(Institut Pasteur) but was only available in limited quantities, while the other (B-10) is 
available commercially from Santa Cruz but has not been used extensively in published 
PKR studies. No positive control for PKR expression was readily available and therefore 
the use of a previously characterised PKR antibody would assist in positive identification 
of the PKR protein. The ability of these antibodies to recognise PKR in both untreated 
and IFNa treated Huh7 cells was analysed by indirect immunofluorescence and confocal
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Figure 5.7. Localisation and levels o f  endogenous PKR expression 
in interferon-treated and untreated Huh7 cells. Cells were treated 
with 1000 U/ml o f interferon-alpha for 18 hrs before being fixed in 
methanol and processed for indirect immunofluorescence. PKR was 
detected by two antibodies a) mouse monoclonal 71/10 (Dr A. 
Hovenessian) and b) mouse monoclonal B-10 (Santa Cruz). Panel 
(c) represents cells probed with goat anti-mouse FITC alone.
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microscopy (Figure 5.7). There was no clear difference in levels of PKR expression 
between IFN-treated and untreated cells with the 71/10 antibody (a). However, with the 
B-10 antibody, there was a noticeable increase in PKR expression in cells treated with 
IFNa (b).
5.1.3.4. Localisation of E2 and PKR
The reported interaction of genotype 1 E2 with PKR (Taylor et al., 1999) can only be 
significant if these two proteins are found in the same compartment within a cell. 
Colocalisation studies using immunofluorescence and confocal microscopy were 
performed to determine if this is the case. It is important to look at this in an appropriate 
cell type. Huh7 cells were transfected with pcH77EiE2 and treated with IFNa before 
probing for both E2 and endogenous PKR with antibodies R646 and 71/10 respectively 
(Figure 5.8.). The cellular localisation of PKR and E2 can be seen in panels (a) and (b) 
respectively and panel (c) shows the merged images of (a) and (b), where areas of 
colocalisation are depicted in yellow. PKR showed cytoplasmic staining as well as faint 
nuclear staining. E2 displayed typical endoplasmic reticulum (ER) staining as shown 
previously in Figure 4.7. The merged image showed small regions of possible 
colocalisation around the nuclear membrane but there was no evidence for definitive 
colocalisation between genotype 1 E2 and PKR. Unfortunately it was not possible to 
repeat this with genotype 3 E2 due to the lack of a polyclonal antibody to recognise type 3 
E2, or conversely, a polyclonal PKR antibody.
5.1.4. Interaction of PKR and E2
5.I.4.I. Lack of evidence for interaction of endogenous PKR and E2.
I further investigated the possibility of a direct interaction of E2 with PKR using 
immunoprecipitation in which an antibody was used to isolate a specific protein and any 
other protein which physically interacted with it. Proteins were then identified by
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Figure 5.8. Dual staining for type 1 E2 and endogenous PKR 
in interferon-treated Huh7 cells. Cells were transfected with 
pcH77EiE2 and treated with interferon as described in Figure 5.7.
They were then fixed and processed for indirect immunofluorescence.
a) endogenous PKR detected with mouse monoclonal 71/10.
b) type 1 E2 detected with rabbit polyclonal R646. c) merged 
image o f a and b. Bound antibodies were detected using goat anti­
mouse FITC and goat anti-rabbit TRITC.
Chapter 5
Western blot using an appropriate antibody. Huh7 cells were transfected with pcH77E2 
and were either treated with IFNa or left untreated. Anti-E2 antibodies (ALP98 or AP33) 
and anti-PKR antibody (B-10), were used to immunoprecipitate either E2 or PKR from the 
cell extracts. Precipitated proteins were separated by SDS-PAGE and then analysed by 
Western blot with anti-E2 or anti-PKR antibodies (Figure 5.9). As the epitope recognised 
by ALP98 lies close to the putative sight of interaction (the PePHD region); AP33 was 
also used for immunoprecipitation of E2. The E2-expressing cell extracts where anti-E2 
was used for both immunoprecipitation and Western blot analysis are visible in lanes 1 
and 4 of (a) and (c). The E2 protein is indicated. In contrast, E2 was not visible when 
anti-PKR was used for immunoprecipitation and anti-E2 for Western blot analysis (lanes 7 
and 10 of (a) and (c)). Likewise, endogenous PKR was visible in lanes 7-12 of (b) and 
(d) when anti-PKR was used for both immunoprecipitation and Western blot analysis. In 
contrast, it was not visible when anti-E2 was used for immunoprecipitation (lanes 1 and 4 
of (b) and (d)). This showed that the anti-E2 antibodies could precipitate E2 and that 
anti-PKR could precipitate PKR but not vice versa, which indicated that genotype 1 E2 
did not interact with PKR. No differences were observed between the IFNa treated cells 
(lanes 4-6 and 10-12) and the untreated cells (lanes 1-3 and 7-9), except for a slight 
increase in PKR expression in the IFN-treated cells (compare lanes 7,8 and 9 to 10, 11 and 
12 in (b) and (c)). The only difference observed between the anti-E2 antibodies, ALP98 
and AP33, was an extra band at approximately 22K (indicated with star) in lanes 1 and 4 
of (c) when using ALP98. This band was also visible in Western blots using ALP98 (see 
Figure 4.2). It is too small to represent the non-glycosylated form of E2 but must 
represent an E2-associated protein, as it was visible only in E2-expressing cells.
5.I.4.2. Effect of interferon on E2 expression in Huh7 cells
A noticeable increase in PKR levels in IFN-treated cells was evident in the previous 
experiment. This was not as evident with E2 due to the high expression levels. To 
assess whether IFN has an effect on E2 expression levels, Huh7 cells were transfected 
with pcH77E2 and the cells either treated with IFNa or left untreated. Two fold dilutions 
of the E2-expressing cell extracts were analysed by Western blot using anti-E2, ALP98
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Figure 5.10. Effect o f interferon treatm ent on E2 expression 
levels. Huh7 cells were transfected with pcH77E2 and treated 
with 1000 U/ml o f interferon for 18 hrs. Two-fold dilutions 
o f the cell extracts were analysed by Western blot using mouse 
m onoclonal anti-E2, ALP98. Lanes 1-7 show two-fold dilutions 
o f cell extract from neat to 1/64.
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(Figure 5.10). Comparison of E2 levels in untreated cells and treated cells revealed that 
there was an approximate two fold decrease in E2 expression in IFN-treated cells 
(compare untreated lane 7 to treated lane 6). Such a small difference is of doubtful 
biological significance.
5.1.5. Discussion
Sequencing of the PePHD region from 14 genotype 3 infected patients revealed only one 
patient where the sequence differed from that of the consensus for type 3. This variant 
contained mutation Q668L, which corresponds to the genotype 1 (or IFN resistant) 
sequence at that position. This patient is a nonresponder, which agrees with the 
hypothesis of Taylor et al. (1999), that variation towards the genotype 1 sequence, leads to 
IFN resistance. However, the PePHD regions were identical in all other patients who 
displayed a range of responses to treatment. Similar results have been reported by other 
studies looking at genotype 3 PePHD sequences (Sarrazin et al., 2000b, Puig-Basagoiti et 
al., 2001 and Abid et al., 2000). Sarrazin et al. (2000b) looked at the PePHD regions and 
the flanking sequences (amino acids 638-704) for 33 type 3 patients and concluded that 
the number of mutations in this region of E2 did not correlate with treatment response.
The authors also did phylogenetic and conformational analyses on these sequences but 
again, were unable to demonstrate any link between the mutations and sensitivity or 
resistance to IFN treatment. Of the 33 patients, 10 were found to have PePHD variants 
and the authors noted that hydrophobic mutations within the hydrophilic region of the 
PePHD, were exclusively found in 4 patients with sustained response. Three of these 
mutations were Q668L, which is identical to the mutation seen in a nonresponder in this 
study and in a responder in the study by Abid et al. (2000). The term “responder” in this 
last study was not defined, nor was the time of sample collection in terms of IFN 
treatment, but these conflicting reports indicate that this mutation does not correlate with 
treatment response. As in this study, Sarrazin et al. (2000b) also looked at the PePHD 
and flanking regions of relapser patients and nonresponders, both before and after 
treatment and also reported no changes over the course of treatment. However, ours is 
the first study to report on the “breakthrough” patients and the lack of PePHD change in
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patients 5 and 6 is particularly important as the “post-treatment” samples were taken while 
IFN therapy was ongoing and showed that there was no selection for IFN-resistant 
variants within this region. In conclusion, there is no evidence that IFN exerts selection 
pressure in the PePHD region of genotype 3 and pre-treatment sequencing of this region is 
unlikely to provide useful information to clinicians as an indicator of treatment response. 
Similar results have been reported for genotype 1 (Berg et al., 2000, Polyak et al., 2000, 
Chayama et al., 2000, Sarrazin et al., 2000b, Puig-Basagoiti et al., 2001 and Abid et al., 
2000).
Although the lack of selection of a PePHD variant during IFN treatment suggests that it is 
not the primary resistance mechanism, it does not preclude a role for E2 in IFN resistance, 
possibly through an interaction with PKR. In the study by Taylor et al. (1999), the major 
evidence for a PKR interaction with genotype 1 E2 came from an in vitro assay using 
bacterially expressed, His-tagged PKR. To prove that this reflects the situation in vivo, it 
was important to investigate the interaction with endogenous PKR in mammalian cells. 
Interferon-a (which was used as part of a treatment regime for HCV-infected patients) 
was used to induce PKR expression. It was first shown that this IFN could activate 
transcription of a reporter gene from an ISRE in cells that are known to have an intact IFN 
signalling pathway (Figure 5.6). It has previously been shown that Huh7 cells (which 
were used in this study) also have an intact IFN signalling system (Melen et al., 2000), 
although Keskinen et al. (1999) have reported that Huh7 cells have a poor ability to 
produce and respond to type I IFN during viral infection (with influenza A, Sendai and 
vesicular stomatitis viruses) in vitro. I investigated the ability of IFN to induce the 
expression of PKR in our Huh7 cells and with the commercial PKR antibody, there was an 
increase in PKR expression in IFN-treated cells, but another antibody failed to make such 
a clear distinction (Figure 5.7). This latter PKR antibody has been well characterised and 
similar immunofluorescence results with interferon treated cells have been reported 
(Jimenez-Garcia et al., 1993), indicating that this technique is possibly not optimal for 
detecting changes in expression levels.
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Having established that endogenous PKR could be detected by indirect 
immunofluorescence in IFN-treated Huh7 cells, this technique was used to detect areas of 
colocalisation for PKR and E2 (Figure 5.8). As described by Taylor et al. (1999), small 
areas of colocalisation were visible in the perinuclear region but this was not convincing 
evidence of colocalisation overall and is most likely due to overlapping staining of E2 in 
the ER and PKR in the cytoplasm. This is in agreement with the report from Francois et 
al. (2000) where no colocalisation was shown between PKR and the entire HCV 
polyprotein. Further investigation of the putative interaction of endogenous PKR and E2 
by immunoprecipitation, showed no evidence for a direct interaction of genotype 1 E2 
with PKR (Figure 5.9). The anti-E2 antibody, ALP98, recognises an epitope close to the 
PePHD region and therefore could possibly block any interaction between E2 and PKR. 
For this reason, another anti-E2 (AP33) was also used but this antibody also failed to co­
precipitate PKR. Therefore, it has not been possible to repeat the in vitro observations of 
Taylor et al. (1999) with endogenous PKR. Interestingly, Podevin et al. (2001) have 
recently shown that NS5A and endogenous PKR do not colocalise or co- 
immunoprecipitate and that neither wild-type nor mutant NS5A has an effect on PKR 
activity. These results contradict those of Gale et al. (1997&1999), however in the latter 
studies, PKR inhibition by NS5A was examined in yeast Saccharomyses cerevisiae and 
NIH 3T3 cells, whereas Podevin et al. used a liver cell line (Huh7).
According to the hypothesis, genotype 3 E2 does not interact with PKR due to the PePHD 
region having less homology to PKR and eIF2a. Unfortunately time constraints meant it 
was not possible to confirm or deny this by repeating this study with genotype 3 E2. In 
addition, all available antibodies that recognise genotype 3 E2, recognise epitopes adjacent 
to the PePHD region which may interfere with any interaction. However, the fact that no 
interaction was observed between genotype 1 E2 and PKR, as proposed, suggests that an
• thinteraction with genotype 3 E2 is unlikely. A recent report at the 8 International HCV 
conference (Pavio et al., 2001) described an unglycosylated form of E2 (termed p38) 
which is found in the cytoplasm. The authors stated that it was this form which was 
found to interact with PKR and not the fully glycosylated form which is ER-bound 
(Taylor, 2001). Firstly, it should be noted that the E2 construct used in their study did not
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contain the full E2 signal sequence (aa 363-377 of polyprotein) and therefore it is not 
surprising to find a cytoplasmic form of E2 which presumably has not been properly 
processed in the ER. Secondly, this finding contradicts that of the original report (Taylor 
et al., 1999), where it was shown that the E2 signal sequence was necessary for efficient 
inhibition of PKR, implying that it is the ER-bound and fully glycosylated form of E2 
which interacts with PKR. No evidence was seen in this present study for an 
unglycosylated form of E2.
5.2. Investigation of E2 interaction with PKR-like 
endoplasmic reticulum resident kinase (PERK).
5.2.1. Introduction
One of the anomalies with the proposed E2 interaction with PKR is that E2 (and 
specifically the PePHD region) is located on the lumenal side of the ER membrane, while 
PKR is most likely associated with ribosomes on the cytoplasmic side of the membrane 
(Besse et al., 1998, Zhu et al., 1997, Jiminez-Garcia et al., 1993). Therefore, the 
identification of an ER-resident eIF2a kinase (PERK) which showed homology to PKR 
initiated interest in investigation of a possible interaction with E2. Although the domain 
showing homology with PKR is located on the cytoplasmic side of the ER membrane (and 
does not include a PePHD region), the lumenal domain of PERK is responsible for 
sensing stress in the ER due to accumulation of misfolded protein. ER stress activates the 
kinase domain of PERK, which phosphorylates serine residue 51 of eIF2a and inhibits 
protein translation (Harding et al, 1999). With the knowledge that expression of the HCV 
glycoproteins leads to accumulation of misfolded protein aggregates (at least in vitro), it 
seemed plausible that an interaction between E2 and the lumenal domain of PERK (either 
directly or indirectly) may have an effect on the downstream signalling of PERK.
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5.2.2. Localisation of E2 and PERK
As with the PKR study, to prove any interaction between E2 and PERK, it was important 
to show that the two proteins are found in the same region of the cell by 
immunofluorescence and confocal microscopy. Huh7 cells were transfected with 
pcH77E2 and probed for both E2 and PERK (Figure 5.11). E2 staining is shown in panel 
(a) and PERK staining in panel (b). Areas of colocalisation of the two proteins are shown 
in yellow and seen in panel (c). Extensive colocalisation in the ER network could be seen 
in panel (c). However, the reason for this clear pattern of colocalisation was realised 
when the appropriate controls were included (Figure 5.12) and it was found that the 
incorrect secondary antibody had been used. E2-expressing cells were stained with 
ALP98 and both FITC- and Cy3-conjugated secondary antibodies (panels a and b). Panel 
(a) showed E2 staining however, the red staining in panel (b) was due to reaction of anti­
goat Cy3 conjugate with goat anti-mouse FITC conjugate. This gave the appearance of 
colocalisation in panel (c) that was not authentic. Therefore the PERK staining in Figure 
5.1 lb was not true and using an appropriate secondary antibody (generated in rabbits), this 
staining was repeated in Figure 5.13. Once again, Huh7 cells were transfected with 
pcH77E2 and probed for E2 (panels a-c) and PERK (panels d-f). The merged images are 
seen in panels (g), (h) and (i). Only cells in panels (c), (f) and (i) were probed for both E2 
and PERK and therefore the yellow areas seen in panel (i) represented regions of 
colocalisation of these two proteins. Although there were distinct areas of colocalisation, 
the staining of PERK alone, in panel (e), did not resemble ER localisation as previously 
reported (Harding et al., 1999).
5.2.3. Colocalisation of PERK and calnexin
To confirm that PERK is localised to the ER, Huh7 cells were probed for PERK and 
calnexin, an ER marker (Figure 5.14). Cells in panels (a), (d) and (g) were probed with 
anti-calnexin and those in panels (b), (e) and (h) were probed with anti-PERK. Panels (g), 
(h) and (i) show the merged images. Only cells in panels (c), (f) and (i) were probed for
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Figure 5.11. Apparent co-localisation o f  E2 and PERK which 
was subsequently found to be due to cross-reaction o f  the 
secondary antibodies. Huh7 cells were transfected w ith pcH77E2 
and fixed in methanol before being processed for indirect 
immunofluorescence using m ouse anti-E2 (ALP98) (a) and goat 
anti-PERK (N-18) (b). Panel (c) represents the m erged image of 
a and b. Bound antibodies were detected using goat anti-mouse 
FITC and rabbit anti-goat Cy3.
Figure 5.12. Controls showing evidence o f cross-reaction between 
the secondary antibodies used in Fig 5.11. Huh7 cells were transfected 
with pcH77E2 and processed for indirect imm unofluorescence. In panels 
(a) and (b), cells were probed with mouse m onoclonal anti-E2 (ALP98) 
and bound antibody was detected with goat anti-m ouse FITC conjugate 
and rabbit anti-goat Cy3 conjugate. In panels (d) and (e), the cells were 
stained with the two secondary antibodies alone. Panels (c) and (f) 
represent the merged images o f panels (a) and (b), and (d) and (e) 
respectively.
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both PERK and calnexin and therefore panel (i) showed areas of colocalisation in yellow. 
This dual staining for PERK and calnexin did not provide convincing evidence of 
colocalisation and therefore casts doubt on the specificity of the anti-PERK antibody. An 
attempt at confirming the specificity of the antibody by Western blot analysis proved 
negative, as the expected 124K protein representing PERK was not seen (data not shown).
5.2.4. Discussion
Initially, dual staining for PERK and E2 showed evidence of extensive colocalisation 
(Figure 5.11). This was expected as PERK is known to localise to the ER (Harding et al., 
1999). However the appropriate controls indicated that this was not a true result as even 
when the PERK antibody was omitted, there was evidence of PERK staining (Figure 
5.12). In fact this was due to cross-reaction of the two secondary antibodies. This was 
corrected by using a secondary antibody generated in a different species and the dual 
staining repeated (Figure 5.13). This time, the extent of colocalisation was not as 
comprehensive, although distinct regions of colocalisation were visible in the perinuclear 
area of the cell. However, the localisation of PERK did not resemble that of an ER- 
localised protein and unfortunately no positive control was available to test the specificity 
of the antibody. To confirm that PERK was not showing ER localisation, cells were 
probed for both PERK and calnexin, which is an ER-marker (Figure 5.14). This showed 
no evidence for colocalisation of PERK and calnexin, implying that PERK does not 
localise to the ER. This would contradict all previously reported data, so the specificity 
of this antibody has to be questioned. The antibody also failed to detect a protein of the 
correct predicted size by Western blot (data not shown). Another phenomenon noted in 
the immunofluorescence studies and visible in Figure 5.14, was the increased levels of 
expression of PERK (or the protein recognised by the antibody) in some cells. These 
were untransfected cells, so cannot be attributed to an overly expressed protein. One 
possible explanation is that the expression of this protein is affected by the cell cycle. As 
the specificity of the antibody could not be assured, this was not investigated further.
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This particular commercial antibody was raised against an N-terminal peptide.
Discussion with the manufacturer revealed that it had been tested against an expressing 
cell line (of unknown type) and they expressed doubt that the level of cellular PERK 
would be high enough for detection. Over-expression of a protein can sometimes lead to 
defects in processing, so it is possible that although the peptide used to raise the antibody 
is accessible in the expressing cell-line, it is hidden in the correctly processed form of 
PERK. In addition, it is possible that the different cell types could lead to differences in 
reactivity, although there is no evidence to suggest this. Another anti-PERK antibody, 
raised against a C-terminal peptide, is available but the high expense of these commercial 
antibodies prevented this from being pursued further.
The failure to investigate a link between E2 and PERK was disappointing and if time had 
permitted, it would have been worthwhile examining the relative levels of phosphorylated 
and unphosphorylated forms of eIF2a in E2-expressing and non-expressing cells. Of 
course it would not be possible to attribute a decrease in the level of phosphorylated eIF2a 
to either PKR or PERK directly, or for that matter to the other two known mammalian 
eIF2a-kinases, HRI and GCN2. However it would give insight as to the effect of HCV 
E2 on downstream signalling events from these kinases. As mentioned earlier, due to the 
intra-lumenal location of E2, it is unlikely to be in close proximity to the cytoplasmic (and 
kinase) domain of PERK. However, as part of the unfolded protein response (UPR), the 
misfolded forms of E2 should be targeted for degradation. This involves them being 
directed to the translocon (in the ER membrane) and retranslocated into the cytosol.
Here, they are ubiquitinated and degraded by the proteosome (Plemper & Wolf, 1999). 
Therefore, during this process, E2 may be in close proximity to the kinase domain of 
PERK. In the absence of a cell-culture system, the high proportion of misfolded HCV 
glycoproteins has previously been attributed to over-expression of these proteins. The 
possibility that these misfolded proteins are part of a viral strategy aimed at preventing the 
cell from initiating a general shutdown in translation (and ultimately cell death), cannot be 
overlooked. If true, it is likely that PERK would play a significant role in this process.
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Chapter 6 
Binding of genotypes 1 and 3 E2 to human CD81
6.1. Introduction
The putative position of El and E2 in the viral envelope suggests that they are directly 
involved in the attachment of the virus to the host cell. It also implies that they would be 
targets for neutralising antibodies. The lack of a cell culture system for HCV made it 
difficult to pursue this line of questioning until the development of a surrogate test for 
binding of virus to the cell, called the neutralisation of binding (NOB) assay (Rosa et al., 
1996). This assay was based on the ability of antibodies or sera to prevent binding of E2 
to the human MOLT-4 T-cell line. E2 bound to these cells with high affinity and binding 
was inhibited by sera from El/E2-vaccinated chimpanzees, which were partially protected 
from challenge with infectious sera. “Neutralising antibodies” were also found in the sera 
of chronically-infected HCV patients and, in those who resolved the infection naturally, 
the emergence of high NOB titres coincided with viral clearance (Ishii et al., 1998). This 
indicated that these antibodies might be responsible for blocking HCV infection in vivo 
and implicated E2 in binding of HCV to target cells. The cellular molecule responsible 
for binding E2 was identified by screening a cDNA library prepared from the MOLT-4 
cell line and identifying a clone which conferred E2-binding to mouse fibroblasts upon 
transient transfection (Pileri et al., 1998). The clone encoded the human CD81 protein, 
leading to its identification as a putative HCV receptor. CD8 l i s a  member of the 
tetraspanin family of proteins. It traverses the membrane four times and has two 
extracellular loops. The E2-binding site was mapped to the large extracellular loop (LEL)
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(Pileri et al., 1998), which is the most variable region of the protein but significantly, is 
highly conserved in humans and chimpanzees, the only known species susceptible to HCV 
infection. However, E2 has since also been shown to bind CD81 of tamarins (Meola et 
al., 2000, Allander et al., 2000a), which are not susceptible to HCV infection, so binding 
of E2 to CD81 alone is apparently insufficient to predict species permissiveness to 
infection. The wide expression of CD81 throughout human tissue (except red blood cells 
and platelets) does not explain the cellular tropism of HCV either, although importantly, 
E2 has been shown to bind to human hepatocytes (Flint et al., 1999a).
Following the identification of the human cell surface molecule (CD81) which interacts 
with HCV E2, there have been several reports aimed at elucidating the structural and 
functional characteristics of E2 that are important for this interaction. In the NOB assay, 
Rosa et al. (1996) demonstrated that sera from patients infected with genotypes 1, 2 and 3 
were all able to neutralise binding of genotype 1 E2. This implies that binding of E2 
involves a region or regions that are conserved between genotypes. However, almost all 
studies on CD81 -binding have concentrated exclusively on E2 of genotype 1 a. This bias 
was first addressed by Allander et al. (2000b) with the isolation of human monoclonal 
antibodies which were selected for reactivity against genotype la  E2 from a genotype 2b- 
infected patient. Some of these antibodies also recognised genotype 1 b E2 but 
recombinant E2 protein for the other genotypes was not available for further analysis.
Four of these conformation-dependent antibodies tested positive in the NOB assay with 
genotype la. This was interpreted as inhibition of E2 binding to CD81 but this cannot be 
verified from these data, as the CD81/E2 interaction was not examined directly. In a 
similar study, Hadlock et al. (2000) isolated monoclonal antibodies from a genotype lb- 
infected patient by selection for reactivity against genotype la  E2. Some of these 
antibodies were also cross-reactive with genotypes 2a and 2b E2 and, as with the previous 
study, almost all recognised conformational epitopes. Six antibodies tested positive in the 
NOB assay with genotype la  E2 and all six were capable of inhibiting the interaction of 
genotypes la, lb, 2a and 2b E2 with CD81. Surprisingly these antibodies were also able 
to recognise the pre-formed E2/CD81 complex, although with some antibodies this was 
genotype specific. This suggests that the antibodies recognise epitopes that are not
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directly involved in binding CD81 and possibly they inhibit CD81 binding by preventing a 
conformational change in E2.
6.2. Lack o f binding o f genotype 3 E2 to hum an CD81.
6.2.1. E2 capture by human CD81.
For evaluating the ability of E2 to bind human CD81, E2 was expressed from the SFV 
constructs described in Table 4.1 and crude cell extract expressing E2 was prepared for 
use in ELISA. BHK cells were used, as human cells would provide endogenous CD81 
which would reduce the amount of E2 available for capture. Pileri et al. (1998) have 
mapped the binding of genotype 1 E2 to the major extracellular loop of human CD81 and 
this portion of the protein was expressed as a GST fusion protein and was kindly provided 
by Arvind Patel. For the sake of simplicity, this will be referred to as CD81. The design 
of the capture ELISA is shown in Figure 6.1. It was essentially the same as that described 
in chapter 4 for testing antibody reactivity apart from the use of CD81 as the capture 
protein and the use of two-fold dilutions of crude cell extract expressing E2 to evaluate the 
effect of E2 concentration on binding. As there was no guarantee that the E2 proteins 
would be expressed at equivalent levels from all constructs, before evaluating CD81 
binding, two-fold dilutions of E2 cell extract were captured in a GNA ELISA and bound 
E2 detected with anti-E2 antibody. The dilution of E2 extract that gave equivalent 
absorbance readings was determined for each construct and this was taken into account 
when calculating the starting dilution of E2 extract for the binding ELISA. This ensured 
that the relative amounts of E2 were equivalent in terms of reactivity with the anti-E2 
antibody that would be used for detecting bound E2. Each CD81 capture ELISA was 
performed in parallel with a GNA capture ELISA as a control for all the remaining 
interactions required for a positive reaction.
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Figure 6.1. Diagrammatic representation o f  the Galanthus 
nivalis agglutinin (GNA) lectin or human C D 81 capture 
ELISA. ELISA plates were coated with GNA lectin or C D 81 
overnight at room temperature. Following blocking, two fold 
dilutions o f crude cell extract expressing E2 was added. 
Bound E2 was detected by the addition o f  mouse monoclonal 
anti-E2, anti-mouse peroxidase-conjugated antibody and 
tetramethyl benzidine (TMB) substrate.
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Figure 6.2 shows the results of a GNA capture ELISA (a) and a CD81 capture ELISA (b) 
where ALP98 was used for detecting bound E2. Both genotype 3 (R3) and genotype 1 
(H77 and Gla) E2 were analysed. Constructs expressing both E2 alone and in the context 
of core and El were included for R3 and H77 to see if this had an effect on CD81 binding. 
Figure 6.2 (a) shows binding to GNA for all E2-expressing constructs. The degree of 
binding was approximately equivalent for all constructs and decreased as the E2 
concentration decreased. In the CD81 capture ELISA (b) only the H77 constructs showed 
evidence of binding. The level of CD81 binding was similar for H77 E2 expressed alone 
and in addition to core and E l . It should be noted that there was less binding of H77 E2 
to CD81 than to GNA. For example, with the H77 E1/E2 construct, compare an 
absorbance reading of 1.5 with CD81 to a reading of over 2.5 with GNA at a V* dilution (2 
on the X-axis). The same experiment is shown in Figure 6.3 except that AP266 was used 
for detecting bound E2. As with the previous experiment, only H77 E2 was capable of 
binding to CD81, although this time it appeared that E2 expressed in conjunction with 
core and El bound CD81 better than E2 expressed alone. Again, the level of CD81 
binding was much reduced compared to GNA binding of E2 for the same constructs. The 
genotype 3 F2 construct was also analysed for CD81 binding in Figure 6.3 but as with R3, 
it did not bind CD81.
One of the complicating factors in interpreting the binding data in Figures 6.2 and 6.3 was 
that crude cell extract was used and therefore the amount of E2 protein was unknown. As 
described earlier, this was controlled by predetermining the dilution of extract that gave 
equivalent reactivity with a particular antibody in a GNA capture ELISA for different 
constructs. In these assays, genotype 1 E2 consistently showed increased reactivity with 
ALP98 compared to the same dilution of the genotype 3 E2 extract (data not shown).
This suggested that either the expression level of genotype 3 E2 was not as high as that of 
genotype 1 E2 or that there was a difference in reactivity of ALP98 with types 1 and 3 E2. 
To investigate these possibilities, the same dilutions of E2 extract that showed this 
phenomenon were analysed by Western blot for reactivity with ALP98 (Figure 6.4). 
ALP98 recognised genotype 3 (R3) E2 down to a dilution of 1/512 (a) and genotype 1 
(H77) E2 down to a dilution of 1/256 (b). Therefore, this data contradicted what was
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Figure 6.2. Capture ELISA o f  two-fold dilutions o f  genotype 
1 and 3 E2 binding to GNA (a) and hum an C D 8 1 (b) as 
m easured by light absorbance at 4 5 0 nm. The ELISA was set 
up as described in Fig. 6.1. and m ouse m onoclonal anti-E2, 
ALP98, was used for detecting bound E2. E2-expressing 
extracts were prepared by electroporating BHK cells with in 
vitro transcribed RNA from genotype 3 constructs 
(pSFVR3cEiE2, pSFVR3E2), genotype 1 constructs 
(pSFVH77cEiE2, pSFVH77E2, pSFVGlacEiE2) and pS F V l.
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Figure 6.3. Capture ELISA o f two-fold dilutions o f  genotype 
1 and 3 E2 binding to GNA (a) and hum an CD81 (b) as 
m easured by light absorbance at 4 5 0 nm. The ELISA was set 
up as described in Fig. 6.1. and m ouse m onoclonal anti-E2, 
AP266 was used for detecting bound E2. E2-expressing 
extracts were prepared by electroporating BEIK cells with in 
vitro transcribed RNA from genotype 3 constructs 
(pSFVR3cEiE2, pSFVR3E2, pSFVF2cEiE2), genotype 1 
constructs (pSFVF177cEiE2, pSFVH77E2, pSFVGlacEiE2) and 
pSF V l.
1 2 3 4 5 6 7 8 9  10 11
<-----  E2
4 5 K  P 5' ¥
3 0 K
a
1 2 3 4 5 6 7 8 9 10 11
2 2 0 K
9 7 K  
66K
4 5 K  
3 0 K
b
Figure 6.4. Com parison o f genotype 3 (a) and genotype 1 (b) 
E2 expression levels. BHK cells were electroporated w ith in 
vitro transcribed RNA from pSFVR3cEiE2 (a) or 
pSFVH77cEiE2 (b) and crude cells extracts were separated by 
SDS-PAGE and analysed by W estern blot using anti-E2, ALP98. 
Lanes 1-11 represent two fold dilutions o f  E2-expressing cell 
extract from neat to 1/1024.
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shown in ELISA analysis. A possible explanation is that GNA had more affinity for H77 
E2 due to the predicted extra glycan.
The amount of protein detected by ALP98 was always greater when bound to GNA than 
to CD81. This may be because CD81 bound only native E2, whereas GNA also bound 
aggregated protein. To assess the ability of both native and misfolded E2 to bind CD81, 
the binding of H77 E2 to GNA and CD81 was analysed by detection with conformation- 
dependent antibodies (Figure 6.5). If only native E2 binds CD81, binding to GNA and 
CD81 should be equivalent when E2 is detected with a conformation-dependent antibody. 
When detected with a linear-epitope antibody, the binding of E2 to GNA should be higher 
than to CD81 as GNA will bind both aggregated and native E2. Three different 
conformation-dependent antibodies (H50, H53 and H60) and a linear epitope antibody 
(ALP98) were used to detect E2 bound to both GNA and CD81. As previously described, 
E2 detected with ALP98 showed increased binding to GNA compared to CD81 and in 
agreement with the theory, E2 detected with H60 showed equivalent binding to GNA and 
CD81. However, the reactivities of neither H50 nor H53 concurred with that of H60.
H50 displayed a reactivity pattern similar to ALP98. H53 detected equivalent amounts of 
E2 binding to CD81 as did H60 but in comparison, it detected increased binding to GNA.
6.2.2. Genotype 3 E2 does not compete with genotype 1 E2 for 
CD81 binding.
In Figures 6.2 and 6.3, slight increases in CD81 binding above non-specific levels were 
observed for genotype 3 (and genotype 1 Gla strain) E2-expressing cell extracts at the 
highest concentrations. This may represent binding on a much smaller scale than 
demonstrated for H77 E2. A procedure for determining if this is the case, is to assess 
whether genotype 3 E2 has the ability to compete with genotype 1 E2 for CD81 binding. 
By using an antibody that recognises only type 1 E2, it is possible to compare the CD81- 
binding ability of type 1 E2 in the presence and absence of genotype 3 E2. If genotype 3 
E2 is able to compete for CD81 binding, the binding of genotype 1 E2 is expected to
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Figure 6.5. Comparison o f genotype 1 E2 binding to GNA 
and human C D 8 1 when detected with conform ational antibodies. 
BHK cells were electroporated with in vitro transcribed RNA 
from pSFVH77E2. E2-expressing cell extract was added to both 
GNA and CD81 coated ELISA plates and bound E2 was 
detected with a linear epitope antibody (ALP98) and 
conform ational epitope antibodies (H50, H53 and H60).
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decrease in the presence of type 3 E2. In Figure 6.6 (a) this was analysed by keeping the 
amount of type 1 E2 constant and increasing the amount of type 3 E2 (blue line) and vice 
versa (pink line). As the concentration of E2 was unknown, the relative amounts of types 
1 and 3 E2 were expressed as percentages ranging from 0% to 50%. The total amount of 
protein was made up with cell extract expressing the SFV proteins from the pSFVl vector. 
E2 bound to CD81 was detected with AP320, which only recognised type 1 E2. There 
was no indication of a decrease in binding of genotype 1 E2 as the amount of type 3 E2 
was increased. To determine whether genotype 3 E2 has an effect on the ability of 
genotype 1 E2 to bind CD81 in a concentration-dependent manner, the binding of 
increasing amounts of type 1 E2 was assessed both in the presence (blue line) and absence 
(pink line) of genotype 3 E2 (Figure 6.6 (b)). If type 3 E2 were able to compete for CD81 
binding with type 1 E2, the blue curve would be expected to shift to the right when 
compared to the pink curve. However, no difference was observed, hence type 3 E2 did 
not interfere with the CD81-binding ability of type 1 E2.
6.2.3. Lack of CD81 binding to E2 when ELISA is performed 
in reverse.
Several studies have used the ELISA format described in Figure 6.1 to demonstrate 
binding of genotype 1 E2 to human CD81. However this form of sandwich ELISA has 
not been used to prove the reverse binding i.e. binding of CD81 to E2. Demonstration 
that an interaction between two proteins is valid for both orientations in an assay provides 
more convincing evidence that the interaction is biologically significant. The format for 
analysing the binding of CD81 to E2 is illustrated in Figure 6.7. E2 was captured by anti- 
E2, ALP98. As with the previous ELISA, E2 was provided in the form of crude cell 
extract from E2-expressing cells and was used in two-fold dilutions. The CD81 protein, 
expressed as a GST fusion protein, was added and bound CD81 was detected with rabbit 
anti-GST antibody, anti-rabbit HRP-conjugated antibody and addition of TMB substrate. 
Both genotype 3 (R3) and genotype 1 (H77 and Gla) E2 were analysed, even though only 
H77 E2 had previously been shown to bind CD81. However, in this format, CD81 did
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Figure 6.6. Analysis o f  the ability o f  type 3 E2 to com pete with 
type 1 E2 for CD81 binding. E2-expressing cell extracts were 
m ade as described before from the relevant type 1 and type 3 
constructs, pSFVH77cEiE2 and pSFVR3cEiE2 respectively. E2 
extracts were added to CD81-coated wells and bound E2 was 
detected by anti-E2 m ouse m onoclonal, AP320 which is specific 
for type 1 E2. In panel (a), the amount o f  type 1 (blue line) or 
type 3 (pink line) E2 extract rem ained constant at 50% o f  the total 
E2 content while the am ount o f type 3 or type 1 E2 respectively, 
was increased from 0-50%. In panel (b) the am ount o f type 3 E2 
either rem ained constant (blue line) or was absent (pink line), while 
the am ount o f type 1 E2 was increased.
Anti-rabbit i ___  TMB
H R P  ^ r substrate
conjugate
Rabbit anti-GST
CD81-GST
Anti-E2 ALP98
Figure 6.7. Diagram matic representation o f  the reverse 
human C D 81 ELISA. ELISA plates were coated with mouse 
m onoclonal anti-E2, ALP98 overnight at room  tem perature. 
Follow ing blocking, two fold dilutions o f  crude cell extract 
expressing E2 was added. The human CD81-G ST protein was 
added and bound CD81 was detected by the addition o f rabbit 
polyclonal anti-GST antibody, anti-rabbit peroxidase- 
conjugate and tetram ethyl benzidine (TM B) substrate.
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not bind to any of these E2 proteins (Figure 6.8). The absorbance values were lower than 
those observed for E2 binding to CD81 in Figures 6.2 and 6.3 and were independent of E2 
concentration with fluctuating absorbance values seen for both E2-expressing and non-E2 
expressing cell extracts. There was a decrease in absorbance between dilutions of 1/32 
and 1/128 but this applied to non-E2 expressing cells as well, so may be due to the 
decrease in concentration of a cellular protein. This was supported by the observation 
that PBSA did not follow this pattern. As this ELISA relied on several individual 
reactions, it was necessary to confirm these before stating that CD81 did not bind E2. 
Firstly, E2 expression from the R3, H77 and Gla constructs was verified by GNA-capture 
ELISA with detection by ALP98 (Figure 6.9(a)). This reverse ELISA relied on E2 
capture by ALP98, which was demonstrated in Figure 6.9 (b) by detection with anti-E2 
polyclonal antibody, R646. The level of non-specific reactivity was higher here than 
previously observed. Evidence that the anti-GST antibody recognised the CD81-GST 
fusion protein is provided in Figure 6.9 (c) where antibody was added to CD81-coated 
wells and reactivity detected by anti-rabbit HRP-conjugated antibody. There was no 
evidence of non-specific reactivity between the conjugated antibody and CD81 when the 
GST antibody was absent. Finally, CD81 was added to ALP98-coated wells and any 
binding detected with anti-GST (Figure 6.9(d)). There was no evidence of non-specific 
binding of CD81 to ALP98 (blue line) and when CD81 was removed from the reaction 
(pink line), the same pattern was observed, indicating that there was no cross-reactivity 
between ALP98 and anti-GST. Therefore the lack of observed binding of CD81 to E2 in 
Figure 6.8 could not be attributed to any of the other required interactions in this ELISA.
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Figure 6.8 ELISA dem onstrating failure o f  CD81 to bind E2 
when E2 is captured by anti-E2, as m easured by light absorbance 
at 450 nm. The ELISA was set up as described in Fig. 6.7 using 
mouse m onoclonal, ALP98 to capture E2 and rabbit anti-GST to 
detect bound CD81-GST protein. E2-expressing extracts were 
prepared by electroporating BHK cells with in vitro transcribed 
RNA from a genotype 3 construct (pSFVR3cEiE2), genotype 1 
constructs (pSFVH77cEiE2,pSFVGlacEiE2) and pS F V l.
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6.3. Binding of virus particles from serum to human 
CD81
T h e  p o te n t ia l  r o le  o f  an  E 2  in te r a c t io n  or  n o n - in te r a c t io n  w ith  C D 8 1  c a n n o t  b e  in terp re ted  
fu l ly  b y  in v e s t ig a t in g  E 2  in  is o la t io n , a s  it  m a y  n o t  r e f le c t  th e  stru ctu re  o f  E 2  in  th e  v ir io n .  
C D 8 1 h a s  b e e n  p r o p o s e d  a s  a  c a n d id a te  H C V  r e c e p to r  b a s e d  o n  th e  f in d in g  th a t fr ee  
v ir io n s  in  c h im p a n z e e  in fe c t io u s  sera  (g e n o ty p e  l a )  b in d  h u m a n  C D 8 1  (P ile r i et al.,
1 9 9 8 ) . T o  a d d  to  th e  E L I S A  e v id e n c e  th a t g e n o ty p e  3 E 2  d o e s  n o t  b in d  C D 8 1 ,1  
a tte m p te d  to  s h o w  th a t g e n o ty p e  3 v ir io n s  d o  n o t  b in d  C D 8 1 u n d er  c o n d it io n s  w h e r e  
g e n o ty p e  1 v ir io n s  d o  b in d .
C h im p a n z e e  in fe c t io u s  p la sm a , a s  u s e d  b y  P ile r i  et al. ( 1 9 9 8 )  a n d  H a d lo c k  et al. ( 2 0 0 0 ) ,  
w a s  n o t  o b ta in a b le  fo r  th is  s tu d y . H o w e v e r  b o th  g e n o ty p e s  1 an d  3 H C V  p o s it iv e  h u m a n  
se r a  w e r e  a v a ila b le . A  q u a n tita tiv e  P C R  d e te c t io n  s y s te m  w a s  u s e d  to  a s s e s s  th e  b in d in g  
o f  v ir io n -a s s o c ia te d  H C V  R N A  to  h u m a n  C D 8 1. T h is  in v o lv e d  c o a t in g  a g a r o se  b e a d s  
w ith  th e  C D 8 1 -G S T  fu s io n  p r o te in  an d  in c u b a tin g  th e s e  b e a d s  w ith  th e  h u m a n  sera . T h e  
n u m b e r  o f  v ir io n s  r e m a in in g  b o u n d  to  th e  b e a d s  w e r e  d e te r m in e d  b y  R T -P C R  u s in g  th e  
G e n e A m p  5 7 0 0  s e q u e n c e  d e te c t io n  s y s te m  (A p p lie d  B io s y s t e m s ) .  A  d ilu t io n  s e r ie s  o f  a  
se r u m  o f  k n o w n  titre , c a lib r a te d  a g a in s t  th e  in te rn a tio n a l stan d ard , w a s  in c lu d e d  for  
g e n e r a t io n  o f  a  stan d ard  c u r v e . F ig u r e  6 .1 0  s h o w s  an  e x a m p le  o f  th e  P C R  r e su lt  fo r  th e  
u n k n o w n  g e n o ty p e s  1 a n d  3 sera  a n d  th e  d i lu t io n  se r ie s  o f  th e  stan d ard . T h e  a m o u n t o f  
P C R  p r o d u c t g e n e r a te d  w a s  m e a su r e d  b y  e m is s io n  o f  f lu o r e s c e n c e  a n d  p lo tte d  a g a in s t  
P C R  c y c le  n u m b er . A  stan d ard  c u r v e  o f  R N A  c o p ie s  p e r  m l v e r s u s  c y c le  n u m b e r  w a s  
d r a w n  fo r  th e  k n o w n  se r u m  a n d  th is  w a s  u s e d  to  d e te r m in e  th e  titre  o f  th e  u n k n o w n  sera . 
A l l  P C R  r e a c t io n s  w e r e  p e r fo r m e d  in  tr ip lic a te  b u t o n ly  o n e  o f  e a c h  is  s h o w n  in  F ig u re  
6 .1 0  so  a s  to  n o t  c o m p lic a te  th e  f ig u r e  u n n e c e s s a r i ly . T h e  c a lc u la te d  a v e r a g e  t itr e s  fo r  th e  
u n k n o w n  g e n o ty p e  1 a n d  g e n o ty p e  3 se r a  are s h o w n  in  F ig u r e  6 . 1 1 (a ). T h e s e  se r a  w e r e  
in c u b a te d  w ith  e ith e r  C D 8 1 -G S T -c o a te d  b e a d s  (C D 8 1 )  or  G S T -c o a te d  b e a d s  (b e a d s )  an d  
th e  a v e r a g e  n u m b e r  o f  b o u n d  v ir u s  p a r t ic le s  are s h o w n  in  F ig u r e  6 .1 1 (b ). W ith  g e n o ty p e  
3 th e r e  w a s  m o r e  b in d in g  to  C D 8 1  th a n  b e a d s  a lo n e  b u t th is  w a s  r e v e r s e d  fo r  g e n o ty p e  1.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
Cycle number
1 unknow n type 3 serum
2 undiluted standard 3 x l 0 6 copies  /ml
3 unknow n type 1 serum
4 Standard lx l  06 co p ie s /m l
5 Standard 1x10s copies /ml
6 Standard lx lO 4 copies /ml
7 RT control
8 No template control
Figure 6.10. Depiction o f  the amount o f  PCR product at each 
PCR cycle as determined by the amount o f  fluorescence measured 
by the GeneAmp 5700 sequence detection system. Everything 
above the threshold (*) is considered positive. A dilution series 
o f  a serum o f known titre is included and a standard curve o f  RNA 
copies /ml vs Cycle number allows the titre o f  an unknown serum 
to be determined. The result o f  this calculation for the unknown 
types 1 and 3 sera are shown in Figure 6 .1 1(a).
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Chapter 6
In  th is  e x p e r im e n t  th e  g e n o ty p e  1 se r u m  w a s  d ilu te d  so  th a t th e  v ira l titre  w a s  e q u iv a le n t  
to  th a t o f  th e  g e n o ty p e  3 se r u m  (a ). T o  v e r ify  th at th is  d id  n o t  a f fe c t  th e  b in d in g  to  C D 8 1, 
in  th e  f o l lo w in g  b in d in g  e x p e r im e n t  b o th  sera  w e r e  u s e d  u n d ilu te d  (F ig u r e  6 .1  l ( c ) & ( d ) ) .  
U n fo r tu n a te ly  n o t  e n o u g h  o f  th e  o r ig in a l g e n o ty p e  3 se r u m  w a s  a v a ila b le , s o  a n  a lter n a tiv e  
w a s  u s e d  in  ( c )  an d  (d ) . A s  e x p e c te d , th e  u n d ilu te d  g e n o ty p e  1 se r u m  s h o w e d  in c r e a se d  
b in d in g  in  F ig u r e  6 . 1 1 (d ) c o m p a r e d  to  (b )  b u t th ere  w a s  n o  n o ta b le  d if f e r e n c e  b e tw e e n  
b in d in g  to  C D 8 1 a n d  b in d in g  to  b e a d s  a lo n e . W ith  th e  n e w  g e n o ty p e  3 se r u m  th e r e  w a s  
in c r e a se d  b in d in g  w ith  C D 8 1  th a n  w ith  th e  b e a d s  o n ly  (d ). T im e  l im ita t io n s  d id  n o t  
a l lo w  fu rth er  e x p e r im e n ta t io n .
6.4. Discussion
T h e  o n ly  rep ort o f  C D 8 1 b in d in g  to  E 2  o th e r  th a n  g e n o ty p e  1 i s  th a t fr o m  H a d lo c k  et al. 
( 2 0 0 0 )  w h ic h  d e m o n s tr a te d  b in d in g  o f  g e n o ty p e  2  E 2  to  C D 8 1 . H o w e v e r , w h e n  
r e c o m b in a n t g e n o ty p e  3 E 2  p r o te in  w a s  a n a ly s e d  h e r e  fo r  C D 8 1 b in d in g  th e r e  w a s  n o  
r e a c t iv ity  (F ig u r e s  6 .2 b  a n d  6 .3 b ) .  T h is  w a s  n o t  d u e  to  th e  a n tib o d y  n o t  r e c o g n is in g  th e  
E 2 /C D 8 1  c o m p le x  a s  s tr o n g  r e a c t iv ity  w a s  s h o w n  w ith  th e  E 2 /C D 8 1  c o m p le x  o f  g e n o ty p e  
l a  (H 7 7 ) .  T h is  d o s e -d e p e n d e n t  b in d in g  c u r v e  fo r  H 7 7  E 1 /E 2  an d  E 2  i s  e q u iv a le n t  to  th at  
rep o r te d  fo r  th e  tru n c a ted  H 7 7  E 2  p r o te in  (P a te l et al., 2 0 0 0 )  a n d  m o r e  s ig n if ic a n t ly ,  H 7 7  
v ir u s - l ik e  p a r tic le s  (V L P s )  g e n e r a te d  in  in s e c t  c e l l s  (O w s ia n k a  et al., 2 0 0 1 ) .  A  p a n e l o f  
a n ti-E 2  a n t ib o d ie s  w a s  a n a ly s e d  fo r  a b ility  to  in h ib it  th e s e  v a r io u s  fo r m s  o f  H 7 7  E 2  fro m  
b in d in g  C D 8 1  (O w s ia n k a  et al., 2 0 0 1 ) .  N e ith e r  A L P 9 8  n o r  A P 2 6 6  w e r e  s h o w n  to  in h ib it  
th e  E 2 -C D 8 1  in te r a c t io n , s o  th e  e p ito p e s  r e c o g n is e d  b y  th e s e  a n t ib o d ie s  are  n o t  in v o lv e d  
in  th e  C D 8 1  in te r a c t io n , w h ic h  is  su p p o rte d  b y  th e  b in d in g  c u r v e s  in  F ig u r e s  6 .2 b  an d  
6 .3 b . In te r e s t in g ly , A P 3 3  w a s  s h o w n  to  in h ib it  C D 8 1  b in d in g  o f  tr u n c a ted  E 2 , fu l l- le n g th  
E 1 /E 2  an d  V L P s , s u g g e s t in g  th a t th e  e p ito p e  r e c o g n is e d  b y  A P 3 3  (a a  4 1 2 - 4 2 3 )  m a y  b e  in  
d ir e c t  c o n ta c t  w ith  C D 8 1 . In  c h a p te r  4  it  w a s  s h o w n  th a t A P 3 3  d o e s  n o t  r e c o g n is e  
g e n o ty p e  3 E 2  a n d  s e q u e n c e  c o m p a r is o n  o f  th e  a n tib o d y  e p ito p e  in d ic a te d  o n ly  o n e  a m in o  
a c id  d if fe r e n c e , a  ly s in e  r e s id u e  in  R 3  c o m p a r e d  to  an  a sp a r a g in e  in  H 7 7  (F ig u r e  4 .6 ) .
T h e  ly s in e  s id e  c h a in  is  la rg er  th a n  th a t o f  a sp a r a g in e  a n d  i s  a ls o  p o s i t iv e ly  c h a r g e d  
w h e r e a s  a sp a r a g in e  i s  u n c h a r g e d , so  th is  a m in o  a c id  c h a n g e  c o u ld  c o n c e iv a b ly  a lter  th e
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p r o te in  stru ctu re  in  th is  r e g io n , w h ic h  m a y  in te r fe re  w ith  th e  E 2 /C D 8 1  in te ra c tio n . 
C o m p a r iso n  o f  th e  s e q u e n c e  v a r ia t io n  at th is  p o s it io n  in  th e  o th e r  fo u r  p u b lis h e d  g e n o ty p e  
3 i s o la t e s  r e v e a ls  a  ly s in e  a t p o s it io n  4 1 5  in  H C V C E N S 1  b u t a n  a sp a r a g in e  in  N Z L 1 ,  
A F 0 4 6 8 6 6  an d  H P C H K 6  (F ig u r e  3 .4 ) . T h e r e fo r e  th e  ly s in e  at p o s it io n  4 1 5  i s  n o t  u n iq u e  
to  G la -3 a  b u t u n fo r tu n a te ly  th ere  are n o  d a ta  a v a ila b le  o n  th e  a b ility  o f  E 2  fr o m  th e se  
o th e r  is o la te s  to  b in d  C D 8 1 . T o  c o n f ir m  th a t th e  ly s in e  r e s id u e  is  r e s p o n s ib le  fo r  th e  lo s s  
o f  C D 8 1 b in d in g  it w o u ld  b e  n e c e s s a r y  to  m u ta te  th is  r e s id u e  to  a n  a sp a r a g in e  an d  
d e te r m in e  i f  th is  c o n fe r s  C D 8 1  b in d in g  o n  g e n o ty p e  3 (R 3 )  E 2 . A p a rt fr o m  a  v a r ia b le  
a m in o  a c id  a t p o s it io n  4 1 4  (e ith e r  v a lin e  or  is o le u c in e ,  a s  in  R 3  a n d  H 7 7 ) ,  th e  r em a in d er  
o f  th e  e p ito p e  is  fu l ly  c o n s e r v e d  b e tw e e n  a ll 5 g e n o ty p e  3 i s o la te s  a n d  H 7 7 , c o n s is te n t  
w ith  th is  b e in g  a  c r it ic a l r e g io n . O w s ia n k a  et al. ( 2 0 0 1 )  a ls o  id e n t if ie d  a  d o w n s tr e a m  
r e g io n  (a a  5 2 8 - 5 3 5 )  th a t is  p o s s ib ly  in v o lv e d  in  th e  E 2 /C D 8 1  in te ra c tio n . It i s  n o t  k n o w n  
i f  th e  a n tib o d y  u s e d  fo r  id e n t ify in g  th is  r e g io n  r e c o g n is e s  g e n o ty p e  3 E 2  b u t a m in o  a c id  
s e q u e n c e  c o m p a r is o n  o f  g e n o ty p e s  1 a n d  3 E 2  s h o w s  th a t 4  o u t  o f  th e  8 r e s id u e s  in  th is  
e p ito p e  v a r y  b e tw e e n  g e n o ty p e  1 an d  e ith e r  2  or  m o r e  g e n o ty p e  3 is o la te s  (F ig u r e  3 .4 ) .  It 
is  th e r e fo r e  u n lik e ly  th a t th e  a n tib o d y  w o u ld  r e c o g n is e  ty p e  3 E 2 . T w o  d if fe r e n t  r e g io n s  
(a a  4 8 0 - 4 9 3  an d  5 4 4 - 5 5 1 )  w e r e  id e n t if ie d  a s  p o te n tia l  s i t e s  o f  C D 8 1  in te r a c t io n  b y  F lin t  et 
al. ( 1 9 9 9 a ) .  H o w e v e r , th e  a n t ib o d ie s  u s e d  fo r  th e  id e n t if ic a t io n  o f  th o s e  r e g io n s  w e r e  
s h o w n  n o t  to  in h ib it  C D 8 1  b in d in g  in  th e  s tu d y  b y  O w s ia n k a  et al. ( 2 0 0 1 ) .
F lin t  et al. ( 2 0 0 0 )  d e m o n s tr a te d  th a t th e  a g g r e g a te d  fo r m  o f  E 2  d id  n o t  b in d  C D 8 1 a n d  th e  
in tr a c e llu la r  fo r m s  o f  E 2  b o u n d  C D 8 1  w ith  g rea ter  a f f in ity  th a n  th e  e x tr a c e llu la r  se c r e te d  
fo r m s . T h e y  s u g g e s te d  th a t o n ly  th e  c o r r e c t ly  fo ld e d  an d  p r o c e s s e d  fo r m  o f  E 2  b o u n d  
C D 8 1. T h is  c o u ld  e x p la in  th e  o b s e r v e d  d e c r e a se  in  b in d in g  o f  H 7 7  E 2  to  C D 8 1 
c o m p a r e d  to  G N A  (F ig u r e s  6 .2  an d  6 .3 ) .  B o th  a g g r e g a te d  an d  n a t iv e  fo r m s o f  E 2  w o u ld  
b e  e x p e c te d  to  b in d  to  G N A  b u t i f  o n ly  th e  n a t iv e  fo r m  b in d s  C D 8 1 , th ere  w o u ld  b e  a  
r e la t iv e  fa l l  in  o b s e r v e d  b in d in g . T h is  th e o r y  c o u ld  b e  te s te d  w ith  th e  u s e  o f  
c o n fo r m a t io n -d e p e n d e n t  a n t ib o d ie s  th a t sh o u ld  r e c o g n is e  o n ly  n a t iv e  fo r m s  o f  E 2 .  
T h e r e fo r e  th e s e  a n t ib o d ie s  s h o u ld  d e te c t  e q u iv a le n t  a m o u n ts  o f  E 2  b in d in g  to  b o th  G N A  
an d  C D 8 1 . F ig u r e  6 .5  in d ic a te s  th a t th is  w a s  true fo r  H 6 0  b u t H 5 3  a n d  H 5 0  b o th  d e te c te d  
m o r e  b in d in g  to  G N A  th a n  C D 8 1. T h is  c o u ld  b e  e x p la in e d  i f  H 5 3  a n d  H 5 0  w e r e  a b le  to
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in h ib it  C D 8 1  b in d in g  b u t fo r  H 5 3 , it  h a s  b e e n  s h o w n  th a t th is  is  n o t  th e  c a s e  (F lin t  et al., 
1 9 9 9 a , O w s ia n k a  et al., 2 0 0 1 ) .  H 5 0  te s te d  p o s it iv e  in  a  N O B  a s s a y  (P a te l et al. 2 0 0 0 ) ,  so  
c o u ld  c o n c e iv a b ly  in h ib it  th e  E 2 /C D 8 1 in te r a c t io n , w h ic h  w o u ld  e x p la in  th e  la c k  o f  
r e a c t iv ity  a g a in s t  C D 8 1  -b o u n d  E 2  in  F ig u r e  6 .5 .  H 5 3  a c tu a lly  r e c o g n is e s  a n  e q u iv a le n t  
a m o u n t o f  C D 8 1  -b o u n d  E 2  to  H 6 0 , so  p o s s ib ly  th e  in c r e a se d  r e a c t iv ity  w ith  G N A -b o u n d  
E 2  is  d u e  to  r e c o g n it io n  o f  a n  e p ito p e  th a t is  a ls o  p r e se n t  o n  th e  a g g r e g a te d  fo r m  o f  E 2 .
T h is  i s  n o t  th e  fir st rep ort o f  an  E 2  p r o te in  fr o m  an  H C V  is o la te  th a t d o e s  n o t  b in d  to  
C D 8 1. P a te l et al. ( 2 0 0 0 )  d e m o n str a te d  th a t th e  tr u n ca ted  E 2  p r o te in  o f  g e n o ty p e  l a  
G la s g o w  stra in  d id  n o t  b in d  C D 8 1  a n d  th is  w a s  c o n f ir m e d  w ith  th e  fu l l - le n g th  E 2  p r o te in  
in  F ig u r e s  6 .2 b  a n d  6 .3 b . T h e s e  a u th o rs  a ls o  fo u n d  th a t G la  E 2  fo r m e d  m o s t ly  h ig h  
m o le c u la r  w e ig h t  a g g r e g a te s  a n d  w a s  n o t  r e c o g n is e d  b y  c o n fo r m a tio n -d e p e n d e n t  
a n t ib o d ie s . C h im e r a s  o f  G la  a n d  H 7 7  E 2  w e r e  c o n s tr u c te d  in  an  a ttem p t to  id e n t ify  a  
r e g io n  in  H 7 7  E 2  th a t c o n fe r r e d  C D 8 1  b in d in g  o n  G la  E 2  or  r e c o g n it io n  b y  c o n fo r m a tio n -  
d e p e n d e n t  a n t ib o d ie s  or  b o th  (P a te l et al., 2 0 0 0 ) .  T h r e e  c h im e r a s  (a ll  c o n ta in in g  th e  C -  
te r m in a l p o r t io n  o f  H 7 7  E 2 )  s h o w e d  r e c o g n it io n  b y  c o n fo r m a tio n -d e p e n d e n t  a n t ib o d ie s  
a n d  im p r o v e d  fo r m a tio n  o f  n a t iv e  E 2  a s  a n a ly s e d  u n d er  n o n -r e d u c in g  c o n d it io n s .  
H o w e v e r , o n ly  o n e  o f  th e s e  th ree  c h im e r a s  w a s  a b le  to  b in d  C D 8 1 . T h is  c h im e r a  
c o n ta in e d  a  la rg e  p o r t io n  o f  H 7 7  E 2  (a a  4 0 6 - 6 6 0 ) ,  in d ic a t in g  th a t th ere  m a y  b e  m u lt ip le  
r e g io n s  in  th e  G la  E 2  p r o te in  w h ic h  are r e s p o n s ib le  fo r  th e  la c k  o f  C D 8 1 b in d in g . It a lso  
in d ic a te d  th a t C D 8 1 -b in d in g  m a y  n o t  b e  e x c lu s iv e ly  r e la ted  to  th e  a b il ity  o f  E 2  to  fo ld  
c o r r e c t ly . Y a g n ik  et al. ( 2 0 0 0 )  c o m p a r e d  th e  C D 8 1  b in d in g  a f f in it ie s  o f  g e n o ty p e  l a  H 7 7  
E 2  a n d  g e n o ty p e  l b  N 2  E 2  a n d  fo u n d  th a t E 2  o f  N 2  stra in  s h o w e d  r e d u c e d  b in d in g  
e f f i c ie n c y  c o m p a r e d  to  H 7 7  E 2 . A n o th e r  g e n o ty p e  l b  E 2  p r o te in  (a m p lif ie d  fr o m  p a tie n t  
se r u m ) w a s  s h o w n  to  b in d  C D 8 1  w ith  n o  in d ic a t io n  o f  r e d u c e d  e f f i c ie n c y  c o m p a r e d  w ith  
g e n o ty p e  l a  E 2  (a ls o  a m p lif ie d  fr o m  p a tie n t  se r u m ) (H a d lo c k  et al., 2 0 0 0 ) .  A s  d iffe r e n t  
i s o la te s  w e r e  u s e d  in  th e s e  tw o  s tu d ie s , it  is  im p o s s ib le  to  c o m p a r e  th e m  d ir e c t ly  b u t th ere  
i s  a  s u g g e s t io n  th a t th e  str en g th  o f  th e  C D 8 1  in te r a c t io n  w ith  E 2  m a y  b e  is o la te  s p e c if ic .
In  F ig u r e s  6 .2 b  a n d  6 .3 b  th ere  is  a  s u g g e s t io n  o f  in c r e a se d  b in d in g  a b o v e  n o n - s p e c if ic  
l e v e ls  w h e n  c o n c e n tr a te d  E 2  e x tr a c ts  o f  R 3  a n d  G la  are u se d . T h is  c o u ld  p o in t  to  v e r y
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l o w  le v e ls  o f  C D 8 1  b in d in g  w ith  th e s e  is o la te s .  T o  in v e s t ig a te  th is  fu rth er, th e  a b ility  o f  
g e n o ty p e  3 (R 3 )  E 2  to  c o m p e te  w ith  g e n o ty p e  1 (H 7 7 )  E 2  for  C D 8 1  b in d in g  w a s  
e x a m in e d  (F ig u r e  6 .6 .) .  H o w e v e r  th ere  w a s  n o  e v id e n c e  th a t th e  p r e s e n c e  o f  g e n o ty p e  3 
E 2  h a d  a n y  e f fe c t  o n  th e  b in d in g  c a p a b il it ie s  o f  g e n o ty p e  1 E 2 , s u g g e s t in g  th a t R 3  E 2  d o e s  
n o t  b in d  C D 8 1 .
T h e  c a p tu r e  E L I S A  h a s  b e e n  u s e d  e x t e n s iv e ly  to  d e m o n str a te  th e  b in d in g  o f  H C V  E 2  to  
h u m a n  C D 8 1 . H o w e v e r , th is  te c h n iq u e  h a s  d e m o n s tr a te d  th e  b in d in g  o f  E 2  to  C D 8 1  o n ly  
a n d  n o t  th e  r e v e r s e  o f  C D 8 1  b in d in g  to  E 2 , w h ic h  s h o u ld  b e  e q u a lly  s tr o n g . S u r p r is in g ly ,  
b in d in g  o f  C D 8 1  to  H 7 7  E 2  c o u ld  n o t  b e  s h o w n  (F ig u r e  6 .8 ) .  A l l  th e  o th e r  r eq u ire d  
in te r a c t io n s  in  th is  E L I S A  w e r e  v e r if ie d  (F ig u r e  6 .9 ) .  It is  p o s s ib le  th a t C D 8 1  in  s o lu t io n  
a n d  C D 8 1  b o u n d  to  th e  p la s t ic  w e l ls ,  h a v e  d if fe r e n t  c o n fo r m a tio n s  a n d  th is  m a y  in te r fe re  
w ith  its  in te r a c t io n  w ith  E 2 . S im ila r ly , E 2  b o u n d  b y  A L P 9 8  m a y  h a v e  a  d iffe r e n t  
c o n fo r m a t io n  fr o m  E 2  in  s o lu t io n . N e ith e r  C D 8 1  n o r  E 2  are p r e se n t  in  a  s o lu b le  fo r m  in 
vivo, a s  th e  p r o p o s e d  in te r a c t io n  i s  p r e su m e d  to  o c c u r  b e tw e e n  c e l l-b o u n d  C D 8 1 a n d  th e  
H C V  v ir io n . In  an  a ttem p t to  r e p lic a te  th e  in vivo s itu a t io n , P ile r i et al. ( 1 9 9 8 )  an d  
H a d lo c k  et al. ( 2 0 0 0 )  s h o w e d  th a t g e n o ty p e  l a  H C V  p a r tic le s  in  in fe c t io u s  c h im p a n z e e  
p la s m a  b o u n d  to  C D 8 1 -c o a te d  p o ly s ty r e n e  b e a d s , a s  d e te r m in e d  b y  q u a n tita t iv e  R T -P C R .
I p e r fo r m e d  a  s im ila r  a s s a y  to  a s s e s s  th e  a b il ity  o f  g e n o ty p e  1 a n d  g e n o ty p e  3 v ir io n s  in  
h u m a n  se r a  to  b in d  C D 8 1 -c o a te d  a g a r o se  b e a d s  (F ig u r e  6 .1 1 ) .  T w o  in d e p e n d e n t  
e x p e r im e n ts  s h o w e d  th a t g e n o ty p e  3 v ir u s  p a r tic le s  ( fr o m  tw o  sep a ra te  sera ) b o u n d  
p r e fe r e n t ia lly  to  C D 8 1 , w h e r e a s  th e  g e n o ty p e  1 v ir u s  p a r t ic le s  s h o w e d  o n ly  n o n - s p e c if ic  
b in d in g  to  th e  a g a r o se  b e a d s . T h e s e  r e su lts  c o n tr a d ic t  th o s e  o f  th e  C D 8 1  ca p tu re  E L I S A ,  
h o w e v e r , t im e  c o n str a in ts  m e a n t th a t th e  p r o c e d u r e  w a s  n o t  fu l ly  o p t im is e d  a n d  m a n y  
m o r e  se r a  n e e d  to  b e  a n a ly s e d  b e fo r e  th e s e  r e su lts  c a n  b e  in te rp re ted  w ith  c o n f id e n c e .
O n ly  a  m in o r  p r o p o r tio n  o f  th e  H C V  in p u t w a s  ca p tu r e d  b y  C D 8 1  (fo r  th e  g e n o ty p e  3 
sera ) a n d  th is  c r e a te d  d if f ic u lt ie s  fo r  q u a n t if ic a t io n  b y  P C R  a s  p r o d u c t  w a s  o n ly  d e te c te d  
at th e  e n d  o f  th e  4 0 - c y c le  P C R  p r o g r a m , w h e r e  th e  s y s te m  is  in h e r e n t ly  l e s s  a c cu ra te .
T h is  e x p la in s  th e  la rg e  stan d ard  d e v ia t io n s  fo r  d e te c t io n  o f  v ir u s  b o u n d  to  th e  a g a r o se  
b e a d s . T h e  le v e l  o f  n o n - s p e c if ic  b in d in g  to  G S T -c o a te d  a g a r o se  b e a d s  w a s  h ig h  an d  
d if fe r e n t  b lo c k in g  p r o c e d u r e s  n e e d  to  b e  in v e s t ig a te d  to  im p r o v e  th is . A n o th e r
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c o m p lic a t in g  fa c to r  is  th a t a n t ib o d ie s  p r e se n t  in  th e  se r a  m a y  in te r fe r e  w ith  b in d in g .  
Id e a lly , o n e  w o u ld  w a n t  to  u s e  se r a  fr o m  a c u te ly  in fe c te d  p a tie n ts  w h e n  th e y  are P C R  
p o s i t iv e  b u t  a n t ib o d y  n e g a t iv e  b u t th e s e  sera  are v e r y  rare, a s  p a t ie n ts  are  u s u a lly  
a sy m p to m a t ic  d u r in g  th is  s ta g e . In  a d d itio n  to  r e p e a tin g  th is  e x p e r im e n t  w ith  m o r e  sera  
o f  b o th  g e n o ty p e s ,  i t  w o u ld  b e  n e c e s s a r y  to  s h o w  th a t th e  o b s e r v e d  b in d in g  is  d u e  to  
C D 8 1  b y  d e m o n s tr a t in g  its  in h ib it io n  b y  a n ti-C D 8 1  a n tib o d y .
T h e s e  c o n f l ic t in g  r ep o rts  o f  s tr o n g  b in d in g , r e d u c e d  b in d in g  a n d  n o  b in d in g  to  C D 8 1 ,  
d e p e n d in g  o n  th e  i s o la te ,  su p p o rt th e  v i e w  th a t C D 8 1  is  n o t  th e  p r im a ry  r e c e p to r  fo r  H C V .  
C le a r ly , th e  e x p r e s s io n  o f  C D 8 1  o n  a  w id e  r a n g e  o f  c e l l  ty p e s  d o e s  n o t  e x p la in  th e  l iv e r  
tr o p ism  o f  H C V . C D 8 1  p o s s ib ly  a c ts  a s  a  c o -r e c e p to r  b u t d if fe r e n t  v ir u s  stra in s m a y  u s e  
r e la te d  b u t  d if fe r e n t  c o -r e c e p to r s  a s  w ith  H IV  an d  th e  c h e m o k in e  r e c e p to r s  (F e n g  et al., 
1 9 9 6 , A lk h a t ib  et al., 1 9 9 6 ) . A lo n g  th e  sa m e  v e in , F lin t  et al. ( 1 9 9 9 b )  d e m o n s tr a te d  that 
a  c e l l  s u r fa c e -e x p r e s s e d  fo r m  o f  E 2  w a s  a b le  to  in te ra c t w ith  s o lu b le  h u m a n  C D 8 1  b u t w a s  
u n a b le  to  in d u c e  c e l l  fu s io n  o f  C D 8 1  -p o s it iv e  H E K  c e l ls ,  w h ic h  w o u ld  b e  n e c e s s a r y  for  
in fe c t io n . H C V  p a r t ic le s  in  p la s m a  h a v e  b e e n  s h o w n  to  b e  a s s o c ia te d  w ith  l ip o p r o te in s ,  
p a r tic u la r ly  lo w - d e n s it y  l ip o p r o te in s  (L D L s )  (P r in c e  et al., 1 9 9 6 ) . T h is  le d  to  th e  
s u g g e s t io n  th a t th e  L D L  r e c e p to r  m a y  b e  a  c a n d id a te  fo r  th e  H C V  r e c e p to r  a n d  it h a s  s in c e  
b e e n  s h o w n  th a t e x p r e s s io n  o f  th e  L D L  r e c e p to r  c o n fe r s  H C V  b in d in g  o n  C O S -7  c e l ls  
(M o n a z a h ia n  et al., 1 9 9 9 ) .  F u r th erm o re , A g n e l lo  et al. ( 1 9 9 9 )  d e m o n s tr a te d  th a t H C V  
a n d  th e  o th e r  F la v iv ir id a e  v ir u s e s , b o v in e  v ira l d ia r rh o ea  v ir u s  ( B V D V )  an d  h e p a tit is  G  
v ir u s , are e n d o c y to s e d  v ia  th e  L D L  r ec ep to r . E n d o c y to s is  c o r r e la te d  w ith  L D L  rec ep to r  
a c t iv i ty  a n d  w a s  in h ib ite d  in  th e  p r e s e n c e  o f  a n ti-L D L  r e c e p to r  a n t ib o d y . H o w e v e r , th ere  
w a s  a ls o  e v id e n c e  o f  s m a ll  a m o u n ts  o f  in tr a ce llu la r  H C V  in  c e l l s  th a t c o u ld  n o t  b e  
in h ib ite d  b y  a n t i-L D L  r e c e p to r  a n tib o d y . T h e r e fo r e  th e  L D L  r e c e p to r  m a y  n o t  b e  th e  
o n ly  m e a n s  o f  v ir a l en try . It m a y  b e  a  g e n e r a l m e c h a n is m  e m p lo y e d  b y  v ir u se s  that 
a s s o c ia te  w ith  l ip o p r o te in s . T h e  H C V  g e n o ty p e  o f  th e  se r a  u s e d  in  th is  s tu d y  w a s  n o t  
s p e c if ie d .  W im s c h m a n n  et al. ( 2 0 0 0 )  in v e s t ig a te d  th e  tw o  p r o p o s e d  H C V  r ec ep to rs ,
C D 8 1 a n d  L D L  r e c e p to r , in  te r m s o f  b in d in g  b o th  E 2  a n d  H C V . T h e  s p e c i f ic  b in d in g  o f  
E 2  (u n s p e c if ie d  is o la t e )  to  s o lu b le  h u m a n  C D 8 1  an d  to  M O L T -4  T  c e l l s  w a s  c o n fir m e d .  
H C V  w a s  a ls o  s h o w n  to  b in d  to  M O L T -4  c e l l s  b u t th e  b in d in g  w a s  s tr o n g ly  d e p e n d e n t o n
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th e  le v e l  o f  L D L  r e c e p to r  e x p r e s s io n  a n d  c o u ld  b e  in h ib ite d  b y  in c r e a se d  c o n c e n tr a t io n s  o f  
L D L , w h e r e a s  b in d in g  o f  E 2  w a s  u n a ffe c te d . E 2  w a s  s h o w n  n o t  to  in te ra c t w ith  e ith er  
L D L  o r  L D L  r e c e p to r , so  a s s o c ia t io n  o f  H C V  w ith  L D L  is  n o t  m e d ia te d  b y  E 2 . T h e se  
d a ta  s u g g e s t  th a t b in d in g  o f  H C V  to  M O L T -4  c e l l s  is  d u e  to  a  L D L  in te r a c t io n  w ith  L D L  
r e c e p to r  a n d  n o t  a n  E 2  in te r a c t io n  w ith  C D 8 1 . H o w e v e r , s im ila r ly  to  A g n e l lo  et al. 
( 1 9 9 9 ) ,  H C V  b in d in g  to  L D L  r e c e p to r  c o u ld  n o t  b e  b lo c k e d  c o m p le t e ly  b y  L D L , so  th e  
in v o lv e m e n t  o f  an o th er  c e llu la r  m o le c u le  in  H C V  a tta ch m en t c a n n o t  b e  r u led  o u t. A g a in ,  
th e  H C V  g e n o ty p e  o f  th e  se r a  u s e d  in  th is  s tu d y  w a s  u n s p e c if ie d  b u t th is  i s  n o t  e x p e c te d  to  
h a v e  a  b e a r in g  o n  H C V  b in d in g  to  th e  L D L  r e c e p to r  v ia  L D L , i f  th e  in te r a c t io n  w ith  L D L  
i s  n o n - s p e c if ic .  In  c o n c lu s io n , th e  r o le  o f  C D 8 1  in  a tta ch m en t o f  H C V  to  c e l l s  is  far  fro m  
c le a r  b u t d if fe r e n c e s  in  b in d in g  e f f i c ie n c y  b e tw e e n  is o la te s  d o  n o t  su p p o rt th e  r o le  o f  
C D 8 1  a s  th e  p r im a ry  H C V  rec ep to r .
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Chapter 7 
General Discussion
7.1. H77 and R3 as representatives of genotypes 1 and 3
T h is  s tu d y  in v o lv e d  th e  d ir e c t  c o m p a r is o n  o f  th e  H C V  g e n o ty p e  3 g ly  c o p r o te in s  w ith  
th o s e  o f  g e n o ty p e  1. F o r  th e s e  p u r p o se s , R 3  a n d  H 7 7  w e r e  u s e d  a s  r e p r e se n ta t iv e s  o f  
g e n o ty p e  3 a n d  g e n o ty p e  1, r e s p e c t iv e ly .  T h e  q u e s t io n  is  h o w  r e p r e se n ta t iv e  o f  th e s e  tw o  
g e n o ty p e s  are th e s e  tw o  c lo n e s ?  T h e  fu l l- le n g th  H 7 7  c lo n e  is  w id e ly  a c c e p te d  a s  b e in g  
n o t  o n ly  r e p r e se n ta t iv e  o f  g e n o ty p e  l a  b u t a ls o  o f  th e  H C V  g e n o m e  in  g e n e r a l, a s  R N A  
tr a n sc r ip ts  fr o m  th is  c lo n e  are in fe c t io u s  w h e n  in je c te d  in to  th e  l iv e r  o f  a  c h im p a n z e e  
(Y a n a g i  et al., 1 9 9 7 , K o ly k h a lo v  et al., 1 9 9 7 ) . T h is  in fe c t io u s  c lo n e  h a s  p r o v e d  
in v a lu a b le  in  fu r th er in g  th e  u n d e r s ta n d in g  o f  H C V  b io lo g y ,  e s p e c ia l ly  in  th e  a b s e n c e  o f  a n  
in vitro p r o p a g a tio n  sy s te m . H o w e v e r , it h a s  m e a n t th a t m a n y  b io lo g ic a l  fe a tu r e s  o f  H C V  
h a v e  b e e n  d e f in e d  in  te r m s  o f  H 7 7  o n ly . A n o th e r  g e n o ty p e  l a  in fe c t io u s  c lo n e  h a s  
r e c e n t ly  b e e n  d e sc r ib e d  (L a n fo r d  et al., 2 0 0 1 )  a n d  it  w i l l  b e  in te r e s t in g  to  s e e  w h a t  
d if f e r e n c e s  th e r e  are b e tw e e n  th e s e  tw o  c lo n e s .  T h e  o n ly  n o n -g e n o ty p e  1 in f e c t io u s  c lo n e  
d e sc r ib e d  s o  far  is  th a t o f  g e n o ty p e  2 a  a n d  in te r e s t in g ly , a  c h im e r ic  g e n o m e  c o n s is t in g  o f  
th e  g e n o ty p e  2 a  stru ctu ra l g e n e s  in  th e  c o n te x t  o f  a  g e n o ty p e  1 a  (H 7 7 )  b a c k b o n e , w a s  
fo u n d  n o t  to  b e  in fe c t io u s  (Y a n a g i  et al., 1 9 9 9 a ) . D u r in g  th e  c o n s tr u c t io n  o f  th e  
in f e c t io u s  c lo n e s ,  it  h a d  b e e n  s h o w n  th a t m in o r  d e v ia t io n s  fr o m  th e  c o n s e n s u s  a m in o  a c id  
s e q u e n c e  r en d e re d  th e  c D N A  c lo n e s  n o n - in fe c t io u s  (Y a n a g i  et al., 1 9 9 7 ) . In  th e  a b s e n c e  
o f  a  g e n o ty p e  3 in fe c t io u s  c lo n e , o r  th e  f a c i l i t ie s  to  p r o d u c e  o n e , th e  o p t im u m  m e th o d  fo r  
o b ta in in g  a  c lo n e  th a t w o u ld  e n c o d e  fu l ly  fu n c t io n a l stru ctu ra l p r o te in s , w a s  to  c o n s tr u c t  a
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c o n s e n s u s  s e q u e n c e  fo r  th is  r e g io n . In  th is  reg a rd , e v e r y  e f fo r t  w a s  m a d e  to  e n su r e  th a t  
th e  a m in o  a c id  s e q u e n c e  o f  th e  R 3  c lo n e  m a tc h e d  th a t o f  th e  P C R  m a jo r ity  s e q u e n c e  ( s e e  
s e c t io n  3 .5 ) .  C o m p a r iso n  w ith  fo u r  p u b lis h e d  g e n o ty p e  3 s e q u e n c e s  c o n f ir m e d  th at th e  
R 3  c lo n e  c o n ta in e d  a  g e n o ty p e  3 s e q u e n c e . It is  m o r e  d if f ic u lt  to  d e te r m in e  h o w  
r e p r e se n ta t iv e  th is  c lo n e  i s  o f  “ ty p ic a l” g e n o ty p e  3 stru ctu ra l p r o te in s  a s  a ll  i s o la te s  h a v e  
a m in o  a c id  d if fe r e n c e s .  T h o s e  a m in o  a c id s  w h ic h  are u n iq u e  to  R 3  m a y  tra n sla te  to  a  
stru ctu ra l or  fu n c t io n a l d if fe r e n c e  w h e n  c o m p a r e d  to  th e  p u b lis h e d  p r o te in  s e q u e n c e s .  
T h e r e  w e r e  13 su c h  p o s it io n s  in  E 2  w h e r e  R 3  d if fe r e d  fr o m  th e  c o n s e n s u s  g e n o ty p e  3 
s e q u e n c e  b u t th e  th r e e  p o s it io n s  th a t in v o lv e  a  p r o lin e  r e s id u e  w o u ld  b e  e x p e c te d  to  b e  
m o s t  im p o r ta n t in  te r m s  o f  p r o te in  stru ctu re. T o  d e te r m in e  i f  th e s e  r e s id u e s  d o  tra n sla te  
in to  a  stru ctu ra l d if fe r e n c e , th e y  w o u ld  h a v e  to  b e  m u ta te d  to  th e  g e n o ty p e  3 c o n s e n s u s  
r e s id u e  at th a t p o s it io n . W o r k  is  cu r re n tly  u n d e r w a y  to  c o n s tr u c t  a  s e c o n d  g e n o ty p e  3 
c lo n e  w ith  w h ic h  to  c o m p a r e  th e  c h a r a c te r is t ic s  o f  th e  R 3  p r o te in s . T h is  sh o u ld  h e lp  to  
d is t in g u is h  b e tw e e n  fe a tu r e s  w h ic h  are tru ly  c h a r a c te r is t ic  o f  g e n o ty p e  3 a n d  th o s e  w h ic h  
are c h a r a c te r is t ic  o f  R 3 .
7.2. Generalised differences between genotypes 1 and 3
In  te r m s  o f  d is e a s e  p r o g r e s s io n  th ere  is  n o  c o n c lu s iv e  e v id e n c e  to  s u g g e s t  th a t g e n o ty p e s  1 
an d  3 d if fe r  in  a n y  r e s p e c ts . H o w e v e r  s te a to s is ,  a  h is to p a th o lo g ic a l  fe a tu re  o f  c h r o n ic  
h e p a t it is  C  in fe c t io n  c h a r a c te r ise d  b y  l ip id  a c c u m u la t io n  in  h e p a to c y te s , h a s  b e e n  s h o w n  
to  b e  m o r e  fr e q u e n t  in  g e n o ty p e  3 in fe c t io n s  (R u b b ia -B r a n d t et al., 2 0 0 1 ) .  T h e  c o r e  
p r o te in  h a s  b e e n  im p lic a te d  in  th e  d e v e lo p m e n t  o f  s t e a to s is  d u e  to  its  a tta ch m en t to  l ip id  
d r o p le ts  (B a r b a  et aL, 1 9 9 7 ) . H o w e v e r , th e  e x a c t  m e c h a n is m  b y  w h ic h  l ip id s  a c c u m u la te  
in  th e  l iv e r  an d  th e  d if fe r e n c e s  b e tw e e n  th e  h ig h ly  c o n s e r v e d  g e n o ty p e s  1 an d  3 c o re  
w h ic h  m a y  a f fe c t  th is  p r o c e s s  r e m a in  to  b e  d e te r m in e d .
T h e  m o s t  e s ta b lis h e d  d if fe r e n c e  b e tw e e n  g e n o ty p e s  1 a n d  3 is  th e  b e tter  r e s p o n s e  o f  
p a t ie n ts  in fe c te d  w ith  H C V  g e n o ty p e  3 to  tr ea tm e n t w ith  in te r fe r o n -a lp h a  ( I F N a ) ,  e ith e r  
£  a lo n e  o r  in  c o m b in a t io n  w ith  r ib a v ir in  (M c H u tc h in s o n  et al., 1 9 9 8 , P o y n a r d  et al., 1 9 9 8 ) .
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M u c h  a tte n tio n  h a s  b e e n  fo c u s s e d  o n  th e  N S 5 A  p r o te in  a n d  its  p o te n t ia l  r o le  in  I F N a  
r e s is ta n c e  v ia  in h ib it io n  o f  P K R . M o s t  s tu d ie s  h a v e  c o n c e n tr a te d  o n  g e n o ty p e  1 N S 5 A  
o n ly . W h e n  p r o v id e d  in  tran s, g e n o ty p e  1 N S 5 A  h a s  b e e n  s h o w n  to  c o n fe r  p artia l 
r e s is ta n c e  to  IF N , a l lo w in g  r e s c u e  o f  I F N -s e n s it iv e  v ir u s e s  fr o m  th e  a n tiv ira l e f fe c t s  o f  
IF N  (P a te r so n  et al., 1 9 9 9 , P o ly a k  et al., 1 9 9 9 ) . H o w e v e r , th ere  h a v e  b e e n  n o  rep o rts  o n  
th e  e f f e c t  o f  g e n o ty p e  3 (o r  2 )  N S 5 A  e x p r e s s io n  o n  th e s e  I F N -s e n s it iv e  v ir u se s . I f  th e y  
to o  c o n fe r  r e s is ta n c e  to  IF N , it  m a y  s u g g e s t  th a t N S 5 A  is  r e s p o n s ib le  fo r  m e d ia t in g  a  
g e n e r a l le v e l  o f  IF N  r e s is ta n c e  fo r  H C V  a n d  a d d itio n a l p a th w a y s  p o s s ib ly  e x is t  for  
c o n fe r r in g  a n  a d d itio n a l le v e l  o f  IF N  r e s is ta n c e  o n  g e n o ty p e  1 H C V . T h is  is  n o t  
su rp r is in g  a s  th e  IF N  r e s p o n s e  in v o lv e s  a  m u lt itu d e  o f  e f f e c t s  w h ic h  are m e d ia te d  b y  th e  
p r o te in  p r o d u c ts  o f  IF N - in d u c e d  g e n e s . T h e r e fo r e  a  v ir u s  h a s  to  c o n te n d  w ith  th is  m u lt i­
p r o n g e d  a tta ck  a n d  o f te n  e v o lv e s  m o r e  th a n  o n e  m e c h a n is m  to  c o u n te r a c t  th e  e f f e c t s  o f  
IF N . F o r  e x a m p le , at le a s t  tw o  I F N -r e s is ta n c e  m e c h a n is m s  h a v e  b e e n  id e n t if ie d  so  far  in  
in f lu e n z a  v ir u s , v a c c in ia  v ir u s , h e r p e s  s im p le x  v ir u s  an d  H IV  (G o o d b o u m  et al., 2 0 0 0 ,  
G a le  &  K a tz e , 1 9 9 8 ) . T h e  id e n t if ic a t io n  o f  th e  P e P H D  r e g io n  in  th e  E 2  p r o te in , w h o s e  
s e q u e n c e  d if fe r e d  b e tw e e n  g e n o ty p e s  1 a n d  2 /3  w a s  p r o p o s e d  a s  a p r e d ic to r  o f  
r e s p o n s iv e n e s s  to  I F N a  tr ea tm e n t (T a y lo r  et al., 1 9 9 9 ) . H o w e v e r  th is  s tu d y  ( s e c t io n  
5 .1 .2 . )  an d  o th e r s  s h o w e d  th a t th e  P e P H D  s e q u e n c e  w a s  h ig h ly  c o n s e r v e d  w ith in  
g e n o ty p e s  a n d  w h e n  m u ta t io n s  d id  o c c u r  th e y  w e r e  n o t  p r e d ic t iv e  o f  tr ea tm e n t o u tc o m e  
(P o ly a k  et al., 2 0 0 0 ,  S a rra z in  et al., 2 0 0 0 a ) .  T h e  m e c h a n is m  b y  w h ic h  g e n o ty p e  1 E 2  
m e d ia te s  r e s is ta n c e  to  IF N  w a s  s h o w n  to  b e  v ia  in te r a c t io n  w ith  an d  in h ib it io n  o f  P K R , 
w h ic h  w a s  d e p e n d e n t  o n  th e  P e P H D  (T a y lo r  et al., 1 9 9 9 ) . H o w e v e r , I c o u ld  n o t  c o n fir m  
th e  in te r a c t io n  o f  g e n o ty p e  1 (H 7 7 )  E 2  w ith  P K R  or  o b s e r v e  c o - lo c a li s a t io n  o f  th e s e  tw o  
p r o te in s  in  th e  c e l l  ( s e c t io n s  5 .1 .3 .  an d  5 .1 .4 .) .  L im ita t io n s  o n  a n tib o d y  c h o ic e ,  m e a n t  
th a t th e  a b il ity  o f  g e n o ty p e  3 E 2  to  in tera c t w ith  P K R  c o u ld  n o t  b e  a n a ly s e d  b u t th is  a sp e c t  
s h o u ld  b e  in v e s t ig a te d  further. T h e r e fo r e  th e  r o le  o f  P K R  a n d  th e  P e P H D  in  E 2  in  
m e d ia t in g  IF N  r e s is ta n c e  r e m a in s  u n d er  q u e s t io n . E x a m in a t io n  o f  th e  le v e ls  o f  
p h o sp h o r y la te d  e I F 2 a  in  th e  p r e s e n c e  a n d  a b s e n c e  o f  b o th  g e n o ty p e  1 an d  3 E 2  w o u ld  
v e r ify  w h e th e r  E 2  e x p r e s s io n  c o u ld  a f fe c t  p r o te in  tr a n sla tio n . T h is  c o u ld  b e  in terp re ted  
as a  d o w n s tr e a m  e f fe c t  o f  P K R  o r  o th e r  m a m m a lia n  e I F 2 a  k in a s e s . T h e r e  h a v e  a lso  b e e n  
n o  rep o rts  o n  th e  a b il ity  o f  E 2  ( o f  e ith er  g e n o ty p e  1 or  3 )  to  c o n fe r  r e s is ta n c e  to  IF N -
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s e n s it iv e  v ir u s e s , w h ic h  w o u ld  g iv e  a n  in d ic a t io n  o f  w h e th e r  E 2  is  in v o lv e d  in  m e d ia t in g  
H C V  r e s is ta n c e  to  th e  a n tiv ira l e f f e c t  o f  IF N .
7.3. Differences between the H77 and R3 glycoproteins 
7.3.1. Antibody recognition
M o n o c lo n a l  a n tib o d y  r e a c t iv ity  p r o v id e s  stru ctu ra l in fo r m a tio n  o n  a  p ro te in .
In te r e s t in g ly , th ere  w e r e  se v e r a l s tr e tc h e s  o f  c o n s e r v e d  a m in o  a c id s  in  E 2  b e tw e e n  H 7 7  
a n d  R 3  a n d  y e t , n o  a n t ib o d ie s  w e r e  s p e c i f ic  fo r  th e s e  r e g io n s . T h e  o n ly  g e n o ty p e  1 
a n t ib o d ie s  th a t w e r e  r e a c t iv e  a g a in s t  b o th  H 7 7  a n d  R 3  r e c o g n is e d  o v e r la p p in g  e p ito p e s  
o v e r  a  h ig h ly  c o n s e r v e d  16  a m in o  a c id  r e g io n . A s  th is  r e g io n  i s  c o n s e r v e d  b e tw e e n  tw o  
m a jo r  g e n o ty p e s ,  it m a y  in d ic a te  th a t it i s  s tru c tu ra lly  or  fu n c t io n a lly  im p o rta n t. T h is  
m a y  b e  b e c a u s e  it c o n ta in s  tw o  c o n s e r v e d  c y s te in e  r e s id u e s , w h ic h  are in v o lv e d  in  
d is u lp h id e  b o n d in g  a s  w e l l  a  c o n s e r v e d  g ly c o s y la t io n  s ite . A s  y e t , th ere  h a v e  b e e n  n o  
rep o rts  o f  a n  in te r a c t io n  w ith  a n o th er  p r o te in  v ia  th is  r e g io n . It is  c le a r  th ere  are  f e w  an ti-  
E 2  a n t ib o d ie s  th a t are c r o s s -r e a c t iv e  b e tw e e n  g e n o ty p e s  a n d  e v e n  b e tw e e n  s u b ty p e s  th ere  
is  o f te n  n o  o b s e r v e d  c r o s s -r e a c t iv ity  (P a te l et al., 2 0 0 0 ,  A lla n d e r  et al., 2 0 0 0 b ) .  T h is  w i l l  
b e  a  m a jo r  o b s ta c le  in  th e  d e s ig n  o f  a n  H C V  v a c c in e . F or  fu tu re  w o r k  w ith  g e n o ty p e  3 
E 2  it w o u ld  b e  b e n e f ic ia l  to  g e n e r a te  g e n o ty p e  3 s p e c i f ic  E 2  a n t ib o d ie s , a s  th e s e  w o u ld  
g iv e  m o r e  in s ig h t  in to  th e  stru ctu ra l fe a tu r e s  o f  g e n o ty p e  3 E 2  an d  h o w  it d if fe r s  fr o m  
g e n o ty p e  1 E 2 . T h e  g e n e r a t io n  o f  g e n o ty p e  3 c o n fo r m a tio n -d e p e n d e n t  a n t ib o d ie s  w o u ld  
b e  e s p e c ia l ly  u s e fu l ,  a s  n o n e  o f  th e  g e n o ty p e  1 c o n fo r m a tio n -d e p e n d e n t  E 2  a n t ib o d ie s  
te s te d  in  th is  s tu d y  w e r e  a b le  to  r e c o g n is e  R 3  E 2 . T h e s e  a n t ib o d ie s  h a v e  b e e n  im p o rta n t  
fo r  d is t in g u is h in g  b e t w e e n  th e  a g g r e g a te  an d  n a t iv e  E 1 E 2  c o m p le x e s  o f  g e n o ty p e  1 an d  
fo r  d e te r m in in g  w h ic h  o f  th e s e  E 2  fo r m s  are in v o lv e d  in  in te r a c t io n s  w ith  o th e r  p r o te in s  
( e .g .  C D 8 1 )  (C o c q u e r e l  et al., 1 9 9 8 , F lin t  et al., 2 0 0 0 ) .
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7.3.2. Protein size and glycosylation states
B o th  th e  E l  a n d  E 2  p r o te in s  o f  R 3  a n d  H 7 7  s h o w e d  d if fe r e n t  m o b il i t ie s  w h e n  se p a r a ted  
b y  S D S -P A G E . F o r  E 2 , th is  c o u ld  b e  e x p la in e d  b y  d if fe r in g  g ly c o s y la t io n  s ta te s , w ith  
H 7 7  E 2  h a v in g  o n e  e x tra  g ly c o s y la t io n  s ite  c o m p a r e d  to  R 3  E 2 . T h e  10  p r e d ic te d  
g ly c o s y la t io n  s ite s  in  R 3  E 2  are c o n s e r v e d  in  th e  fo u r  p u b lis h e d  g e n o ty p e  3 s e q u e n c e s  an d  
in  H 7 7  E 2 , so  are p r e su m a b ly  im p o rta n t fo r  s ta b ility  o r  b io lo g ic a l  a c t iv ity . E x te n s iv e  
g ly c o s y la t io n  is  c h a r a c te r is t ic  o f  v ira l g ly c o p r o te in s  a n d  h a s  b e e n  s u g g e s te d  to  s e r v e  a s  a  
p r o te c t io n  m e c h a n is m  b y  c o v e r in g  p o te n tia l  im m u n o g e n ic  e p ito p e s  (B r a a k m a n  &  v a n  
A n k e n , 2 0 0 0 ) .  T h e r e fo r e , is  th e  ex tra  g ly c o s y la t io n  s ite  in  H 7 7  E 2  s ig n if ic a n t?  D o e s  it 
c o n fe r  e x tr a  p r o te c t io n  fr o m  th e  im m u n e  s y s te m  or  d o e s  it a l lo w  fo r  in te r a c t io n s  w ith  
o th e r  p r o te in s  th at are n o t  s e e n  w ith  g e n o ty p e  3 E 2 ?  I f  g ly c o s y la t io n  s ta tu s  w a s  id e n t if ie d  
a s  m o d u la t in g  a  c er ta in  b io lo g ic a l  a c t iv ity  o f  E 2 , m u ta n ts  o f  g e n o ty p e  3 E 2  c o u ld  b e
tfig e n e r a te d  to  s e e  i f  th e  p r e s e n c e  o f  a n  11 g ly c a n  a f fe c t s  th is  a c t iv ity .
F iv e  p r e d ic te d  g ly c o s y la t io n  s ite s  are c o n s e r v e d  b e tw e e n  H 7 7 , R 3  a n d  th e  fo u r  p u b lish e d
thg e n o ty p e  3 s e q u e n c e s .  H o w e v e r , it h a s  b e e n  s h o w n  th a t th e  5 s ite  in  g e n o ty p e  1 E l  is  
n o t  u s e d  (M e u n ie r  et al., 1 9 9 9 )  an d  s iz e  c o m p a r is o n  o f  H 7 7  E l  a n d  R 3  E l  in d ic a te d  th a t  
R 3  E l  h a s  an  a d d itio n a l g ly c a n . T h e  5 th s ite  in  g e n o ty p e  1 E l  is  sa id  n o t  to  b e  u s e d  d u e  to  
th e  p r e s e n c e  o f  a  p r o lin e  r e s id u e  im m e d ia te ly  a fter  th e  tr ip ep tid e  r e c o g n it io n  s e q u e n c e  
(M e u n ie r  et al., 1 9 9 9 )  b u t th is  s e q u e n c e  is  p r e se n t  in  R 3  a s  w e l l ,  so  w h y  is  th is  s ite  
g ly c o s y la t e d  in  R 3 b u t n o t  in  H 7 7 ?  P o s s ib ly  th ere  is  a n o th er  s ite  in  H 7 7  E l  th a t is  n o t  
u s e d  o r  c o n v e r s e ly ,  an  a d d itio n a l g ly c o s y la t io n  s ite  in  R 3  E l  th a t w o u ld  a c c o u n t  fo r  th e  
d if f e r e n c e s  in  p r o te in  m o b il ity .  A  d if fe r e n c e  w a s  a ls o  o b s e r v e d  b e tw e e n  th e  m o b il i t y  o f  
th e  H 7 7  E l  p r o te in s  w h e n  a n a ly s e d  u n d er  r e d u c in g  an d  n o n -r e d u c in g  c o n d it io n s  a n d  th is  
w a s  n o t  s e e n  w ith  R 3  E l . T h is  s u g g e s t s  e ith er  a  d if fe r e n c e  in  stru ctu re  o r  m o d if ic a t io n  
b e tw e e n  th e  H 7 7  E l  p r o te in  in v o lv e d  in  th e  n a t iv e  c o m p le x  a n d  th a t in v o lv e d  in  th e  
a g g r e g a te . T h is  c h a r a c te r is t ic  m a y  n o t  b e  a ttr ib u ta b le  to  a ll  g e n o ty p e  1 E l  p r o te in s , a s  it 
w a s  n o t  o b s e r v e d  fo r  th e  g e n o ty p e  l a  G la s g o w  is o la te . L ik e w is e ,  fu rth er  a n a ly s is  o f  o th er  
g e n o ty p e  3 is o la te s  is  r eq u ire d  to  d e te r m in e  i f  th is  fe a tu re  o f  R 3  is  tru e  o f  a ll  g e n o ty p e  3 
E l  p r o te in s . M u ta g e n e s is  o f  th e  p r e d ic te d  g ly c o s y la t io n  s ite s  o n  H 7 7  E l  a n d  R 3  E l
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w o u ld  h e lp  to  d e te r m in e  th e  true g ly c o s y la t io n  s ta tu s  o f  th e  E l  p r o te in s . A  fu rth er  
a n o m a ly  w a s  o b s e r v e d  w h e n  th e  u n g ly c o s y la te d  fo r m s  o f  E l  w e r e  c o m p a r e d  in  th a t H 7 7  
E l  a p p ea r e d  to  b e  sm a lle r  th a n  R 3  E l . T h is  is  n o t  p r e d ic te d  fr o m  th e  s e q u e n c e  an d  th e  
o n ly  e x p la n a t io n  is  th a t H 7 7  E l  i s  fo ld e d  in to  a  m o r e  c o m p a c t  stru ctu re  th a n  R 3  E l .  
T h e r e  are o b v io u s  d if fe r e n c e s  b e tw e e n  H 7 7  E l  a n d  R 3  E l  b u t th e s e  fe a tu r e s  s h o u ld  b e  
a n a ly s e d  in  o th e r  is o la te s  b e fo r e  th e y  are  r e c o g n is e d  a s  g e n u in e  d if fe r e n c e s  b e tw e e n  
g e n o ty p e  1 a n d  g e n o ty p e  3 .
7.3.3. CD81 interaction
O n e  o f  th e  m o s t  in te r e s t in g  d if fe r e n c e s  o b s e r v e d  b e tw e e n  H 7 7  a n d  R 3  w a s  th e  la c k  o f  
b in d in g  o f  R 3  E 2  to  h u m a n  C D 8 1  c o m p a r e d  to  H 7 7  E 2 . A p a rt fr o m  th e  rep o rted  b in d in g  
o f  g e n o ty p e  2  E 2  (H a d lo c k  et al., 2 0 0 0 ) ,  a ll  o th e r  p r e v io u s  d o c u m e n ta t io n  o f  E 2 /C D 8 1  
b in d in g  h a s  in v o lv e d  g e n o ty p e  1 E 2 . A  p o s s ib le  s ite  o f  d ir e c t  in te r a c t io n  w ith  C D 8 1  h a s  
b e e n  id e n t if ie d  o n  E 2 , w h ic h  sp a n s  th e  e p ito p e  r e c o g n is e d  b y  th e  a n ti-E 2  a n t ib o d y , A P 3 3  
(O w s ia n k a  et al., 2 0 0 1 ) .  T h is  a n tib o d y  d id  n o t  s h o w  a n y  r e a c t iv ity  a g a in s t  R 3  E 2 , w h ic h  
is  p r o b a b ly  d u e  to  a  s in g le  a m in o  a c id  d if fe r e n c e  in  th e  A P 3 3  e p ito p e  b e tw e e n  th e  E 2  
p r o te in s  o f  R 3  a n d  H 7 7 . D o e s  th is  a m in o  a c id  d if fe r e n c e  a ls o  r esu lt  in  in h ib it io n  o f  a  
C D 8 1  in te r a c t io n  w ith  R 3  E 2 ?  T o  a n s w e r  th is , th e  a m in o  a c id  d if fe r e n c e  in  R 3  w i l l  b e  
m u ta te d  to  m a tc h  th a t o f  H 7 7  to  s e e  i f  th is  c o n fe r s  C D 8 1  -b in d in g  o n  R 3  E 2 . T h e  m a jo r  
q u e s t io n  is  w h e th e r  th e  la c k  o f  C D 8 1  b in d in g  is  c h a r a c te r is t ic  o f  a ll g e n o ty p e  3 is o la te s  or  
j u s t  R 3 ?  S e q u e n c e  a n a ly s is  o f  th e  o th e r  fo u r  p u b lis h e d  g e n o ty p e  3 s e q u e n c e s  s h o w e d  th at  
o n e  o th e r  is o la te  c o n ta in s  th e  sa m e  a m in o  a c id  d if fe r e n c e  in  th e  A P 3 3  e p ito p e  a s  R 3  b u t  
th e  o th e r  3 m a tc h  th e  H 7 7  s e q u e n c e  at th a t p o s it io n . It w o u ld  b e  in te r e s t in g  to  k n o w  i f  
th e  E 2  p r o te in  o f  th e s e  is o la te s  s h o w s  b in d in g  to  C D 8 1. T h e  r e g io n  o n  E 2  in v o lv e d  in  th e  
in te r a c t io n  w ith  C D 8 1  is  b e l ie v e d  to  b e  d is c o n t in u o u s , so  th e  a m in o  a c id  s e q u e n c e  o f  o th e r  
r e g io n s ,  in  a d d it io n  to  th e  A P 3 3  e p ito p e , are l ik e ly  to  in f lu e n c e  C D 8 1  b in d in g  o f  E 2 . 
R e s e a r c h  i s  u n d e r w a y  to  d e lin e a te  th e  p r e c is e  lo c a t io n  o f  th e  r e s id u e s  o n  E 2  in v o lv e d  in  
th e  C D 8 1  in te r a c t io n . A  la r g e -s c a le  c o m p a r is o n  o f  th e  C D 8 1 -b in d in g  a b ility  o f  E 2  
p r o te in s  fr o m  a  n u m b e r  o f  i s o la te s  o f  d if fe r e n t  g e n o ty p e s ,  c o m b in e d  w ith  s e q u e n c e
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c o m p a r is o n , w i l l  p r o v id e  a  b e tter  p ic tu r e  o f  w h e th e r  C D 8 1 -b in d in g  is  g e n o ty p e - s p e c i f ic  or  
i s o la t e - s p e c if ic .
In  c o n tr a st  to  th e  w o r k  w ith  r e c o m b in a n t E 2 , a s s e s s m e n t  o f  th e  a b il ity  o f  v ir io n s  in  h u m a n  
sera  to  b in d  C D 8 1 -c o a te d  a g a r o se  b e a d s , s u g g e s te d  th a t g e n o ty p e  3 v ir io n s  d id  b in d  C D 8 1  
b u t g e n o ty p e  1 v ir io n s  d id  n o t. T im e  lim ita t io n s  m e a n t th a t th e  te c h n iq u e  w a s  n o t  fu l ly  
o p t im is e d  a n d  n o t  e n o u g h  se r a  w e r e  a n a ly s e d  to  c o n f ir m  th is  c o r r e la t io n , s o  th is  is  a  
p r e lim in a r y  o b s e r v a t io n . W h a t is  th e  s ig n if ic a n c e  o f  th e s e  o b s e r v a t io n s?  H u m a n  C D 8 1  
h a s b e e n  p r o p o s e d  a s  a  r e c e p to r  fo r  H C V  b u t it  is  b e c o m in g  in c r e a s in g ly  c le a r  that  
a d d itio n a l fa c to r s  are req u ire d  fo r  e n d o c y to s is ,  w ith  th e  L D L -r e c e p to r  b e in g  p r o p o s e d  a s  
a n o th er  H C V  r e c e p to r  ( A g n e l lo  et al., 1 9 9 9 ) . T h ere  m a y  b e  a  n u m b e r  o f  c e l l- s u r fa c e  
fa c to r s  in v o lv e d  in  b in d in g  H C V  an d  in d u c in g  e n d o c y to s is .  O n e  o f  th e se  fa c to r s  m a y  b e  
s p e c if ic  fo r  h e p a to c y te s  (a n d  p o s s ib ly  P B M C s )  a n d  w o u ld  e x p la in  th e  c e llu la r  tr o p ism  o f  
H C V , w h ic h  is  n o t  e x p la in e d  b y  C D 8 1  e x p r e s s io n . It is  a ls o  p o s s ib le  th a t rather th an  
h a v in g  s p e c i f ic i t y  fo r  C D 8 1, H C V  c a n  in tera c t w ith  o th e r  m e m b e r s  o f  th e  te tr a sp a n in  
fa m ily  a s  w e l l  a n d  p e r h a p s s o m e  H C V  is o la te s  s h o w  g rea ter  a f f in ity  fo r  th e s e  o th er  
m e m b e r s . A  rep ort at a  r e c e n t  H C V  m e e t in g  d e sc r ib e d  h ig h  le v e ls  o f  e x p r e s s io n  o f  
te tr a sp a n in  m o le c u le s ,  C D 9 , C D 8 1 , C D 8 2  an d  C D 1 5 1  o n  th e  su r fa c e  o f  p r im a ry  h u m a n  
h e p a to c y te s  (C h a rr in  et al., 2 0 0 1 )  b u t it  is  n o t  y e t  k n o w n  i f  H C V  c a n  b in d  s p e c i f ic a l ly  to  
a n y  o f  th e s e  a lte r n a tiv e  m o le c u le s .
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